

CITATION REPORT

List of articles citing

The biology of VEGF and its receptors

DOI: 10.1038/nm0603-669

Nature Medicine, 2003, 9, 669-76.

Source: <https://exaly.com/paper-pdf/35290627/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2217	Keratinocyte growth factor induces vascular endothelial growth factor-A expression in colorectal cancer cells. 1992 , 34, 355		2
2216	Hypoxia-induced reduction of sVEGFR-2 levels in human colonic microvascular endothelial cells in vitro: Comparative study with HUVEC. 1998 , 23, 49		1
2215	Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. 2003 , 93, 1074-81		499
2214	Protein-based signaling systems in tissue engineering. 2003 , 14, 559-65		151
2213	Inhibition of angiogenesis by NSAIDs: molecular mechanisms and clinical implications. 2003 , 81, 627-36		81
2212	VEGF and PlGF: two pleiotropic growth factors with distinct roles in development and homeostasis. 2003 , 314, 5-14		118
2211	Genesis and pathogenesis of lymphatic vessels. 2003 , 314, 69-84		79
2210	EG-VEGF and Bv8, a novel family of tissue-selective mediators of angiogenesis, endothelial phenotype, and function. 2003 , 13, 276-82		43
2209	The hypoxic response of tumors is dependent on their microenvironment. 2003 , 4, 133-46		345
2208	Angiogenesis and bone repair. 2003 , 8, 980-9		567
2207	Retinal and choroidal angiogenesis: pathophysiology and strategies for inhibition. 2003 , 22, 721-48		193
2206	From the cradle to the clinic: VEGF in developmental, physiological, and pathological angiogenesis. 2003 , 69, 363-74		48
2205	VEGF(121) and VEGF(165) regulate blood vessel diameter through vascular endothelial growth factor receptor 2 in an in vitro angiogenesis model. 2003 , 83, 1873-85		104
2204	Angiogenesis in health and disease. <i>Nature Medicine</i> , 2003 , 9, 653-60	50.5	3248
2203	Measuring tumour vascular response to antivasular and antiangiogenic drugs. 2003 , 76 Spec No 1, S23-35		61
2202	Arteriogenesis induced by intramyocardial vascular endothelial growth factor 165 gene transfer in chronically ischemic pigs. 2003 , 14, 1307-18		39
2201	Novel approaches in oncology at AstraZeneca. 2003 , 1, 3-8		7

2200	Thicker than blood: conserved mechanisms in Drosophila and vertebrate hematopoiesis. 2003 , 5, 673-90	317
2199	Angiogenesis: new opportunities and solutions for drug development. Predictive markers for antiangiogenic drugs. 2003 , 12, 2001-4	
2198	Phosphorylation and action of the immunomodulator FTY720 inhibits vascular endothelial cell growth factor-induced vascular permeability. 2003 , 278, 47281-90	318
2197	Etk/Bmx transactivates vascular endothelial growth factor 2 and recruits phosphatidylinositol 3-kinase to mediate the tumor necrosis factor-induced angiogenic pathway. 2003 , 278, 51267-76	118
2196	Up-regulation of matrix metalloproteinase-9 in T lymphocytes of mammary tumor bearers: role of vascular endothelial growth factor. 2003 , 171, 4340-51	70
2195	Building a better Trap. 2003 , 100, 8624-5	19
2194	Clinical symptoms in patients with myositis-an acquired metabolic myopathy?. 2003 , 15, 675-8	8
2193	Lymphangiogenesis. 2003 , 5, 59-66	
2192	Vascular endothelial growth factor as a therapeutic target in cancer. 2004 , 61, S4-11	28
2191	Mast cell-derived angiopoietin-1 plays a critical role in the growth of plasma cell tumors. 2004 , 114, 1317-25	100
2190	Angiogenesis in leukemia and lymphoma. 2004 , 121, 221-38	4
2189	Vascular Endothelial Growth Factor Receptors. 2004 , 337-342	
2188	Gene transfer for therapeutic vascular growth in myocardial and peripheral ischemia. 2004 , 52, 117-64	24
2187	Development of coronary vessels. 2004 , 62, 225-59	48
2186	Vascular endothelial growth factor and its receptor, Flk-1/KDR, are cytoprotective in the extravascular compartment of the ovarian follicle. 2004 , 145, 2896-905	124
2185	The c-Cbl/CD2AP complex regulates VEGF-induced endocytosis and degradation of Flt-1 (VEGFR-1). 2004 , 18, 929-31	80
2184	A vascular gene trap screen defines RasGRP3 as an angiogenesis-regulated gene required for the endothelial response to phorbol esters. 2004 , 24, 10515-28	42
2183	Down syndrome critical region protein 1 (DSCR1), a novel VEGF target gene that regulates expression of inflammatory markers on activated endothelial cells. 2004 , 104, 149-58	131

2182	Coordinated regression of adrenocortical endocrine and endothelial compartments under adrenocorticotropin deprivation. 2004 , 30, 543-9	2
2181	The role of alpha-blockers in the management of prostate cancer. 2004 , 5, 1279-85	28
2180	Complex role of heme oxygenase-1 in angiogenesis. 2004 , 6, 858-66	70
2179	Vascular endothelial growth factor stimulates skeletal muscle regeneration in vivo. 2004 , 10, 844-54	231
2178	Thromboxane A2 receptor signaling inhibits vascular endothelial growth factor-induced endothelial cell differentiation and migration. 2004 , 95, 372-9	84
2177	Serum response factor is a critical requirement for VEGF signaling in endothelial cells and VEGF-induced angiogenesis. 2004 , 18, 1264-6	72
2176	A novel snake venom vascular endothelial growth factor (VEGF) predominantly induces vascular permeability through preferential signaling via VEGF receptor-1. 2004 , 279, 46304-14	76
2175	The minimal active domain of endostatin is a heparin-binding motif that mediates inhibition of tumor vascularization. 2004 , 64, 9012-7	47
2174	Physiological levels of amyloid peptides stimulate the angiogenic response through FGF-2. 2004 , 18, 1943-5	44
2173	Deletion of Vhlh in chondrocytes reduces cell proliferation and increases matrix deposition during growth plate development. 2004 , 131, 2497-508	105
2172	Angiogenesis-dependent and independent phases of intimal hyperplasia. 2004 , 110, 2436-43	157
2171	Estrogen receptor-alpha agonists promote angiogenesis in human myometrial microvascular endothelial cells. 2004 , 11, 529-35	17
2170	Vascular endothelial growth factor gene polymorphisms and pre-eclampsia. 2004 , 10, 321-4	63
2169	The axonal attractant Netrin-1 is an angiogenic factor. 2004 , 101, 16210-5	254
2168	Disruption of the Rb--Raf-1 interaction inhibits tumor growth and angiogenesis. 2004 , 24, 9527-41	90
2167	Mechanisms and regulation of lung vascular development. 2004 , 64, 73-99	20
2166	Vascular endothelial growth factor and related molecules in acute lung injury. 2004 , 97, 1605-17	148
2165	Cathepsin D processes human prolactin into multiple 16K-like N-terminal fragments: study of their antiangiogenic properties and physiological relevance. 2004 , 18, 2522-42	68

2164	Vascular endothelial growth factor (VEGF)-D and VEGF-A differentially regulate KDR-mediated signaling and biological function in vascular endothelial cells. 2004 , 279, 36148-57	63
2163	Vascular endothelial growth factor165 resolves glomerular inflammation and accelerates glomerular capillary repair in rat anti-glomerular basement membrane glomerulonephritis. 2004 , 15, 2655-65	74
2162	Differential activation of the phosphatidylinositol 3'-kinase/Akt survival pathway by ionizing radiation in tumor and primary endothelial cells. 2004 , 64, 5398-406	46
2161	Advances in immune-based therapies of renal cell carcinoma. 2004 , 4, 1081-96	29
2160	Evidence for the involvement of SDF-1 and CXCR4 in the disruption of endothelial cell-branching morphogenesis and angiogenesis by TNF-alpha and IFN-gamma. 2004 , 76, 217-26	41
2159	The Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) K1 protein induces expression of angiogenic and invasion factors. 2004 , 64, 2774-81	128
2158	Differential expression of vascular endothelial growth factor (VEGF), endocrine gland derived-VEGF, and VEGF receptors in human placentas from normal and preeclamptic pregnancies. 2004 , 89, 2484-90	99
2157	Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. 2004 , 64, 5617-23	180
2156	Cytophaga-flavobacterium gliding motility. 2004 , 7, 63-71	59
2155	PPARalpha activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1-dependent DNA binding and transactivation. 2004 , 94, 324-32	98
2154	Vascular endothelial growth factor receptor-3 in hypoxia-induced vascular development. 2004 , 18, 1507-15	39
2153	Annexin A2 is a novel RNA-binding protein. 2004 , 279, 8723-31	97
2152	Vascular endothelial growth factor and its receptors in embryonic zebrafish blood vessel development. 2004 , 62, 127-52	24
2151	Transforming growth factor-beta1 stimulates vascular endothelial growth factor 164 via mitogen-activated protein kinase kinase 3-p38alpha and p38delta mitogen-activated protein kinase-dependent pathway in murine mesangial cells. 2004 , 279, 33213-9	47
2150	Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist. 2005 , 15, 1C-6C	45
2149	Modulating angiogenesis: more vs less. 2004 , 292, 972-7	75
2148	Genetics in zebrafish, mice, and humans to dissect congenital heart disease: insights in the role of VEGF. 2004 , 62, 189-224	27
2147	The transcriptional activation program of human neutrophils in skin lesions supports their important role in wound healing. 2004 , 172, 7684-93	164

2146	Integrins and angiogenesis. 2004 , 64, 207-38	230
2145	The multifunctional role of IGF-1 in peripheral nerve regeneration. 2004 , 26, 204-10	57
2144	Induction by hypoxia combined with low glucose or low bicarbonate and high posttranslational stability upon reoxygenation contribute to carbonic anhydrase IX expression in cancer cells. 2004 , 24, 995	11
2143	Effects of potent VEGF blockade on experimental Wilms tumor and its persisting vasculature. 2004 , 25, 549	3
2142	Dead Cells Don't Form Tumors: HIF-Dependent Cytotoxins. 2004 , 3, 155-158	9
2141	Dual hormonal regulation of endocrine tissue mass and vasculature by adrenocorticotropin in the adrenal cortex. 2004 , 145, 4320-9	53
2140	Hirudo medicinalis: avascular tissues for clear-cut angiogenesis studies?. 2004 , 10, 1979-88	20
2139	Identification of placenta growth factor determinants for binding and activation of Flt-1 receptor. 2004 , 279, 43929-39	42
2138	Vascular endothelial-cadherin regulates cytoskeletal tension, cell spreading, and focal adhesions by stimulating RhoA. 2004 , 15, 2943-53	156
2137	SCL interacts with VEGF to suppress apoptosis at the onset of hematopoiesis. 2004 , 131, 693-702	33
2136	Podocyte-derived vascular endothelial growth factor mediates the stimulation of alpha3(IV) collagen production by transforming growth factor-beta1 in mouse podocytes. 2004 , 53, 2939-49	90
2135	Age-related changes in vascular endothelial growth factor dependency and angiopoietin-1-induced plasticity of adult blood vessels. 2004 , 94, 984-92	102
2134	Characterization of a peptide inhibitor of Janus kinase 2 that mimics suppressor of cytokine signaling 1 function. 2004 , 172, 7510-8	77
2133	Anti-chemorepulsive effects of vascular endothelial growth factor and placental growth factor-2 in dorsal root ganglion neurons are mediated via neuropilin-1 and cyclooxygenase-derived prostanoid production. 2004 , 279, 30654-61	38
2132	Mice transgenic for IL-1 receptor antagonist protein are resistant to herpetic stromal keratitis: possible role for IL-1 in herpetic stromal keratitis pathogenesis. 2004 , 172, 3736-44	54
2131	Decay-accelerating factor induction on vascular endothelium by vascular endothelial growth factor (VEGF) is mediated via a VEGF receptor-2 (VEGF-R2)- and protein kinase C-alpha/epsilon (PKCalpha/epsilon)-dependent cytoprotective signaling pathway and is inhibited by cyclosporin A. 2004 , 279, 41611-8	45
2130	The tyrosine kinase inhibitor ZD6474 inhibits tumour growth in an intracerebral rat glioma model. 2004 , 91, 1174-80	45
2129	Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. 2004 , 167, 223-9	383

2128	Pathogenesis of high altitude pulmonary edema: does alveolar epithelial lining fluid vascular endothelial growth factor exacerbate capillary leak?. 2004 , 5, 399-409	28
2127	Cell-deregulated liberation of VEGF121 from fibrin implants induces local and controlled blood vessel growth. 2004 , 94, 1124-32	327
2126	Common cues in vascular and axon guidance. 2004 , 19, 348-54	29
2125	Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. 2004 , 22, 2184-91	1682
2124	Cortical microvascular remodeling in the stenotic kidney: role of increased oxidative stress. 2004 , 24, 1854-9	132
2123	Adenoviral gene transfer with soluble vascular endothelial growth factor receptors impairs angiogenesis and perfusion in a murine model of hindlimb ischemia. 2004 , 110, 2424-9	75
2122	Antioxidant intervention prevents renal neovascularization in hypercholesterolemic pigs. 2004 , 15, 1816-25	66
2121	Inducible nitric oxide synthase-derived nitric oxide promotes glomerular angiogenesis via upregulation of vascular endothelial growth factor receptors. 2004 , 15, 2307-19	23
2120	Metastasis models: the green fluorescent revolution?. 2004 , 25, 2285-92	24
2119	VEGFA is necessary for chondrocyte survival during bone development. 2004 , 131, 2161-71	301
2118	Thioredoxin reductase regulates angiogenesis by increasing endothelial cell-derived vascular endothelial growth factor. 2004 , 50, 221-31	40
2117	c-Myc as a therapeutic target in cancer. 2004 , 4, 289-302	76
2116	Targeting protein kinases in cancer therapy: a success?. 2004 , 4, 1113-24	41
2115	Angiogenic imbalance in the pathophysiology of preeclampsia: Newer insights. 2004 , 24, 548-556	84
2114	Vascular endothelial growth factor and the nervous system. 2004 , 30, 427-46	86
2113	Lymphangiogenic growth factors as markers of tumor metastasis. 2004 , 112, 539-49	59
2112	Kaposi sarcoma herpesvirus-induced cellular reprogramming contributes to the lymphatic endothelial gene expression in Kaposi sarcoma. 2004 , 36, 687-93	379
2111	Isolated small intestinal segments support auxiliary livers with maintenance of hepatic functions. <i>Nature Medicine</i> , 2004 , 10, 749-53	50.5 27

2110	Direct evidence that the VEGF-specific antibody bevacizumab has antivasular effects in human rectal cancer. <i>Nature Medicine</i> , 2004 , 10, 145-7	50.5	1648
2109	Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. 2004 , 3, 391-400		1872
2108	VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis. 2004 , 23, 2800-10		268
2107	Adenovirus-based vascular endothelial growth factor gene delivery to human pancreatic islets. 2004 , 11, 1105-16		43
2106	eIF4E--from translation to transformation. 2004 , 23, 3172-9		372
2105	Destabilization of vascular endothelial growth factor mRNA by the zinc-finger protein TIS11b. 2004 , 23, 8673-80		100
2104	Vascular endothelial growth factor-A is expressed both on lymphoma cells and endothelial cells in angioimmunoblastic T-cell lymphoma and related to lymphoma progression. 2004 , 84, 1512-9		82
2103	Assembly and patterning of vertebrate blood vessels. 2004 , 14, 138-43		9
2102	Sustained delivery of vascular endothelial growth factor with alginate beads. 2004 , 96, 463-72		207
2101	Human/mouse cross-reactive anti-VEGF receptor 2 recombinant antibodies selected from an immune b9 allotype rabbit antibody library. 2004 , 288, 149-64		36
2100	Autocrine signaling in carcinoma: VEGF and the alpha6beta4 integrin. 2004 , 14, 115-22		60
2099	Therapeutic targeting of the tumor vasculature. 2004 , 14, 222-32		21
2098	Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. 2004 , 102, 61-85		138
2097	Evidence for the functional activity of hypoxia-inducible transcription factors overexpressed in preeclamptic placentae. 2004 , 25, 763-9		174
2096	Early clinical data with small-molecule vascular endothelial growth factor tyrosine kinase receptor inhibitors. 2004 , 6, 74-6		1
2095	Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. 2004 , 31, 2-11		276
2094	Future directions in the use of antiangiogenic agents in patients with colorectal cancer. 2004 , 31, 17-21		37
2093	Genomic and proteomic analyses of vascular endothelial growth factor and insulin-like growth factor-binding protein 3 in lung adenocarcinomas. 2004 , 5, 307-12		19

2092	What's new in colon and rectal surgery. 2004 , 199, 917-23	3
2091	Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine. 2004 , 498, 9-18	37
2090	Redox-dependent effects of nitric oxide on microvascular integrity in oxygen-induced retinopathy. 2004 , 37, 1885-94	54
2089	Genetic dissection of tumor angiogenesis: are PlGF and VEGFR-1 novel anti-cancer targets?. 2004 , 1654, 79-94	32
2088	Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. 2004 , 6, 485-95	450
2087	Evidence supporting a role for blockade of the vascular endothelial growth factor system in the pathophysiology of preeclampsia. Young Investigator Award. 2004 , 190, 1541-7; discussion 1547-50	281
2086	Regulation of VEGF-A, VEGFR-I, thrombospondin-1, -2, and -3 expression in a human pituitary cell line (HP75) by TGFbeta1, bFGF, and EGF. 2004 , 24, 141-6	18
2085	Rebamipide activates genes encoding angiogenic growth factors and Cox2 and stimulates angiogenesis: a key to its ulcer healing action?. 2004 , 49, 202-9	60
2084	Differential expression of VEGF-A mRNA by 17beta-estradiol in breast tumor cells lacking classical ER-alpha may be mediated through a variant form of ER-alpha. 2004 , 262, 215-24	5
2083	Transplanted bone marrow cells preferentially home to the vessels of in situ generated murine tumors rather than of normal organs. 2004 , 22, 86-92	27
2082	Molecular regulation of lymphangiogenesis. 2004 , 1014, 76-87	29
2081	Increase of both angiogenesis and bone mass in response to exercise depends on VEGF. 2004 , 19, 1471-80	81
2080	Increased VEGF expression in the epiphyseal cartilage after ischemic necrosis of the capital femoral epiphysis. 2004 , 19, 2041-8	40
2079	Vascular endothelial growth factor in colorectal cancer. 2004 , 19, 510-7	44
2078	Coronary artery anomalies. Part I: Recent insights from molecular embryology. 2004 , 93, 929-37	21
2077	In vivo videomicroscopy reveals differential effects of the vascular-targeting agent ZD6126 and the anti-angiogenic agent ZD6474 on vascular function in a liver metastasis model. 2004 , 7, 157-64	20
2076	The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. 2004 , 7, 225-33	138
2075	VEGF treatment induces signaling pathways that regulate both actin polymerization and depolymerization. 2004 , 7, 313-21	53

2074	Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. 2004 , 7, 335-45	321
2073	The VEGF receptor tyrosine kinase inhibitor, ZD6474, inhibits angiogenesis and affects microvascular architecture within an orthotopically implanted renal cell carcinoma. 2004 , 7, 347-54	32
2072	Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma. 2004 , 11, 517-27	133
2071	Isoindolinone ureas: a novel class of KDR kinase inhibitors. 2004 , 14, 4505-9	27
2070	Vascular endothelial growth factor blockade reduces plasma cytokines in a murine model of polymicrobial sepsis. 2004 , 28, 271-8	32
2069	Vascular endothelial cadherin and beta-catenin in human fetoplacental vessels of pregnancies complicated by Type 1 diabetes: associations with angiogenesis and perturbed barrier function. 2004 , 47, 695-709	41
2068	Molecular targeting of angiogenesis for imaging and therapy. 2004 , 31, 1327-41	29
2067	New molecular targets for treatment of lymphoma. 2004 , 6, 360-8	2
2066	Angiopoietins in tumours: the angiogenic switch. 2004 , 204, 1-10	183
2065	Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?. 2004 , 59, 91-100	34
2064	Microvascular development: learning from pancreatic islets. 2004 , 26, 1069-75	97
2063	The effects of endothelin-1 on degranulation, cytokine, and growth factor production by skin-derived mast cells. 2004 , 34, 1910-9	59
2062	Secretion of cytokines and growth factors into autosomal dominant polycystic kidney disease liver cyst fluid. 2004 , 40, 836-846	67
2061	Angiogenesis in chronic inflammatory liver disease. 2004 , 39, 1185-95	167
2060	Vascular interference: a blockade to tumor epithelial growth. 2004 , 39, 1491-4	5
2059	Intussusceptive angiogenesis: its emergence, its characteristics, and its significance. 2004 , 231, 474-88	269
2058	Differential regulation of VEGF, HIF1alpha and angiopoietin-1, -2 and -4 by hypoxia and ionizing radiation in human glioblastoma. 2004 , 108, 833-8	45
2057	Structural and functional characteristics of S1P receptors. 2004 , 92, 913-22	389

2056	Vascular endothelial growth factor expression in heart of rats exposed to hypobaric hypoxia: differential response between mRNA and protein. 2004 , 200, 107-15	20
2055	Two-dimensional multiarray formation of hepatocyte spheroids on a microfabricated PEG-brush surface. 2004 , 5, 850-5	115
2054	Imaging of angiogenesis. 2004 , 11, 617-33	35
2053	Stimulation of in vivo angiogenesis by cytokine-loaded hyaluronic acid hydrogel implants. 2004 , 25, 2789-98	135
2052	Herpes simplex virus amplicon delivery of a hypoxia-inducible angiogenic inhibitor blocks capillary formation in hepatocellular carcinoma. 2004 , 8, 812-22; discussion 822-3	9
2051	Experimental ischemia of porcine growth cartilage produces lesions of osteochondrosis. 2004 , 22, 1201-9	61
2050	The angiogenic status of B-CLL B cells: role of the VEGF receptors. 2004 , 28, 221-2	16
2049	Inhibitors of angiogenesis and cancer-related receptor tyrosine kinases. 2004 , 8, 432-41	39
2048	Oligonucleotides used as template calibrators for general application in quantitative polymerase chain reaction. 2004 , 335, 299-304	8
2047	VEGF-A promotes tissue repair-associated lymphatic vessel formation via VEGFR-2 and the alpha1beta1 and alpha2beta1 integrins. 2004 , 18, 1111-3	263
2046	Dopamine in vivo inhibits VEGF-induced phosphorylation of VEGFR-2, MAPK, and focal adhesion kinase in endothelial cells. 2004 , 287, H1554-60	66
2045	Vascular endothelial growth factor as a target for anticancer therapy. 2004 , 9 Suppl 1, 2-10	462
2044	Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. 2004 , 64, 4040-8	351
2043	Laurenditerpenol, a new diterpene from the tropical marine alga <i>Laurenciaintricata</i> that potently inhibits HIF-1 mediated hypoxic signaling in breast tumor cells. 2004 , 67, 2002-7	70
2042	Vascular endothelial growth factor stimulates differential signaling pathways in in vivo microcirculation. 2004 , 287, H1590-8	64
2041	Experimental ischemia of porcine growth cartilage produces lesions of osteochondrosis. 2004 ,	
2040	Perillyl alcohol is an angiogenesis inhibitor. 2004 , 311, 568-75	67
2039	The vascular endothelial growth factor family and its receptors. 2004 , 18, 951-71, vii	45

2038	Evidence for a proangiogenic activity of TNF-related apoptosis-inducing ligand. 2004 , 6, 364-73	47
2037	Angiogenesis in colorectal cancer: therapeutic implications and future directions. 2004 , 18, 1087-119, ix	5
2036	Pancreatic cancer: future outlook, promising trials, newer systemic agents, and strategies from the Gastrointestinal Intergroup Pancreatic Cancer Task Force. 2004 , 13, 751-60, xi	9
2035	Vascular endothelial growth factors C and D in colorectal cancers. 2004 , 4, 23-5	3
2034	Effects of gene delivery on collateral development in chronic hypoperfusion: diverse effects of angiopoietin-1 versus vascular endothelial growth factor. 2004 , 44, 897-903	6
2033	Blood vessel signals during development and beyond. 2004 , 62, 1-36	8
2032	Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. 2004 , 350, 2335-42	8493
2031	Vascular endothelial growth factor: basic science and clinical progress. 2004 , 25, 581-611	2749
2030	Oxygen sensing in the circulation: "cross talk" between red blood cells and the vasculature. 2004 , 6, 1000-10	20
2029	Blood vessel patterning at the embryonic midline. 2004 , 62, 55-85	36
2028	Targeting angiogenesis in cancer: clinical development of bevacizumab. 2004 , 1, 39-43	76
2027	Enhancement of pleural dissemination and lymph node metastasis of intrathoracic lung cancer cells by vascular endothelial growth factors (VEGFs). 2004 , 45, 325-37	43
2026	Preclinical data targeting vascular endothelial growth factor in colorectal cancer. 2004 , 4 Suppl 2, S55-61	10
2025	What is the purpose of the embryonic heart beat? Or how facts can ultimately prevail over physiological dogma. 2004 , 77, 333-45	73
2024	JunD reduces tumor angiogenesis by protecting cells from oxidative stress. 2004 , 118, 781-94	478
2023	VEGF expression in adult permanent thyroid cartilage: implications for lack of cartilage ossification. 2004 , 35, 543-52	20
2022	Focal changes in blood supply during normal epiphyseal growth are central in the pathogenesis of osteochondrosis in pigs. 2004 , 35, 1294-306	91
2021	New roles for VEGF in nervous tissue—beyond blood vessels. 2004 , 187, 246-53	223

2020	Anti-vascular tumor therapy: recent advances, pitfalls and clinical perspectives. 2004 , 7, 125-38	62
2019	Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. 2004 , 7, 289-300	72
2018	Bmx is a downstream Rap1 effector in VEGF-induced endothelial cell activation. 2004 , 320, 70-5	9
2017	VEGF selectively induces Down syndrome critical region 1 gene expression in endothelial cells: a mechanism for feedback regulation of angiogenesis?. 2004 , 321, 648-56	62
2016	Angiogenic and cardiac functional effects of dual gene transfer of VEGF-A165 and PDGF-BB after myocardial infarction. 2004 , 322, 292-6	27
2015	ANP and BNP but not VEGF are regionally overexpressed in ischemic human myocardium. 2004 , 322, 287-91	21
2014	Heterodimerization with vascular endothelial growth factor receptor-2 (VEGFR-2) is necessary for VEGFR-3 activity. 2004 , 324, 909-15	51
2013	Plasminogen activator inhibitor-1 increases the expression of VEGF in human glioma cells. 2004 , 294, 130-9	19
2012	Differential activation of vascular genes by hypoxia in primary endothelial cells. 2004 , 299, 476-85	99
2011	Dynamic regulation of gene expression by the Flt-1 kinase and Matrigel in endothelial tubulogenesis. 2004 , 84, 185-92	12
2010	Simvastatin enhances myocardial angiogenesis induced by vascular endothelial growth factor gene transfer. 2004 , 37, 1235-44	10
2009	Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. 2004 , 165, 35-52	632
2008	Regulated angiogenesis and vascular regression in mice overexpressing vascular endothelial growth factor in airways. 2004 , 165, 1071-85	104
2007	Role of eNOS in neovascularization: NO for endothelial progenitor cells. 2004 , 10, 143-5	187
2006	VEGF: necessary to prevent motoneuron degeneration, sufficient to treat ALS?. 2004 , 10, 275-82	38
2005	Involvement of the vascular endothelial growth factor receptor-1 in murine hepatocellular carcinoma development. 2004 , 41, 97-103	27
2004	Angiogenesis and hepatocellular carcinoma. 2004 , 41, 864-80	286
2003	Endocrine and paracrine control of follicular development and ovulation rate in farm species. 2004 , 82-83, 461-77	148

2002	Effect of inhibition of multiple steps of angiogenesis in syngeneic murine pleural mesothelioma. 2004 , 78, 1042-51; discussion 1042-51	21
2001	Vascular morphogenesis and the formation of vascular networks. 2004 , 6, 479-82	8
2000	Androgen receptor YAC transgenic mice recapitulate SBMA motor neuronopathy and implicate VEGF164 in the motor neuron degeneration. 2004 , 41, 687-99	155
1999	Placental growth factor induces FosB and c-Fos gene expression via Flt-1 receptors. 2004 , 557, 93-8	23
1998	Heritability of circulating growth factors involved in the angiogenesis in healthy human population. 2004 , 27, 152-8	30
1997	Heart valve development: endothelial cell signaling and differentiation. 2004 , 95, 459-70	504
1996	HIF-VEGF-VEGFR-2, TNF-alpha and IGF pathways are upregulated in critical human skeletal muscle ischemia as studied with DNA array. 2004 , 174, 111-20	82
1995	Effect of VEGF receptor-2 antibody on vascular function and oxygenation in spontaneous and transplanted tumors. 2004 , 72, 221-30	54
1994	Urine vascular endothelial growth factor-A is not a useful marker for endometriosis. 2004 , 81, 1507-12	16
1993	Direct injection of vascular endothelial growth factor into the ovary of mice promotes follicular development. 2004 , 82 Suppl 3, 1101-5	31
1992	Effects of gene delivery on collateral development in chronic hypoperfusionDiverse effects of angiopoietin-1 versus vascular endothelial growth factor. 2004 , 44, 897-903	24
1991	Angiogenic switch in multiple myeloma. 2004 , 9, 377-81	20
1990	The design and preclinical testing of Ad5FGF-4 to treat chronic myocardial ischaemia*1. 2004 , 6, E12-E17	0
1989	Tumor endothelial markers: new targets for cancer therapy. 2004 , 16, 44-9	108
1988	Cyclosporin A toxicity, and more: vascular endothelial growth factor (VEGF) steps forward. 2004 , 19, 285-8	15
1987	Induction of cutaneous delayed-type hypersensitivity reactions in VEGF-A transgenic mice results in chronic skin inflammation associated with persistent lymphatic hyperplasia. 2004 , 104, 1048-57	258
1986	VEGF causes pulmonary hemorrhage, hemosiderosis, and air space enlargement in neonatal mice. 2004 , 287, L134-42	101
1985	DNA microarray analysis of neonatal mouse lung connects regulation of KDR with dexamethasone-induced inhibition of alveolar formation. 2004 , 286, L411-9	32

1984	Esophageal and Gastrointestinal Microcirculation: Essential for Mucosal Protection, a Target for Injury, and a Critical Component of Injury and Ulcer Healing. 2005 , 49-61	1
1983	Signal transduction in angiogenesis. 2005 , 267-300	6
1982	Role of Immunohistochemical Expression of Cyclooxygenase-2 in Ovarian Serous Carcinoma. 2005 , 4, 381-385	
1981	Targets and Approaches for Cancer Drug Discovery. 2005 , 1343-1373	
1980	Angiogenesis in lymphoproliferative disorders: a therapeutic target?. 2005 , 12, 279-83	5
1979	New treatments for denervating diseases. 2005 , 20, 258-62	3
1978	Combined vascular endothelial growth factor and platelet-derived growth factor inhibition in rat cardiac allografts: beneficial effects on inflammation and smooth muscle cell proliferation. 2005 , 79, 182-9	31
1977	Role of vascular endothelial growth factor receptor 1 and vascular endothelial growth factor receptor 2 in the vasodilator response to vascular endothelial growth factor in the neonatal piglet lung. 2005 , 33, 860-6	20
1976	Update on angiogenesis inhibitors. 2005 , 17, 578-83	64
1975	A phase I clinical trial of a ribozyme-based angiogenesis inhibitor targeting vascular endothelial growth factor receptor-1 for patients with refractory solid tumors. 2005 , 4, 948-55	69
1974	Thrombopoietin gene transfer-mediated enhancement of angiogenic responses to acute ischemia. 2005 , 97, 337-45	25
1973	Microarray analysis of mechanical shear effects on flexor tendon cells. 2005 , 116, 1393-404; discussion 1405-6	34
1972	Plasma vascular endothelial growth factor in severe sepsis. 2005 , 23, 35-8	132
1971	Vasculogenesis and Angiogenesis in the Diabetic Placenta. 2005 , 17, 110-126	3
1970	Wnt signaling can repress thrombospondin-1 expression in colonic tumorigenesis. 2005 , 4, 1361-6	17
1969	VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate. 2005 , 26, 98-101	85
1968	Inhibition of vascular endothelial growth factor receptor 2-mediated endothelial cell activation by Axl tyrosine kinase receptor. 2005 , 105, 1970-6	90
1967	Vascular endothelial growth factor regulation of Weibel-Palade-body exocytosis. 2005 , 105, 207-14	68

1966	Tumor metastasis but not tumor growth is dependent on Src-mediated vascular permeability. 2005 , 105, 1508-14	106
1965	Vascular endothelial growth factor promotes sensitivity to ultraviolet B-induced cutaneous photodamage. 2005 , 105, 2392-9	55
1964	Roles of vascular endothelial growth factor receptor 3 signaling in differentiation of mouse embryonic stem cell-derived vascular progenitor cells into endothelial cells. 2005 , 105, 2372-9	43
1963	Thrombopoietin enhances expression of vascular endothelial growth factor (VEGF) in primitive hematopoietic cells through induction of HIF-1alpha. 2005 , 105, 4258-63	88
1962	The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. 2005 , 105, 1383-95	277
1961	CLL, but not normal, B cells are dependent on autocrine VEGF and alpha4beta1 integrin for chemokine-induced motility on and through endothelium. 2005 , 105, 4813-9	65
1960	Erratum for vol. 104, p. 2368. 2005 , 105, 1395-1395	
1959	Direct recruitment of CRK and GRB2 to VEGFR-3 induces proliferation, migration, and survival of endothelial cells through the activation of ERK, AKT, and JNK pathways. 2005 , 106, 3423-31	129
1958	Neuropilin-1 regulates attachment in human endothelial cells independently of vascular endothelial growth factor receptor-2. 2005 , 105, 1992-9	102
1957	Vasculogenesis. 909-924	
1956	Different cascades in the signaling pathway of two vascular endothelial growth factor (VEGF) receptors for the VEGF-mediated murine hepatocellular carcinoma development. 2005 , 13, 853	
1955	Effects of exopolysaccharide fraction (EPSF) from a cultivated <i>Cordyceps sinensis</i> fungus on c-Myc, c-Fos, and VEGF expression in B16 melanoma-bearing mice. 2005 , 201, 745-50	36
1954	Trapping of growth factors by catechins: a possible therapeutical target for prevention of proliferative diseases. 2005 , 16, 259-66	47
1953	Impact of adjuvant inhibition of vascular endothelial growth factor receptor tyrosine kinases on tumor growth delay and local tumor control after fractionated irradiation in human squamous cell carcinomas in nude mice. 2005 , 61, 908-14	39
1952	Structural basis for the interaction of a vascular endothelial growth factor mimic peptide motif and its corresponding receptors. 2005 , 12, 1075-83	35
1951	In vitro characterization of vascular endothelial growth factor and dexamethasone releasing hydrogels for implantable probe coatings. 2005 , 26, 3285-97	89
1950	Current issues in Wilms tumor management. 2005 , 29, 221-60	32
1949	Gorham-Stout syndrome: a monocyte-mediated cytokine propelled disease. 2006 , 21, 207-18	53

1948	Genetic variations in vascular endothelial growth factor and endothelial nitric oxide synthase and their contributions to human disease. 2005 , 12, 129-140	13
1947	Angiogenesis: the major abnormality of the keratin-14 IL-4 transgenic mouse model of atopic dermatitis. 2005 , 12, 455-76	22
1946	VEGF as a therapeutic target in cancer. 2005 , 69 Suppl 3, 11-6	450
1945	Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. 2005 , 23, 1011-27	2248
1944	Intravital imaging of tumour vascular networks using multi-photon fluorescence microscopy. 2005 , 57, 135-52	122
1943	Systemic therapy for colorectal cancer. 2005 , 352, 476-87	925
1942	Review: hypoxia-inducible factor-1 (HIF-1): a novel transcription factor in immune reactions. 2005 , 25, 297-310	201
1941	Angiogenesis: update 2005. 2005 , 3, 1835-42	235
1940	Tumor cell-associated neuropilin-1 and vascular endothelial growth factor expression as determinants of tumor growth in neuroblastoma. 2005 , 25, 178-87	23
1939	Non-steroidal anti-inflammatory drugs for the prevention and treatment of cancer. 2005 , 258, 115-23	93
1938	The MAPK-AP-1/Runx2 signalling axes are implicated in chondrosarcoma pathobiology either independently or via up-regulation of VEGF. 2005 , 47, 565-74	32
1937	Review article: angiogenesis soluble factors as liver disease markers. 2005 , 22, 23-30	23
1936	The realisation of targeted antitumour therapy. 2005 , 92 Suppl 1, S2-5	16
1935	ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity. 2005 , 92 Suppl 1, S6-13	133
1934	A comparison of the effects of unfractionated heparin, dalteparin and danaparoid on vascular endothelial growth factor-induced tumour angiogenesis and heparanase activity. 2005 , 146, 333-43	35
1933	Intracellular pathways triggered by the selective FLT-1-agonist placental growth factor in vascular smooth muscle cells exposed to hypoxia. 2005 , 146, 568-75	55
1932	Remodeling of cortical bone allografts mediated by adherent rAAV-RANKL and VEGF gene therapy. <i>Nature Medicine</i> , 2005 , 11, 291-7	50.5 231
1931	VEGF: multitasking in ALS. 2005 , 8, 5-7	21

1930	Metazoan mechanotransduction mystery finally solved. 2005 , 8, 7-8	7
1929	Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. 2005 , 8, 85-92	429
1928	Pegaptanib sodium. 2005 , 4, 187-8	50
1927	Vector-based RNA interference against vascular endothelial growth factor-A significantly limits vascularization and growth of prostate cancer in vivo. 2005 , 12, 926-34	31
1926	Mechanisms of hyperbaric oxygen-induced neuroprotection in a rat model of subarachnoid hemorrhage. 2005 , 25, 554-71	176
1925	The interaction between KDR and interleukin-3 receptor (IL-3R) beta common modulates tumor neovascularization. 2005 , 24, 6394-405	13
1924	Therapeutic angiogenesis and vasculogenesis for tissue regeneration. 2005 , 90, 315-26	145
1923	VEGF contributes to mammary tumor growth in transgenic mice through paracrine and autocrine mechanisms. 2005 , 85, 608-23	60
1922	Pathophysiological consequences of VEGF-induced vascular permeability. 2005 , 437, 497-504	655
1921	From angiogenesis to neuropathology. 2005 , 438, 954-9	416
1920	Angiogenesis as a therapeutic target. 2005 , 438, 967-74	2127
1919	Understanding heart development and congenital heart defects through developmental biology: a segmental approach. 2005 , 45, 107-18	26
1918	Hyaluronan promotes tumor lymphangiogenesis and intralymphatic tumor growth in xenografts. 2005 , 37, 601-6	11
1917	Developing animals flout prominent assumptions of ecological physiology. 2005 , 141, 430-9	36
1916	Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. 2005 , 8, 299-309	1338
1915	A mouse model for studying therapy-induced cancers. 2005 , 8, 271-3	3
1914	Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed. 2005 , 8, 269-71	57
1913	Immunohistochemical study about the Flt-1/VEGFR1 expression in the gastrointestinal tract of mouse, rat, dog, swine and monkey. 2005 , 57, 149-59	10

1912	Expression of pulmonary VEGF family declines with age and is further down-regulated in lipopolysaccharide (LPS)-induced lung injury. 2005 , 40, 315-23	34
1911	Guidance of vascular and neural network formation. 2005 , 15, 108-15	152
1910	Monte Carlo simulations of VEGF binding to cell surface receptors in vitro. 2005 , 1746, 95-107	35
1909	Aggravation of hemorrhagic transformation by early intraarterial infusion of low-dose vascular endothelial growth factor after transient focal cerebral ischemia in rats. 2005 , 1049, 95-103	44
1908	Stimulation of HIF-1alpha, HIF-2alpha, and VEGF by prolyl 4-hydroxylase inhibition in human lung endothelial and epithelial cells. 2005 , 38, 1002-13	78
1907	Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: role of vascular endothelial growth factor. 2005 , 46, 938-48	166
1906	Targeting vascular endothelial growth factor and angiogenesis for the treatment of colorectal cancer. 2005 , 32, 61-8	33
1905	Current management of advanced non-small cell lung cancer: targeted therapy. 2005 , 32, 315-28	39
1904	The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors. 2005 , 32, S23-9	20
1903	Defects in activation of nitric oxide synthases occur during delayed angiogenesis in aging. 2005 , 126, 467-73	30
1902	Endothelial cell proliferation and progenitor maturation by fibrin-bound VEGF variants with differential susceptibilities to local cellular activity. 2005 , 101, 93-109	142
1901	Molecular lymphangiogenesis: new players. 2005 , 15, 434-41	108
1900	Antibody neutralization of vascular endothelial growth factor (VEGF) fails to attenuate vascular permeability and brain edema in experimental pneumococcal meningitis. 2005 , 160, 170-7	18
1899	Vascular endothelial growth factor is regulated by hypoxic stress via MAPK and HIF-1 alpha in the inner ear. 2005 , 163, 84-91	13
1898	Abrogation of delayed type hypersensitivity response to <i>Candida albicans</i> produced by a molecular mimic of phosphorylated prolactin. 2005 , 170, 31-40	6
1897	Macrophage density in the pregnant rat uterine cervix is modulated by mast cell degranulation. 2005 , 65, 147-58	17
1896	Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma. 2005 , 4, 167-74	31
1895	Targeting multiple signal transduction pathways in lung cancer. 2005 , 7 Suppl 1, S39-44	18

1894	Cellular response to tissue hypoxia and its involvement in disease progression. 2005 , 55, 603-10	64
1893	Culture of human umbilical vein endothelial cells on immobilized vascular endothelial growth factor. 2005 , 74, 659-65	52
1892	The potential of angiogenesis soluble markers in chronic hepatitis C. 2005 , 42, 696-701	59
1891	Vascular endothelial growth factor receptor-1 promotes migration and invasion in pancreatic carcinoma cell lines. 2005 , 104, 427-38	173
1890	VEGF as a predictive marker of rectal tumor response to preoperative radiotherapy. 2005 , 104, 2517-21	45
1889	Vascular endothelial growth factor gene variability is associated with increased risk for AD. 2005 , 57, 373-80	107
1888	AdVEGF165 gene transfer increases survival in overdimensioned skin flaps. 2005 , 7, 297-306	36
1887	The anti-angiogenic effect of sinomenine. 2005 , 8, 3-12	76
1886	Stress alters vascular-endothelial growth factor expression in rat arteries: role of nerve growth factor. 2005 , 100, 121-30	24
1885	Upregulation of transforming growth factor-beta1 and vascular endothelial growth factor in cultured keloid fibroblasts: relevance to angiogenic activity. 2005 , 297, 161-9	61
1884	Identification of Chlamydia pneumoniae within human choroidal neovascular membranes secondary to age-related macular degeneration. 2005 , 243, 1080-90	57
1883	Critical limb ischemia classification and therapeutic angiogenesis. 2005 , 14, 49-59	3
1882	Vascular endothelial growth factor in salivary pleomorphic adenomas: one of the reasons for their poorly vascularized stroma. 2005 , 446, 653-62	26
1881	Expression of amino acid sequences of the chromogranin A molecule and synaptic vesicle protein 2 in neuroendocrine tumors of the lung. 2005 , 446, 604-12	10
1880	Anti-Angiogenese bei neovaskulärer Makuladegeneration: Neue therapeutische Strategien. 2005 , 19, 317-325	1
1879	Cyclooxygenase-2 increases hypoxia-inducible factor-1 and vascular endothelial growth factor to promote angiogenesis in gastric carcinoma. 2005 , 12, 229-41	82
1878	The merits of vascular targeting for gynecologic malignancies. 2005 , 7, 444-50	2
1877	Non-angiogenic functions of VEGF in breast cancer. 2005 , 10, 283-90	63

1876	Essential role of PI-3K, ERKs and calcium signal pathways in nickel-induced VEGF expression. 2005 , 279, 35-43	21
1875	Biological significance of c-erbB family oncogenes in head and neck cancer. 2005 , 24, 47-69	142
1874	Quantification of vascular endothelial growth factor and neuropilins mRNAs during rat brain maturation by real-time PCR. 2005 , 25, 1035-41	5
1873	Effect of preterm birth on hypoxia-inducible factors and vascular endothelial growth factor in primate lungs. 2005 , 40, 538-46	46
1872	Dual inhibition of the epidermal growth factor and vascular endothelial growth factor phosphorylation for antivascular therapy of human prostate cancer in the prostate of nude mice. 2005 , 65, 203-15	33
1871	Vascular endothelial growth factor and neo-angiogenesis in H. pylori gastritis in humans. 2005 , 207, 277-84	31
1870	Development of angiogenesis inhibitors to vascular endothelial growth factor receptor 2. Current status and future perspective. 2005 , 10, 1415-39	50
1869	Neovascularization and mandibular condylar bone remodeling in adult rats under mechanical strain. 2005 , 10, 74-82	29
1868	Identification of biomarkers for tumor endothelial cell proliferation through gene expression profiling. 2005 , 4, 413-25	19
1867	Expression of vascular endothelial growth factor and its receptors in heart tissue following short-term swimming training. 2005 , 3, 91-99	3
1866	Riluzole inhibits VEGF-induced endothelial cell proliferation in vitro and hyperoxia-induced abnormal vessel formation in vivo. 2005 , 46, 4780-7	18
1865	Heat shock protein 70, heat shock protein 32, and vascular endothelial growth factor production and their effects on lipopolysaccharide-induced apoptosis in porcine aortic endothelial cells. 2005 , 10, 340-8	31
1864	Crotalid venom vascular endothelial growth factors has preferential affinity for VEGFR-1. Characterization of Protobothrops mucrosquamatus venom VEGF. 2005 , 93, 331-8	16
1863	Isolation and Characterization of a Parapoxvirus from Sheep with Papular Stomatitis. 2005 , 39, 197-203	16
1862	Hypoxia induces the expression of membrane-type 1 matrix metalloproteinase in retinal glial cells. 2005 , 46, 3817-24	28
1861	Vascular endothelial growth factor and soluble FLT-1 receptor interactions and biological implications. 2005 , 14, 1565	1
1860	Glycol-Splitting as a Device for Modulating Inhibition of Growth Factors and Heparanase by Heparin and Heparin Derivatives. 2005 , 461-481	5
1859	Role of neural guidance signals in blood vessel navigation. 2005 , 65, 629-38	75

1858	Expression and function of laminins in the embryonic and mature vasculature. 2005 , 85, 979-1000	410
1857	Growth factor-induced therapeutic angiogenesis in the heart: protein therapy. 2005 , 65, 649-55	62
1856	Growth factor-induced therapeutic angiogenesis and arteriogenesis in the heart--gene therapy. 2005 , 65, 656-64	66
1855	VEGF receptor antagonism blocks arteriogenesis, but only partially inhibits angiogenesis, in skeletal muscle of exercise-trained rats. 2005 , 288, H759-68	69
1854	Antitumor activity of rapamycin in a transgenic mouse model of ErbB2-dependent human breast cancer. 2005 , 65, 5325-36	87
1853	Angiogenesis in lymphoma: a short review. 2005 , 5, 609-13	3
1852	Recombinant human VEGF treatment enhances alveolarization after hyperoxic lung injury in neonatal rats. 2005 , 289, L529-35	159
1851	Identification and characterization of regulator of G protein signaling 4 (RGS4) as a novel inhibitor of tubulogenesis: RGS4 inhibits mitogen-activated protein kinases and vascular endothelial growth factor signaling. 2005 , 16, 609-25	57
1850	Placental growth factor promotes atherosclerotic intimal thickening and macrophage accumulation. 2005 , 111, 2828-36	123
1849	Pleural effusion. 2005 , 81, 702-10	46
1848	Placenta growth factor expression is correlated with survival of patients with colorectal cancer. 2005 , 54, 666-72	91
1847	Liver failure after delivery. 2005 , 54, 672, 709	2
1846	Essential role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice. 2005 , 102, 1076-81	250
1845	Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy. 2005 , 4, 715-25	26
1844	Reveromycin A inhibits osteolytic bone metastasis of small-cell lung cancer cells, SBC-5, through an antiosteoclastic activity. 2005 , 11, 8822-8	42
1843	A distinct strategy to generate high-affinity peptide binders to receptor tyrosine kinases. 2005 , 18, 417-24	49
1842	Protein kinase C-dependent protein kinase D activation modulates ERK signal pathway and endothelial cell proliferation by vascular endothelial growth factor. 2005 , 280, 33262-9	139
1841	Inhaled nitric oxide enhances distal lung growth after exposure to hyperoxia in neonatal rats. 2005 , 58, 22-9	150

1840	Two-Dimensional Array Formation of Multi-Cellular Spheroids on Micro-Patterned Polymer Brush Surface. 2005 , 288-289, 449-452	
1839	Stabilized HIF-1alpha is superior to VEGF for angiogenesis in skeletal muscle via adeno-associated virus gene transfer. 2005 , 19, 1365-7	109
1838	RNA Silencing. 2005 ,	
1837	Synergy between interstitial flow and VEGF directs capillary morphogenesis in vitro through a gradient amplification mechanism. 2005 , 102, 15779-84	223
1836	Cathepsin B regulates the intrinsic angiogenic threshold of endothelial cells. 2005 , 16, 3488-500	99
1835	CHIR-258: a potent inhibitor of FLT3 kinase in experimental tumor xenograft models of human acute myelogenous leukemia. 2005 , 11, 5281-91	93
1834	Vascular endothelial growth factor contributes to prostate cancer-mediated osteoblastic activity. 2005 , 65, 10921-9	81
1833	Decreased expression of angiogenic factors in placentas with chorioamnionitis after preterm birth. 2005 , 58, 607-12	40
1832	Vascular endothelial growth factor and diabetic retinopathy: role of oxidative stress. 2005 , 6, 511-24	189
1831	Anti-vascular endothelial growth factor gene therapy attenuates lung injury and fibrosis in mice. 2005 , 175, 1224-31	132
1830	[Treatment of neovascular age-related macular degeneration with Ranibizumab/Lucentis]. 2005 , 222, 480-4	19
1829	Angiogenic and antiangiogenic gene therapy. 2005 , 12 Suppl 1, S159-69	24
1828	Role of angiogenesis in cardiovascular disease: a critical appraisal. 2005 , 112, 1813-24	347
1827	Vascular endothelial growth factor receptor 2 blockade disrupts postnatal lung development. 2005 , 32, 420-7	91
1826	Changes in fetal lung distension alter expression of vascular endothelial growth factor and its isoforms in developing rat lung. 2005 , 58, 30-7	38
1825	New antiangiogenic strategies for the treatment of proliferative synovitis. 2005 , 14, 1-17	28
1824	Increased pituitary vascular endothelial growth factor-a in dopaminergic D2 receptor knockout female mice. 2005 , 146, 2952-62	61
1823	[Angiogenesis VEGF165 gene therapy with AdVEGF- a new delay procedure for flaps]. 2005 , 37, 365-74	7

1822	Retinoic acid and erythropoietin maintain alveolar development in mice treated with an angiogenesis inhibitor. 2005 , 33, 622-8	31
1821	Proliferation of endothelial and tumor epithelial cells by progestin-induced vascular endothelial growth factor from human breast cancer cells: paracrine and autocrine effects. 2005 , 146, 3632-41	61
1820	Inhibition of gene expression in vivo using multiplex siRNA. 2005 , 309, 197-203	1
1819	The biology of vascular endothelial growth factors. 2005 , 65, 550-63	557
1818	Targeting angiogenesis: structural characterization and biological properties of a de novo engineered VEGF mimicking peptide. 2005 , 102, 14215-20	195
1817	The ubiquitin-proteasome system--micro target for macro intervention?. 2005 , 7, 5-13	7
1816	Emerging biological therapies for age-related macula degeneration. 2005 , 5, 1373-85	3
1815	Angiotensin II regulates vascular endothelial growth factor via hypoxia-inducible factor-1alpha induction and redox mechanisms in the kidney. 2005 , 7, 1275-84	45
1814	How do endothelial cells orientate?. 2005 , 3-15	58
1813	Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer. 2005 , 92, 553-61	87
1812	Expression patterns of angiogenic and lymphangiogenic factors in ductal breast carcinoma in situ. 2005 , 92, 1720-8	35
1811	Alteration of splicing signals in a genomic/cDNA hybrid VEGF gene to modify the ratio of expressed VEGF isoforms enhances safety of angiogenic gene therapy. 2005 , 12, 716-24	31
1810	Gene targeting of VEGF-A in thymus epithelium disrupts thymus blood vessel architecture. 2005 , 102, 10587-92	56
1809	Multiple roles for the receptor tyrosine kinase axl in tumor formation. 2005 , 65, 9294-303	151
1808	Epstein-Barr virus lytic infection is required for efficient production of the angiogenesis factor vascular endothelial growth factor in lymphoblastoid cell lines. 2005 , 79, 13984-92	81
1807	Molecular mechanisms underlying the proangiogenic effect of factor XIII. 2005 , 25, 526-32	57
1806	Impaired revascularization in a mouse model of type 2 diabetes is associated with dysregulation of a complex angiogenic-regulatory network. 2005 , 25, 1603-9	98
1805	Cytokine preconditioning promotes codifferentiation of human fetal liver CD133+ stem cells into angiomyogenic tissue. 2005 , 111, 1175-83	54

1804	Angiopoietin-2 causes inflammation in vivo by promoting vascular leakage. 2005 , 314, 738-44	180
1803	Antitumor vascular strategy for controlling experimental metastatic spread of human small-cell lung cancer cells with ZD6474 in natural killer cell-depleted severe combined immunodeficient mice. 2005 , 11, 8789-98	40
1802	Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. 2005 , 169, 681-91	600
1801	Cutting edge: proangiogenic properties of alternatively activated dendritic cells. 2005 , 175, 2788-92	107
1800	Branch retinal artery occlusion during coronary angiography. 2005 , 81, 710	4
1799	Growth factors in lung development. 2005 , 40, 261-316	49
1798	Polyneuropathy in POEMS syndrome: role of angiogenic factors in the pathogenesis. 2005 , 128, 1911-20	184
1797	Molecularly-targeted therapies for non-small cell lung cancer. 2005 , 6, 2667-79	5
1796	Increased mRNA expression of VEGF within the hematoma and imbalance of angiopoietin-1 and -2 mRNA within the neomembranes of chronic subdural hematoma. 2005 , 22, 518-28	82
1795	Drugs to suppress cough. 2005 , 14, 19-27	34
1794	The lymphangiogenic vascular endothelial growth factors VEGF-C and -D are ligands for the integrin alpha9beta1. 2005 , 280, 4544-52	153
1793	Integration/Interaction of Oncologic Growth. 2005 ,	3
1792	A reassessment of vascular endothelial growth factor in central nervous system pathology. 2005 , 103, 853-68	39
1791	Enhanced susceptibility of irradiated tumor vessels to vascular endothelial growth factor receptor tyrosine kinase inhibition. 2005 , 65, 5374-9	47
1790	Anti-flt1 peptide, a vascular endothelial growth factor receptor 1-specific hexapeptide, inhibits tumor growth and metastasis. 2005 , 11, 2651-61	91
1789	Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. 2005 , 11, 8403-12	78
1788	Mechanism of VEGF-induced uterine venous hyperpermeability. 2005 , 42, 47-54	10
1787	VEGF as a target of therapy in gastrointestinal oncology. 2005 , 22, 282-93	5

1786	Angiopoietin 2 displays a vascular endothelial growth factor dependent synergistic effect in hepatocellular carcinoma development in mice. 2005 , 54, 1768-75	55
1785	Regulation of vascular endothelial growth factor bioactivity in patients with acute lung injury. 2005 , 60, 153-8	29
1784	Intraluminal application of vascular endothelial growth factor enhances healing of microvascular anastomosis in a rat model. 2005 , 42, 202-13	26
1783	A Review of Vasculogenesis Models. 2005 , 6, 1-19	53
1782	Uterine venous permeability in the rat is altered in response to pregnancy, vascular endothelial growth factor, and venous constriction. 2005 , 12, 81-8	9
1781	Macrophage colony-stimulating factor induces vascular endothelial growth factor production in skeletal muscle and promotes tumor angiogenesis. 2005 , 174, 7531-8	56
1780	Activation of hypoxia-inducible factors in hyperoxia through prolyl 4-hydroxylase blockade in cells and explants of primate lung. 2005 , 102, 10212-7	80
1779	A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165. 2005 , 102, 18902-7	181
1778	Cyclooxygenase-2 inhibitors decrease vascular endothelial growth factor expression in colon cancer cells by enhanced degradation of Sp1 and Sp4 proteins. 2005 , 68, 317-29	103
1777	Mice null for Frizzled4 (Fzd4 ^{-/-}) are infertile and exhibit impaired corpora lutea formation and function. 2005 , 73, 1135-46	109
1776	Granulocyte colony-stimulating factor promotes neovascularization by releasing vascular endothelial growth factor from neutrophils. 2005 , 19, 2005-7	195
1775	Regulatory role of dynamin-2 in VEGFR-2/KDR-mediated endothelial signaling. 2005 , 19, 1692-4	66
1774	Association of genetic polymorphisms in the VEGF gene with breast cancer survival. 2005 , 65, 5015-9	133
1773	VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. 2005 , 201, 1089-99	566
1772	Positive correlation between estradiol and vascular endothelial growth factor but not fibroblast growth factor-2 in normal human breast tissue in vivo. 2005 , 11, 8036-41	49
1771	A predictive model of rectal tumor response to preoperative radiotherapy using classification and regression tree methods. 2005 , 11, 5440-3	42
1770	Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. 2005 , 11, 5639-44	79
1769	Activation of angiogenesis under influence of red low level laser radiation. 2005 , 5968, 45	3

1768	Enhanced antimetastatic effect of fetal liver kinase 1 extracellular domain and interferon-gamma fusion gene-modified dendritic cell vaccination. 2005 , 12, 742-50	12
1767	Vascular Endothelial Growth Factor Signaling. 2005 , 91-104	4
1766	Vascular endothelial growth factor and its relationships with endogenous inhibitors in a breast cancer microenvironment manipulated by hormonal therapy: a hypothetical consideration. 2005 , 59 Suppl 2, S344-7	5
1765	Mechanisms for the induction of HNE- MDA- and AGE-adducts, RAGE and VEGF in retinal pigment epithelial cells. 2005 , 80, 567-80	102
1764	Vascular endothelial growth factor gene polymorphisms and idiopathic recurrent pregnancy loss. 2005 , 83, 959-63	61
1763	Effect of 17 beta-estradiol, progesterone, synthetic progestins, tibolone, and tibolone metabolites on vascular endothelial growth factor mRNA in breast cancer cells. 2005 , 84, 485-91	22
1762	VEGF189 stimulates endothelial cells proliferation and migration in vitro and up-regulates the expression of Flk-1/KDR mRNA. 2005 , 309, 24-31	51
1761	Cardiovascular molecular imaging. 2005 , 35, 73-81	31
1760	Inhibition of Src kinase activity by Ad-mda7 suppresses vascular endothelial growth factor expression in prostate carcinoma cells. 2005 , 12, 707-15	45
1759	Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. 2005 , 11, 3647-53	198
1758	Genes to vaccines for immunotherapy: how the molecular biology revolution has influenced cancer immunology. 2005 , 4, 1645-52	26
1757	Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. 2005 , 40, 352-68	190
1756	Enhanced antitumor effect of the combination of tumstatin gene therapy and gemcitabine in murine models. 2005 , 16, 1075-86	18
1755	Mechanisms of Angiogenesis. 2005 ,	5
1754	Targeted therapy in renal cell carcinoma. 2005 , 14, 1251-8	14
1753	Angiogenesis: where do we stand now?. 2005 , 111, 1556-66	354
1752	Endothelial precursors and mature endothelial cells are increased in the peripheral blood of myelodysplastic syndromes. 2005 , 46, 1345-51	36
1751	Angiogenesis and lung cancer: prognostic and therapeutic implications. 2005 , 23, 3243-56	207

1750	Angiogenesis inhibitors localized in hypovascular mesenchymal tissues: chondromodulin-I and tenomodulin. 2005 , 46, 3-11	29
1749	Novel therapeutics in adult malignant brain gliomas. 2005 , 14, 643-58	4
1748	Antibody-based antiangiogenic cancer therapy. 2005 , 9, 1235-45	5
1747	Angiogenesis, vasculogenesis, and induction of healing in chronic wounds. 2005 , 39, 293-306	176
1746	Immunological factors in the pathogenesis and treatment of age-related macular degeneration. 2005 , 13, 3-11	84
1745	Evidence supporting that the excess of the sVEGFR-1 concentration in maternal plasma in preeclampsia has a uterine origin. 2005 , 18, 9-16	85
1744	Oncogenes as novel targets for cancer therapy (part I): growth factors and protein tyrosine kinases. 2005 , 5, 173-90	21
1743	Differential regulation of vascular endothelial growth factor receptors (VEGFR) revealed by RNA interference: interactions of VEGFR-1 and VEGFR-2 in endothelial cell signaling. 2005 , 44, 15064-73	26
1742	Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. 2005 , 23, 3697-705	762
1741	Bevacizumab in the treatment of colorectal cancer. 2005 , 5, 997-1005	47
1740	Terpenoid tetrahydroisoquinoline alkaloids emetine, klugine, and isocephaline inhibit the activation of hypoxia-inducible factor-1 in breast tumor cells. 2005 , 68, 947-50	51
1739	Synthesis and structure-activity relationships of pyrazine-pyridine biheteroaryls as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors. 2005 , 48, 4892-909	29
1738	Tyrosine kinases as targets for cancer therapy. 2005 , 353, 172-87	1084
1737	Evidence of angiogenesis in primary biliary cirrhosis: an immunohistochemical descriptive study. 2005 , 42, 124-31	108
1736	Adaptative bile duct proliferative response in experimental bile duct ischemia. 2005 , 42, 257-65	51
1735	VEGF-induced angiogenesis drives collateral circulation in portal hypertension. 2005 , 43, 6-8	25
1734	Insulin enhances vascular endothelial growth factor, interleukin-8, and plasminogen activator inhibitor 1 but not interleukin-6 release by human adipocytes. 2005 , 54, 220-6	36
1733	CCR2 expression by brain microvascular endothelial cells is critical for macrophage transendothelial migration in response to CCL2. 2005 , 70, 53-64	54

1732	Vascular endothelial growth factor receptor-2 and low affinity VEGF binding sites on human glomerular endothelial cells: Biological effects and advanced glycosilation end products modulation. 2005 , 70, 179-88	20
1731	p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells. 2005 , 93, 173-82	28
1730	Expression and cellular localization of vascular endothelial growth factor A and its receptors in acute and chronic leukemias: an immunohistochemical study. 2005 , 36, 797-805	23
1729	Immunohistochemical analysis of tumor angiogenic factors in human pituitary adenomas. 2005 , 36, 1090-5	54
1728	Role of heme oxygenase-1 in hydrogen peroxide-induced VEGF synthesis: effect of HO-1 knockout. 2005 , 326, 670-6	67
1727	Gene regulation of a novel angiogenesis inhibitor, vasohibin, in endothelial cells. 2005 , 327, 700-6	80
1726	Transcription regulation of the vegf gene by the BMP/Smad pathway in the angioblast of zebrafish embryos. 2005 , 329, 324-30	51
1725	Chondromodulin-I and tenomodulin: a new class of tissue-specific angiogenesis inhibitors found in hypovascular connective tissues. 2005 , 333, 299-307	76
1724	Saururus cernuus lignans--potent small molecule inhibitors of hypoxia-inducible factor-1. 2005 , 333, 1026-33	59
1723	Simulated hypogravity impairs the angiogenic response of endothelium by up-regulating apoptotic signals. 2005 , 334, 491-9	61
1722	VEGF induces proliferation, migration, and TGF-beta1 expression in mouse glomerular endothelial cells via mitogen-activated protein kinase and phosphatidylinositol 3-kinase. 2005 , 334, 1049-60	61
1721	Intraovarian actions of anti-angiogenic agents disrupt periovulatory events during the menstrual cycle in monkeys. 2005 , 71, 239-48	36
1720	Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. 2005 , 16, 159-78	1005
1719	Transcriptional regulation of vascular endothelial growth factor in cancer. 2005 , 16, 77-89	100
1718	Use of angiogenesis inhibitors in tumour treatment. 2005 , 41, 1109-16	58
1717	Recent developments in the regulation of the angiogenic switch by cellular stress factors in tumors. 2005 , 218, 1-14	108
1716	Prospects for therapeutic inhibition of neuroblastoma angiogenesis. 2005 , 228, 171-9	34
1715	Vascular changes in the subventricular zone after distal cortical lesions. 2005 , 194, 139-50	40

1714	Novel function for vascular endothelial growth factor receptor-1 on epidermal keratinocytes. 2005 , 167, 1257-66	98
1713	Inhibitors of cytochrome P450 4A suppress angiogenic responses. 2005 , 166, 615-24	81
1712	Angiogenesis and lipoxins. 2005 , 73, 271-5	9
1711	Soluble factors released by endothelial progenitor cells promote migration of endothelial cells and cardiac resident progenitor cells. 2005 , 39, 733-42	634
1710	In vitro and in vivo evaluation of [123I]-VEGF165 as a potential tumor marker. 2005 , 32, 431-6	24
1709	Differential expression of vascular endothelial growth factor implies the limbal origin of pterygia. 2005 , 112, 1023-30	46
1708	Hypoxia and HIF-1 alpha in chondrogenesis. 2005 , 16, 539-46	82
1707	Expression of VEGF and angiopoietins in subfoveal membranes from patients with age-related macular degeneration. 2005 , 139, 589-96	66
1706	Angiogenesis in male breast cancer. 2005 , 3, 16	13
1705	Revisiting immunosurveillance and immunostimulation: Implications for cancer immunotherapy. 2005 , 3, 8	71
1704	VEGF as a key mediator of angiogenesis in cancer. 2005 , 69 Suppl 3, 4-10	1006
1703	Neuroprotective role of vascular endothelial growth factor: signalling mechanisms, biological function, and therapeutic potential. 2005 , 14, 207-21	209
1702	Herpes simplex virus amplicon delivery of a hypoxia-inducible soluble vascular endothelial growth factor receptor (sFlk-1) inhibits angiogenesis and tumor growth in pancreatic adenocarcinoma. 2005 , 12, 1025-36	18
1701	Targeted therapy in colorectal cancer: do we know enough?. 2006 , 38, 71-7	5
1700	Vascular endothelial growth factor co-ordinates proper development of lung epithelium and vasculature. 2005 , 122, 877-86	57
1699	Brain tumor tropism of transplanted human neural stem cells is induced by vascular endothelial growth factor. 2005 , 7, 623-9	166
1698	Antineovascular therapy, a novel antiangiogenic approach. 2005 , 9, 63-76	17
1697	Investigating the potential of bevacizumab in other indications: metastatic renal cell, non-small cell lung, pancreatic and breast cancer. 2005 , 69 Suppl 3, 46-56	75

1696	Synthesis and discovery of pyrazine-pyridine biheteroaryl as a novel series of potent vascular endothelial growth factor receptor-2 inhibitors. 2005 , 48, 1886-900	34
1695	Molecular prediction of tamoxifen resistance in breast cancer. 2005 , 7, 1	78
1694	Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. 2005 , 23, 1028-43	326
1693	Plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated prior to the clinical diagnosis of pre-eclampsia. 2005 , 17, 3-18	272
1692	Molecular Biology of Human Cancers. 2005 ,	4
1691	Genomic analysis of human breast cancer in families and populations. 2005 , 7, 1	78
1690	Dynamic imaging of plasticity and escape in tumor cell invasion. 2005 , 7, 1	78
1689	Comparative genomic hybridization using oligonucleotide arrays and total genomic DNA. 2005 , 7, 1	78
1688	Hypoxia promotes invasion and metastasis of breast cancer cells by increasing lysyl oxidase expression. 2005 , 7, 1	1
1687	Brn-3b transcription factor in breast tumorigenesis: regulation of genes associated with growth and migration of cancer cells. 2005 , 7, 1	78
1686	Mammary development fate and breast cancer risk. 2005 , 7, 1	78
1685	Molecular profiling of early breast cancer in relation to detection of micrometastases and outcome. 2005 , 7, 1	1
1684	Real-time PCR-based expression profiling of BRCA1-induced genes in primary breast tumors. 2005 , 7, 1	78
1683	Breast tumors induced by high-dose radiation display similar genetic profiles. 2005 , 7, 1	78
1682	Stromal and epithelial TGF- β signaling in mammary tumorigenesis. 2005 , 7, 1	78
1681	The extracellular matrix composition and responsiveness to breast carcinoma therapy. 2005 , 7, 1	78
1680	Determining the factors affecting breast cancer infectivity by oncolytic adenovirus. 2005 , 7, 1	78
1679	HER2 and ER α downregulate estrogen-responsive element-mediated transcription activity of ER β -positive cells in response to estrogen stimulation. 2005 , 7, 1	1

1678	Establishment and characterization of two breast cancer xenografts in immunodeficient mice for studies on hormone-dependent and hormone-independent tumor growth, progression and invasion. 2005, 7, 1	2
1677	Functional genomic approaches to breast cancer. 2005, 7, 1	78
1676	Cell differentiation and dominant signaling pathway signatures in the molecular classification of human breast cancer cell lines. 2005, 7, 1	3
1675	Potential mechanisms whereby estrogens induce breast cancer in women. 2005, 7, 1	1
1674	Potentiated phospho-protein networks in cancer cells. 2005, 7, 1	1
1673	Identification of molecular apocrine breast tumours by microarray analysis. 2005, 7, 1	8
1672	Identification of novel sequence alterations and the functional analysis of the BRCA1 promoter/5'-UTR in families from Upper Silesia, Poland. 2005, 7, 1	78
1671	Comparison of the expression profile in breast cancer and ovarian cancer. 2005, 7, 1	1
1670	Targeting estrogen to kill ER-positive and ER-negative breast cancer. 2005, 7, 1	78
1669	High-throughput experimental verification of predicted tissue-specific and tumor-specific splice isoforms. 2005, 7, 1	78
1668	The intracellular domain of ErbB4 induces differentiation of mammary epithelial cells. 2005, 7, 1	0
1667	Cigarette smoking and breast cancer risk among non-drinking women. 2005, 7, 1	78
1666	Screening for germline rearrangements in BRCA1 and BRCA2 in Norwegian families with breast or breast/ovarian cancer. 2005, 7, 1	78
1665	Genome-wide expression profiling of microdissected human breast tumor cells: tumor classification predictive of metastases and clinical outcome. 2005, 7, 1	78
1664	Gene expression profiling in breast cancer challenges the existence of intermediate histological grade. 2005, 7, 1	78
1663	Molecular approaches to understanding pregnancy-induced protection against breast cancer. 2005, 7, 1	78
1662	Cooperation between extracellular signaling and intracellular Ras activation leads to immortalization and epithelial-to-mesenchymal transition of variant human mammary epithelial cells. 2005, 7, 1	78
1661	Immortalization-associated gene signature in breast cancer. 2005, 7, 1	78

1660	Genetic determinants of breast cancer characteristics and outcome in women under 50 years of age. 2005, 7, 1	78
1659	Identification of differentially expressed genes in canine mammary tumor cell lines using a newly developed canine-specific cDNA microarray. 2005, 7, 1	78
1658	Genetic and epigenetic changes in early carcinogenesis. 2005, 7, 1	78
1657	Biological features and xenograft models of a very early human premalignant breast lesion. 2005, 7, 1	78
1656	Myoepithelial cell layer disruption and human breast cancer invasion. 2005, 7, 1	1
1655	HER2 upregulates fatty acid synthase and acetyl-CoA carboxylase at a translational level in breast cancer cells. 2005, 7, 1	78
1654	Clinical outcome for BRCA1 and BRCA2 mutation carriers after contralateral prophylactic mastectomy. 2005, 7, 1	78
1653	Chromosomal imbalances mapped by array-based comparative genomic hybridization in an integrated approach to combat breast cancer in Denmark. 2005, 7, 1	1
1652	DNA copy number changes in breast cancer samples using array-CGH profiling. 2005, 7, 1	78
1651	Genomic and transcriptional events associated with poor clinical responses to conventional therapies. 2005, 7, 1	78
1650	Expression profiling of peripheral blood cells for early detection. 2005, 7, 1	78
1649	HIN-1, an inhibitor of cell growth, invasion, and AKT1 activation. 2005, 7, 1	78
1648	Genome-wide scanning for linkage in 56 Dutch breast cancer families selected for a minimal probability of being due to BRCA1 or BRCA2. 2005, 7, 1	78
1647	Mapping the location of recurring amplicons in array-CGH data. 2005, 7, 1	78
1646	Predicting survival from gene expression data by generalized partial least squares regression. 2005, 7, 1	2
1645	Large-scale single nucleotide polymorphism analysis of candidates for low-penetrance breast cancer genes. 2005, 7, 1	1
1644	Molecular distinctions among ERBB2-overexpressing breast cancers. 2005, 7, 1	78
1643	In vitro models for tumor protein d52 function in cancer cells. 2005, 7, 1	78

1642	Protein expression and gene amplification of primary cyclins (A, B1, D1, D3 and E) and secondary cyclins (C and H) in relation to prognosis in breast cancer patients. 2005, 7, 1	0
1641	TP53 mutations among molecular subtypes of HER2-positive tumors. 2005, 7, 1	78
1640	Comparison of methods for pharmacogenomics: SNaPshot, SNPstream UHT, Nanogen, and RFLP. 2005, 7, 1	78
1639	Targeting the cell cycle for prognosis and therapy of breast cancer. 2005, 7, 1	78
1638	Expression profiling as a prognostic and predictive factor in breast cancer. 2005, 7, 1	78
1637	Lack of evidence for nuclear IGFBP5 in mammary epithelial cells. 2005, 7, 1	78
1636	Expression of wild-type and mutated TP53 in breast carcinomas. 2005, 7, 1	78
1635	Cancer gene mutation discovery and detection using array-based resequencing. 2005, 7, 1	78
1634	The rare ERBB2 variant Ile654Val is associated with an increased familial breast cancer risk. 2005, 7, 1	78
1633	High-resolution representational oligonucleotide microarray analysis and fluorescence in situ hybridization analysis of aneuploid and diploid breast tumors. 2005, 7, 1	78
1632	A single nucleotide polymorphism in the HDM-2 gene regulates the p53 apoptotic response and influences the age of onset of cancers in humans: the SNP 309 HDM-2 polymorphism. 2005, 7, 1	78
1631	Microcell-mediated transfer of chromosome 6 into the breast cancer cell line MDA-MB-231: a specific set of genes is involved in the reversion of the tumorigenic phenotype. 2005, 7, 1	78
1630	Prognostic value genotypes and LOH at TP53 codon 72 and TP53 mutations in primary breast cancer. 2005, 7, 1	78
1629	Detection of minimal disease in breast cancer. 2005, 7, 1	78
1628	Association of NCOA3 (AIB1) polymorphisms with breast cancer risk. 2005, 7, 1	1
1627	A critical need for molecular markers of breast cancer risk and risk reduction. 2005, 7, 1	78
1626	TP53 and additional pathways in therapy resistance. 2005, 7, 1	78
1625	Hypermethylation of cyclin D2 and DAP kinase is associated with the lobular subtype of breast cancer. 2005, 7, 1	78

1624	Development of a rapid screening approach for candidate gene sets in cancer. 2005, 7, 1	78
1623	Monitoring of minimal residual cancer in bone marrow in high-risk breast cancer patients treated with high-dose chemotherapy. 2005, 7, 1	78
1622	High-density screening of the Zbtb7 gene in breast cancer patients. 2005, 7, 1	1
1621	Effects of oestrogen on gene expression in the epithelium and stroma of the normal human breast. 2005, 7, 1	78
1620	Role of HER2 in local relapse and metastasis. 2005, 7, 1	78
1619	Development of CDK inhibitors as cancer therapeutics. 2005, 7, 1	1
1618	Expression profiling of Wnt pathway genes in breast cancer. 2005, 7, 1	78
1617	Gene expression studies in radiation-sensitive cell lines. 2005, 7, 1	78
1616	Breast tumors induce the recruitment of AC133+KDR+ endothelial precursor cells mobilized by plasma vascular endothelial growth factor. 2005, 7, 1	2
1615	Identification of drug targets for the treatment of Basal-like tumors. 2005, 7, 1	1
1614	BRCA1 directly modulates gene expression required for estrogen biosynthesis: a possible mechanism of tissue-specific tumor suppression. 2005, 7, 1	78
1613	The search for low-penetrance breast cancer genes. 2005, 7, 1	2
1612	Molecular characterization of breast cell lines: a tool for breast cancer studies. 2005, 7, 1	78
1611	SNPS in putative regulatory loci controlling gene expression in cancer. 2005, 7, 1	78
1610	Characterization of extracellular matrix composition in breast carcinoma. 2005, 7, 1	78
1609	The anti-estrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF7 breast cancer cells refractory to long-term estrogen deprivation through downregulation of ER and IGF signalling. 2005, 7, 1	78
1608	Proteomic approaches to early detection of breast cancer. 2005, 7, 1	78
1607	Reproducibility of molecular portraits in early stage breast cancer. 2005, 7, 1	78

1606	Gene expression signature of hereditary breast cancer. 2005, 7, 1	78
1605	ATM mutations associated with breast cancer. 2005, 7, 1	78
1604	The future of breast cancer prevention. 2005, 7, 1	78
1603	A model of the BRCA1/BRCA2 network. 2005, 7, 1	78
1602	The interaction of the ER with ERBB2 and PI3K results in elevated levels of AKT and p90RSK in tamoxifen-resistant MCF-7 cells. 2005, 7, 1	4
1601	Gene expression profiling to identify parity-induced changes in the human mammary gland. 2005, 7, 1	1
1600	Envisioning new targets and new approaches for molecular-based cancer therapeutics. 2005, 7, 1	78
1599	High prevalence of a BRCA1 gene founder mutation, 5083del19, in unselected breast/ovarian cancer patients from Southern Italy: genotype/phenotype correlations. 2005, 7, 1	2
1598	Lymph node metastases display gene expression profiles of their primary breast carcinomas. 2005, 7, 1	78
1597	Comparative expressed sequence hybridisation revealed distinct chromosomal regions of differential gene expression in breast cancer subtypes. 2005, 7, 1	78
1596	ER α in normal and malignant breast. 2005, 7, 1	78
1595	RNA integrity number: towards standardization of RNA quality assessment for better reproducibility and reliability of gene expression experiments. 2005, 7, 1	1
1594	Essential functions of the Janus kinase 2 (Jak2) during mammary gland development and tumorigenesis. 2005, 7, 1	78
1593	Mutation screening of BRCA1, BRCA2 and CHEK2*1100delC in Slovak HBOC families. 2005, 7, 1	78
1592	Promoter composition predicts gene classes in microarray expression analyses of breast cancer. 2005, 7, 1	78
1591	Predicting response/resistance to endocrine therapy for breast cancer. 2005, 7, 1	78
1590	The role of the tumor microenvironment in breast cancer progression. 2005, 7, 1	78
1589	Ex vivo isolation of adult stem cells from normal and tumour mouse mammary parenchyma. 2005, 7, 1	78

1588	6-(1-oxobutyl)-5,8-dimethoxy-1,4-naphthoquinone exerts anti-angiogenic activity via inhibition of vascular endothelial cell growth factor and hypoxia-inducible factor 1 alpha in hypoxia-exposed MCF breast cancer cells. 2005, 7, 1	78
1587	Low-dose ionizing radiation significantly increases the risk of breast cancer among BRCA1/2 mutation carriers in the International BRCA1/2 Carrier Cohort Study (IBCCS). 2005, 7, 1	78
1586	Discovering genetic profiles by array-CGH in familial breast tumors. 2005, 7, 1	78
1585	A breast cancer progression model: the importance of three-dimensional tissue architecture and metalloproteinases. 2005, 7, 1	1
1584	Regulation of epithelial cell polarity during carcinogenesis. 2005, 7, 1	1
1583	Imprint as a reliable diagnostic tool in breast cancer and possible usefulness for research purposes. 2005, 7, 1	78
1582	Altered signaling in anti-estrogen-resistant human breast cancer cells. 2005, 7, 1	78
1581	Oral contraceptives and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). 2005, 7, 1	78
1580	Morphogenesis of the mammary gland and the role of keratin expression. 2005, 7, 1	78
1579	Outcome signature genes in breast cancer: is there a unique set?. 2005, 7, 1	5
1578	Quality control of DNA with on-chip electrophoresis for oligonucleotide-array comparative genomic hybridization. 2005, 7, 1	78
1577	DNA polymorphisms of several genes and predisposition to breast cancer. 2005, 7, 1	1
1576	Stem cells in human breast development and cancer. 2005, 7, 1	78
1575	Expression of STAT1 target genes and interferon gamma in human mammary carcinoma tissue. 2005, 7, 1	78
1574	Who gets cancer?. 2005, 7, 1	78
1573	Gene expression profiles and the TP53 mutation status are powerful prognostic markers of breast cancer. 2005, 7, 1	1
1572	Chromosome-wide pharmacogenetics: localisation and linkage disequilibrium of genes coding for ROS metabolism and signalling. 2005, 7, 1	78
1571	Insulin-like growth factor regulation of mammary gland development and tumorigenesis. 2005, 7, 1	78

1570	Tailored therapies based upon tumor subtype biology. 2005, 7, 1	78
1569	Functional characterization of genes involved in the development of breast cancer. 2005, 7, 1	78
1568	IL-8 is a novel marker for breast cancer. 2005, 7, 1	1
1567	Mutant p53 exerts its gain of function through activation of the NF- κ B pathway. 2005, 7, 1	78
1566	Evaluation of the arrayed primer extension resequencing assay for TP53 mutation detection. 2005, 7, 1	78
1565	Genetic polymorphisms in the 5' flanking region of glutathione S-transferase P1 affect promoter methylation. 2005, 7, 1	78
1564	Apoptotic chemotherapies. 2005, 7, 1	78
1563	Genomic profiling of breast cancer. 2005, 7, 1	78
1562	Deletions at the chromosome 3 common eliminated region 1 on 3p21.3 in human breast tumors. 2005, 7, 1	78
1561	Identification of clinically relevant gene sets and pathways using functional models of breast tumor suppression. 2005, 7, 1	78
1560	Independent prognostic value of somatic TP53 gene mutations in 1794 breast cancer patients. 2005, 7, 1	78
1559	Detection of circulating cancer cells in peripheral blood as a prognostic factor in early breast cancer. 2005, 7, 1	78
1558	Alpha-1 antitrypsin genotypes in breast cancer patients. 2005, 7, 1	2
1557	ZBTB7 HapMap in a worldwide population study. 2005, 7, 1	1
1556	Evading p53 action during tumor development and therapy. 2005, 7, 1	78
1555	Epigenetic silencing of tropomyosin alters transforming growth factor beta control of cell invasion and metastasis. 2005, 7, 1	78
1554	Postoperative serum proteomic profiles and identification of biomarkers with prognosis value in high-risk early breast cancer patients. 2005, 7, 1	78
1553	Polymorphisms in the CRK gene and their association with breast cancer risk. 2005, 7, 1	78

1552	Gene expression profiling in whole-blood samples from postmenopausal women exposed to hormone replacement therapy. 2005, 7, 1	78
1551	Targeting new therapies in combination with hormonal therapies for ER-positive breast cancer. 2005, 7, 1	78
1550	Methylation profiling of carcinogenesis-associated genes in sporadic breast cancer. 2005, 7, 1	78
1549	Application of microarray analyses to identify genes involved in radiation-induced fibrosis. 2005, 7, 1	1
1548	Dissection of molecular pathways of cancer by high-throughput biochip technologies and RNA interference. 2005, 7, 1	1
1547	Subclassification and molecular characterization of early stage breast carcinomas using Applied Biosystems Human Genome Survey Microarrays. 2005, 7, 1	1
1546	DNA damage response pathways in cancer causation and treatment. 2005, 7, 1	78
1545	Magnetic resonance spectroscopy of breast cancer tissue used for tumor classification and lymph node prediction. 2005, 7, 1	1
1544	Sex-hormone binding globulin receptor-mediated growth inhibition in breast cancer cells: a proteomics approach. 2005, 7, 1	78
1543	Hereditary breast cancer – spectrum of pathogenic mutations and unknown variants of BRCA1 and BRCA2 genes in the Czech Republic: efficiency of testing and clinical follow-up. 2005, 7, 1	78
1542	Genes, genomes, and cancer. 2005, 7, 1	78
1541	Abstract withdrawn. 2005, 7, 1	78
1540	Abstract withdrawn. 2005, 7, 1	78
1539	The challenges in translating present knowledge of the molecular biology of breast cancer into clinical use. 2005, 7, 1	0
1538	Update on HER2-directed therapy. 2005, 7, 1	1
1537	The vascular endothelial growth factor (VEGF) family: angiogenic factors in health and disease. 2005, 6, 209	362
1536	Therapeutic options to target angiogenesis in human malignancies. 2006, 11, 635-50	63
1535	Breast Cancer and Molecular Medicine. 2006,	2

1534	Lessons from phase III clinical trials on anti-VEGF therapy for cancer. 2006 , 3, 24-40	865
1533	Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. 2006 , 355, 2542-50	4760
1532	Long-term increase in mVEGF164 in mouse hindlimb muscle mediated by phage phiC31 integrase after nonviral DNA delivery. 2006 , 17, 871-6	30
1531	Applications in the Clinic: The Anti-VEGF Aptamer. 2006 , 443-460	1
1530	A role of the anti-angiogenic factor sVEGFR-1 in the 'mirror syndrome' (Ballantyne's syndrome). 2006 , 19, 607-13	75
1529	Combined immunologic and anti-angiogenic therapy reduces hepatic micrometastases in a murine ocular melanoma model. 2006 , 31, 557-62	22
1528	Sunitinib malate for the treatment of solid tumours: a review of current clinical data. 2006 , 15, 553-61	94
1527	Mastic oil from Pistacia lentiscus var. chia inhibits growth and survival of human K562 leukemia cells and attenuates angiogenesis. 2006 , 55, 86-93	65
1526	Transmyocardial laser revascularization causes sustained VEGF secretion. 2006 , 18, 43-5	
1525	[Vascular development in inflammatory bowel disease]. 2006 , 29, 414-21	11
1524	Plasmin modulates vascular endothelial growth factor-A-mediated angiogenesis during wound repair. 2006 , 168, 670-84	99
1523	Increased melanoma growth and metastasis spreading in mice overexpressing placenta growth factor. 2006 , 169, 643-54	83
1522	Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth. 2006 , 169, 1739-52	131
1521	Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. 2006 , 11, 753-64	221
1520	The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma. 2006 , 103, 19478-83	168
1519	Hypoxia signalling in cancer and approaches to enforce tumour regression. 2006 , 441, 437-43	1318
1518	A neurotrophic model for stress-related mood disorders. 2006 , 59, 1116-27	2473
1517	The effect of preterm birth on neonatal cerebral vasculature studied with magnetic resonance angiography at 3 Tesla. 2006 , 32, 1050-9	27

1516	Eph receptor and ephrin ligand-mediated interactions during angiogenesis and tumor progression. 2006 , 312, 642-50	128
1515	Medical Treatment of Advanced Renal Cell Carcinoma: Present Options and Future Directions. 2006 , 5, 619-626	1
1514	Immunotherapy of hepatocellular carcinoma. 2006 , 45, 868-78	64
1513	NOR-1 is involved in VEGF-induced endothelial cell growth. 2006 , 184, 276-82	44
1512	Relationship of smoking and fibrosis in patients with chronic hepatitis C. 2006 , 4, 797-801	42
1511	Bioavailability of VEGF in tumor-shed vesicles depends on vesicle burst induced by acidic pH. 2006 , 8, 96-103	143
1510	Advances in chemotherapy for colorectal cancer. 2006 , 4, 808-21	17
1509	Heparin binding nanostructures to promote growth of blood vessels. 2006 , 6, 2086-90	374
1508	Novel targeted therapies for non-small cell lung cancer. 2006 , 16, 353-66	1
1507	Molecular and structural basis of portal hypertension. 2006 , 10, 445-57, vii	26
1506	Vascular endothelial growth factor stimulates rat cholangiocyte proliferation via an autocrine mechanism. 2006 , 130, 1270-82	159
1505	Targeting lymphoma cells and their microenvironment with novel antibodies. 2006 , 7 Suppl 1, S33-40	2
1504	Participation of the PI-3K/Akt-NF-kappa B signaling pathways in hypoxia-induced mitogenic factor-stimulated Flk-1 expression in endothelial cells. 2006 , 7, 101	20
1503	Clinical implications for vascular endothelial growth factor in the lung: friend or foe?. 2006 , 7, 128	85
1502	Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor. 2006 , 49, 2143-6	119
1501	Growth factors and the epididymis. 2006 , 27, 348-57	16
1500	Expression of vascular endothelial growth factor and hypoxia-inducible factor in the airway of asthmatic patients. 2006 , 97, 794-9	35
1499	Mathematical modeling of tumor-induced angiogenesis. 2006 , 8, 233-57	200

1498	Role of receptor tyrosine kinase transmembrane domains in cell signaling and human pathologies. 2006 , 45, 6241-51	181
1497	Atorvastatin increases plasma soluble Fms-like tyrosine kinase-1 and decreases vascular endothelial growth factor and placental growth factor in association with improvement of ventricular function in acute myocardial infarction. 2006 , 48, 43-50	51
1496	The placenta growth factor in skin angiogenesis. 2006 , 41, 11-9	54
1495	Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer. 2006 , 53, 91-6	121
1494	Vascular endothelial growth factor signaling pathways: therapeutic perspective. 2006 , 12, 5018-22	446
1493	The early responses of VEGF and its receptors during acute lung injury: implication of VEGF in alveolar epithelial cell survival. 2006 , 10, R130	56
1492	Immunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluation. 2006 , 59, 790-800	132
1491	Genetics and biology of pancreatic ductal adenocarcinoma. 2006 , 20, 1218-49	818
1490	KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties. 2006 , 66, 9134-42	158
1489	Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors. 2006 , 66, 2173-80	180
1488	Incidence and management of bevacizumab-related toxicities in colorectal cancer. 2006 , 5, 553-66	86
1487	Regulation of angiogenic factors in angiotensin II infusion model in association with tubulointerstitial injuries. 2006 , 19, 718-27	31
1486	Krypton laser photocoagulation induces retinal vascular remodeling rather than choroidal neovascularization. 2006 , 83, 263-75	4
1485	Biology of vascular endothelial growth factors. 2006 , 580, 2879-87	355
1484	VEGF at the neurovascular interface: therapeutic implications for motor neuron disease. 2006 , 1762, 1109-21	80
1483	Vascular endothelial growth factor signalling in endothelial cell survival: a role for NFkappaB. 2006 , 340, 984-94	61
1482	Interleukin-6 triggers human cerebral endothelial cells proliferation and migration: the role for KDR and MMP-9. 2006 , 342, 1396-404	89
1481	Regulation of vascular endothelial growth factor receptor-2 expression in pancreatic cancer cells by Sp proteins. 2006 , 345, 292-301	63

1480	HESR1/CHF2 suppresses VEGFR2 transcription independent of binding to E-boxes. 2006 , 346, 637-48	33
1479	Identification of derlin-1 as a novel growth factor-responsive endothelial antigen by suppression subtractive hybridization. 2006 , 348, 1272-8	7
1478	Expression of VEGFR-2 on HaCaT cells is regulated by VEGF and plays an active role in mediating VEGF induced effects. 2006 , 349, 31-8	42
1477	Malignant hematopoietic cells induce an increased expression of VEGFR-1 and VEGFR-3 on bone marrow endothelial cells via AKT and mTOR signalling pathways. 2006 , 349, 1003-10	19
1476	L1 on ovarian carcinoma cells is a binding partner for Neuropilin-1 on mesothelial cells. 2006 , 239, 212-26	38
1475	Endothelial monocyte-activating polypeptide-II and its functions in (patho)physiological processes. 2006 , 17, 339-48	45
1474	Selective regulation of arterial branching morphogenesis by synectin. 2006 , 10, 783-95	116
1473	Key cancer cell signal transduction pathways as therapeutic targets. 2006 , 42, 290-4	118
1472	Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1. 2006 , 79, 2370-81	130
1471	Salvage effect of the vascular endothelial growth factor on chemically induced acute severe liver injury in rats. 2006 , 44, 568-75	32
1470	Crystal structure of human vascular endothelial growth factor-B: identification of amino acids important for receptor binding. 2006 , 359, 76-85	32
1469	Induction of immunomodulator transcriptional responses by cholera toxin. 2006 , 43, 1020-8	10
1468	Cholera toxin induced novel genes in human lymphocytes and monocytes. 2006 , 43, 1267-74	8
1467	Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation. 2006 , 72, 3-11	150
1466	A VEGF165-induced phenotypic switch from increased vessel density to increased vessel diameter and increased endothelial NOS activity. 2006 , 72, 91-100	40
1465	The differential expression of VEGF, VEGFR-2, and GLUT-1 proteins in disease subtypes of systemic sclerosis. 2006 , 37, 190-7	80
1464	Placental growth factor in the cerebrospinal fluid of women with preeclampsia. 2006 , 92, 32-7	15
1463	Increased angiogenic capabilities of endothelial cells from microvessels of malignant human gliomas. 2006 , 6, 90-9	28

1462	Lysophosphatidic acid (LPA)-induced vascular endothelial growth factor (VEGF) by mesothelial cells and quantification of host-derived VEGF in malignant ascites. 2006 , 130, 94-101	20
1461	Interaction between stromal fibroblasts and colorectal cancer cells in the expression of vascular endothelial growth factor. 2006 , 134, 270-7	21
1460	The biology of vascular endothelial growth factor-B (VEGF-B). 2006 , 19, 61-9	70
1459	Vascular endothelial growth factor-B (VEGFB) stimulates neurogenesis: evidence from knockout mice and growth factor administration. 2006 , 289, 329-35	143
1458	VEGF-A signaling through Flk-1 is a critical facilitator of early embryonic lung epithelial to endothelial crosstalk and branching morphogenesis. 2006 , 290, 177-88	108
1457	Cigarette smoke exposure impairs VEGF-induced endothelial cell migration: role of NO and reactive oxygen species. 2006 , 41, 275-84	93
1456	Cancers of the bowel and hepatobiliary tract. 2006 , 1, 353-365	1
1455	Role of vascular endothelial growth factor in prostate cancer. 2006 , 68, 244-8	34
1454	Microvessel density is a prognostic marker of human gastric cancer. 2006 , 12, 7598-603	40
1453	New Technologies in Cardiovascular Research: Gene Therapy. 2006 , 85-101	
1452	Short interfering RNA-mediated gene silencing of vascular endothelial growth factor: effects on cellular proliferation in colon cancer cells. 2006 , 141, 367-74; discussion 374	25
1451	ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model. 2006 , 16, 15-26	40
1450	Ocular versus extraocular neovascularization: mirror images or vague resemblances. 2006 , 47, 462-74	39
1449	Immunolocalization and expression of vascular endothelial growth factor receptors (VEGFRs) and neuropilins (NRPs) on keratinocytes in human epidermis. 2006 , 12, 127-36	81
1448	CD151 gene delivery activates PI3K/Akt pathway and promotes neovascularization after myocardial infarction in rats. 2006 , 12, 214-20	30
1447	Vascular endothelial growth factor upregulates expression of ADAMTS1 in endothelial cells through protein kinase C signaling. 2006 , 47, 4059-66	33
1446	. 2006 ,	106
1445	Therapeutic Angiogenesis. 2006 ,	

1444	Ex Vivo Analysis of Dialysis Effluent-Derived Mesothelial Cells as an Approach to Unveiling the Mechanism of Peritoneal Membrane Failure. 2006 , 26, 26-34	52
1443	Puerarin induces angiogenesis in myocardium of rat with myocardial infarction. 2006 , 29, 945-50	76
1442	Protein Tyrosine Kinases as Targets for Cancer and Other Indications. 2006 , 1-29	3
1441	Estradiol and nicotine exposure enhances A549 bronchioloalveolar carcinoma xenograft growth in mice through the stimulation of angiogenesis. 2006 , 28, 337	1
1440	Polymeric Conjugates for Angiogenesis-Targeted Tumor Imaging and Therapy. 2006 , 159-184	
1439	Up-regulation of the Notch ligand Delta-like 4 inhibits VEGF-induced endothelial cell function. 2006 , 107, 931-9	295
1438	The kinase insert domain-containing receptor is an angiogenesis-associated antigen recognized by human cytotoxic T lymphocytes. 2006 , 107, 1476-83	12
1437	Deletion of the selection cassette, but not cis-acting elements, in targeted Flk1-lacZ allele reveals Flk1 expression in multipotent mesodermal progenitors. 2006 , 107, 111-7	232
1436	Redundant roles of VEGF-B and PlGF during selective VEGF-A blockade in mice. 2006 , 107, 550-7	35
1435	The angiogenic function of nucleolin is mediated by vascular endothelial growth factor and nonmuscle myosin. 2006 , 107, 3564-71	147
1434	Bone marrow mononuclear cells are recruited to the sites of VEGF-induced neovascularization but are not incorporated into the newly formed vessels. 2006 , 107, 3546-54	130
1433	Ligand-induced internalization selects use of common receptor neuropilin-1 by VEGF165 and semaphorin3A. 2006 , 107, 3892-901	68
1432	Soluble HLA-G1 inhibits angiogenesis through an apoptotic pathway and by direct binding to CD160 receptor expressed by endothelial cells. 2006 , 108, 2608-15	153
1431	Vascular endothelial cell-specific phosphotyrosine phosphatase (VE-PTP) activity is required for blood vessel development. 2006 , 107, 4754-62	124
1430	Signaling of vascular endothelial growth factor receptor-1 tyrosine kinase promotes rheumatoid arthritis through activation of monocytes/macrophages. 2006 , 108, 1849-56	142
1429	Angiogenic proteins are expressed by brain blood vessels in Alzheimer's disease. 2006 , 10, 111-8	89
1428	Rac1 and RhoA as regulators of endothelial phenotype and barrier function in hypoxia-induced neonatal pulmonary hypertension. 2006 , 290, L1173-82	80
1427	Tumor Angiogenesis. 1087-1106	0

1426	Vitreous fluid biomarkers. 2006 , 42, 111-66	9
1425	Identification of H-2Db-specific CD8+ T-cell epitopes from mouse VEGFR2 that can inhibit angiogenesis and tumor growth. 2006 , 29, 32-40	21
1424	Expression levels of vascular endothelial growth factor and its receptors in Parkinson's disease. 2006 , 17, 705-9	71
1423	Review of selected patents for cancer therapy targeting tumor angiogenesis. 2006 , 1, 153-61	4
1422	Expression of vascular endothelial growth factor and its receptors in the central nervous system in amyotrophic lateral sclerosis. 2006 , 65, 26-36	75
1421	The Signature from Messenger RNA Expression Profiling Can Predict Lymph Node Metastasis with High Accuracy for Non-small Cell Lung Cancer. 2006 , 1, 622-628	1
1420	Ranibizumab treatment of patients with ocular diseases. 2006 , 46, 131-40	12
1419	Evaluation of anterior chamber inflammatory activity in eyes treated with intravitreal bevacizumab. 2006 , 26, 877-81	52
1418	Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. 2006 , 17, 1227-9	34
1417	New drugs in prostate cancer. 2006 , 16, 138-45	19
1416	Activation of VEGF and FGF induced angiogenesis under influence of low level laser radiation in vitro. 2006 ,	
1415	New Developments in the Management of Pleural Effusions. 2006 , 2, 305-311	
1414	Sorafenib. 2006 , 18, 615-21	55
1413	Growth Factors. 2006 ,	
1412	Wnt/Frizzled signaling in the vasculature: new angiogenic factors in sight. 2006 , 21, 181-8	61
1411	VEGF receptors on PC12 cells mediate transient activation of ERK1/2 and Akt: comparison of nerve growth factor and vascular endothelial growth factor. 2006 , 5, 8	3
1410	Expression and localization of VEGF-C and VEGFR-3 in glioblastomas and haemangioblastomas. 2006 , 209, 34-43	68
1409	Inhibition of vascular endothelial growth factor receptor 2 activity in experimental brain contusions aggravates injury outcome and leads to early increased neuronal and glial degeneration. 2006 , 23, 21-34	53

1408	Minor contribution of bone marrow-derived endothelial progenitors to the vascularization of murine gliomas. 2003 , 13, 582-97	86
1407	Angiogenesis in gliomas: biology and molecular pathophysiology. 2005 , 15, 297-310	254
1406	Induction of transcription factor CEBP homology protein mediates hypoglycaemia-induced necrotic cell death in human neuroblastoma cells. 2006 , 99, 952-64	12
1405	Factor XIII (FXIII) and angiogenesis. 2006 , 4, 19-25	73
1404	Effects of 17beta-estradiol, progesterone, synthetic progestins, tibolone, and raloxifene on vascular endothelial growth factor and Thrombospondin-1 messenger RNA in breast cancer cells. 2006 , 16 Suppl 2, 560-3	14
1403	Ocular angiogenesis: the role of growth factors. 2006 , 84, 282-8	77
1402	Antiangiogenic cancer therapies get their act together: current developments and future prospects of growth factor- and growth factor receptor-targeted approaches. 2006 , 15, 175-86	37
1401	Time course analysis of hypoxia, granulation tissue and blood vessel growth, and remodeling in healing rat cutaneous incisional primary intention wounds. 2006 , 14, 277-88	42
1400	Peptide-based molecules in angiogenesis. 2006 , 67, 115-26	81
1399	Overexpression of VEGF-A induces neovascularization and increased vascular leakage in rabbit eye after intravitreal adenoviral gene transfer. 2006 , 187, 447-57	12
1398	Giant cell granuloma of the jawbones--a proliferative vascular lesion? Immunohistochemical study with vascular endothelial growth factor and basic fibroblast growth factor. 2006 , 35, 613-9	40
1397	Regeneration of vascularized bone. 2006 , 41, 109-22	62
1396	Intrinsic tyrosine kinase activity is required for vascular endothelial growth factor receptor 2 ubiquitination, sorting and degradation in endothelial cells. 2006 , 7, 1270-82	144
1395	Granulocyte/macrophage colony-stimulating factor treatment of human chronic ulcers promotes angiogenesis associated with de novo vascular endothelial growth factor transcription in the ulcer bed. 2006 , 154, 34-41	62
1394	t(8;21) acute myeloid leukaemia cells are dependent on vascular endothelial growth factor (VEGF)/VEGF receptor type2 pathway and phosphorylation of Akt. 2006 , 135, 673-82	19
1393	Decreased expression of VEGF-A in rat experimental autoimmune encephalomyelitis and in cerebrospinal fluid mononuclear cells from patients with multiple sclerosis. 2006 , 64, 609-22	33
1392	Vascular endothelial growth factor C--a potent risk factor in childhood acute lymphoblastic leukaemia: an immunocytochemical approach. 2006 , 49, 170-7	6
1391	VEGF controls endothelial-cell permeability by promoting the beta-arrestin-dependent endocytosis of VE-cadherin. 2006 , 8, 1223-34	768

1390	Chemical modulation of receptor signaling inhibits regenerative angiogenesis in adult zebrafish. 2006 , 2, 265-73		111
1389	VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. <i>Nature Medicine</i> , 2006 , 12, 793-800	50.5	131
1388	Hyperoxia causes angiopoietin 2-mediated acute lung injury and necrotic cell death. <i>Nature Medicine</i> , 2006 , 12, 1286-93	50.5	273
1387	VEGF-C is a trophic factor for neural progenitors in the vertebrate embryonic brain. 2006 , 9, 340-8		144
1386	Ranibizumab. 2006 , 5, 815-6		23
1385	The place of VEGF inhibition in the current management of renal cell carcinoma. 2006 , 94, 1217-20		15
1384	TRAIL inhibits angiogenesis stimulated by VEGF expression in human glioblastoma cells. 2006 , 94, 1428-35		53
1383	Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting. 2006 , 147 Suppl 2, S144-52		58
1382	FGF-2 overexpression opposes the beta amyloid toxic injuries to the vascular endothelium. 2006 , 13, 1088-96		34
1381	Glycosaminoglycan modification of neuropilin-1 modulates VEGFR2 signaling. 2006 , 25, 3045-55		134
1380	Plasmid-mediated VEGF gene transfer induces cardiomyogenesis and reduces myocardial infarct size in sheep. 2006 , 13, 1133-42		67
1379	RNA interference in the mouse vascular endothelium by systemic administration of siRNA-lipoplexes for cancer therapy. 2006 , 13, 1360-70		164
1378	Aspirin-triggered Lipoxin A4 inhibition of VEGF-induced endothelial cell migration involves actin polymerization and focal adhesion assembly. 2006 , 25, 122-9		71
1377	Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors. 2006 , 25, 5969-84		132
1376	The role of vascular endothelial growth factor (VEGF) in inflammatory bowel disease. 2006 , 12, 870-8		42
1375	Kinase inhibitors in the treatment of renal cell carcinoma. 2006 , 60, 216-26		26
1374	Inhibitors of VEGF receptors-1 and -2 based on the 2-((pyridin-4-yl)ethyl)pyridine template. 2006 , 16, 1913-9		9
1373	Synthesis and biological study of 4-aminopyrimidine-5-carboxaldehyde oximes as antiproliferative VEGFR-2 inhibitors. 2006 , 16, 6063-6		21

1372	The impact of proteinase-induced matrix degradation on the release of VEGF from heparinized collagen matrices. 2006 , 27, 1608-16	56
1371	Dual growth factor-induced angiogenesis in vivo using hyaluronan hydrogel implants. 2006 , 27, 1868-75	131
1370	Comparison of VEGF-producing cells in periprosthetic osteolysis. 2006 , 27, 3882-7	13
1369	The correlation between difference in foreign body reaction between implant locations and cytokine and MMP expression. 2006 , 27, 5763-70	55
1368	Stimulation of in vivo angiogenesis using dual growth factor-loaded crosslinked glycosaminoglycan hydrogels. 2006 , 27, 5935-43	104
1367	The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). 2006 , 30, 801-11	42
1366	Enzymatic esterification of flavonoids with unsaturated fatty acids: Effect of the novel esters on vascular endothelial growth factor release from K562 cells. 2006 , 41, 2029-2034	101
1365	Design and synthesis of novel photoaffinity reagents for labeling VEGF receptor tyrosine kinases. 2006 , 47, 2915-2919	10
1364	HDAC3 is crucial in shear- and VEGF-induced stem cell differentiation toward endothelial cells. 2006 , 174, 1059-69	212
1363	Hypoxia and HIF-1alpha in chondrogenesis. 2006 , 1068, 66-73	43
1362	Upregulation of VEGF by 15-deoxy-Delta12,14-prostaglandin J2 via heme oxygenase-1 and ERK1/2 signaling in MCF-7 cells. 2006 , 1090, 375-84	45
1361	Estrogens in human vascular diseases. 2006 , 1089, 431-43	13
1360	Antibodies for angiogenesis inhibition, vascular targeting and endothelial cell transcytosis. 2006 , 58, 735-54	23
1359	Osmotic-driven release kinetics of bioactive therapeutic proteins from a biodegradable elastomer are linear, constant, similar, and adjustable. 2006 , 23, 782-9	22
1358	Enhancing angiogenesis in collagen matrices by covalent incorporation of VEGF. 2006 , 17, 735-41	86
1357	Angiopoietin 2 expression in invasive ductal carcinoma of the breast: its relationship to the VEGF expression and microvessel density. 2006 , 98, 261-6	49
1356	Targeting growth factors and angiogenesis; using small molecules in malignancy. 2006 , 25, 279-92	22
1355	Reduced glioma infiltration in Src-deficient mice. 2006 , 78, 19-29	46

1354	VEGFR-2 expression in brain injury: its distribution related to brain-blood barrier markers. 2006 , 113, 487-96	37
1353	Angiogenesis - understanding the mathematical challenge. 2006 , 9, 127-38	15
1352	Induction of three-dimensional assembly and increase in apoptosis of human endothelial cells by simulated microgravity: impact of vascular endothelial growth factor. 2006 , 11, 749-64	121
1351	Fast alterations of vascular endothelial growth factor (VEGF) expression and that of its receptors (Flt-1, Flk-1 and Neuropilin) in the cochlea of guinea pigs after moderate noise exposure. 2007 , 264, 121-8	16
1350	COX-2 expression of ampullary carcinoma: correlation with different histotypes and clinicopathological parameters. 2006 , 449, 334-40	14
1349	Antiangiogene Therapiestrategien in der gyn&ologischen Onkologie. 2006 , 39, 153-157	
1348	Antiangiogenic chimeric anti-endoglin (CD105) antibody: pharmacokinetics and immunogenicity in nonhuman primates and effects of doxorubicin. 2006 , 55, 140-50	28
1347	A case of Takayasu arteritis complicated with glomerulonephropathy mimicking membranoproliferative glomerulonephritis: a case report and review of the literature. 2006 , 27, 103-7	8
1346	[Translational research in renal cell cancer. Illustrated by the example of the vascular endothelial growth factor pathway]. 2006 , 45, 328, 330-5	0
1345	Heparin-regulated release of growth factors in vitro and angiogenic response in vivo to implanted hyaluronan hydrogels containing VEGF and bFGF. 2006 , 27, 5242-51	285
1344	Contribution of VEGF and PEDF to choroidal angiogenesis: a need for balanced expressions. 2006 , 39, 267-76	72
1343	Mathematical modelling of dynamic adaptive tumour-induced angiogenesis: clinical implications and therapeutic targeting strategies. 2006 , 241, 564-89	293
1342	New antiangiogenetic agents and non-small cell lung cancer. 2006 , 60, 76-86	19
1341	Effects of estradiol-17beta on expression of mRNA for seven angiogenic factors and their receptors in the endometrium of ovariectomized (OVX) ewes. 2006 , 30, 333-42	38
1340	Targeted therapies in colorectal cancer: Complications and management. 2006 , 2, 125-133	2
1339	Gene therapy of the ischemic lower limb--Therapeutic angiogenesis. 2006 , 44, 395-405	35
1338	Complex formation between tissue transglutaminase II (tTG) and vascular endothelial growth factor receptor 2 (VEGFR-2): proposed mechanism for modulation of endothelial cell response to VEGF. 2006 , 312, 2973-82	53
1337	Hypoxia-induced mitogenic factor enhances angiogenesis by promoting proliferation and migration of endothelial cells. 2006 , 312, 3559-69	24

1336	TGFbeta1-induced aortic endothelial morphogenesis requires signaling by small GTPases Rac1 and RhoA. 2006 , 312, 3604-19	20
1335	Melanotransferrin stimulates t-PA-dependent activation of plasminogen in endothelial cells leading to cell detachment. 2006 , 1763, 393-401	11
1334	Role of haematopoietic cells and endothelial progenitors in tumour angiogenesis. 2006 , 1766, 159-66	49
1333	ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells. 2006 , 71, 479-85	32
1332	New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. 2006 , 33, 407-20	209
1331	Prognostic factors in renal cell carcinoma. 2006 , 33, 563-75	34
1330	Mechanisms of action of bevacizumab as a component of therapy for metastatic colorectal cancer. 2006 , 33, S1-7	104
1329	The role of vascular endothelial growth factor (VEGF) in oral dysplasia and oral squamous cell carcinoma. 2006 , 42, 337-42	44
1328	Cellular and molecular therapeutic modalities for arterial obstructive syndromes. 2006 , 109, 263-73	14
1327	Mechanisms of endothelial cell guidance and vascular patterning in the developing mouse retina. 2006 , 25, 277-95	127
1326	Cluster analysis of networks generated through homology: automatic identification of important protein communities involved in cancer metastasis. 2006 , 7, 2	124
1325	Proteolytic regulatory mechanisms in the formation of extracellular morphogen gradients. 2006 , 78, 243-55	7
1324	Contribution of angiogenic genes to the complex genetic trait underlying Kawasaki disease. 2006 , 54, 1361-5	4
1323	Vascular endothelial growth factor gene haplotypes in Kawasaki disease. 2006 , 54, 1588-94	44
1322	Lymphangiogenesis by blind-ended vessel sprouting is concurrent with hemangiogenesis by vascular splitting. 2006 , 288, 233-47	23
1321	Development of antibody-based therapeutics for oncology indications. 2006 , 67, 699-728	2
1320	Differential expression of VEGF-A and angiopoietins in cartilage tumors and regulation by interleukin-1beta. 2006 , 106, 2028-38	29
1319	Emodin inhibits vascular endothelial growth factor-A-induced angiogenesis by blocking receptor-2 (KDR/Flk-1) phosphorylation. 2006 , 118, 2711-20	84

1318	Tumor lymphangiogenesis and metastatic spread-new players begin to emerge. 2006 , 119, 1755-60	109
1317	Human mesenchymal stem cells (hMSCs) expressing truncated soluble vascular endothelial growth factor receptor (tsFlk-1) following lentiviral-mediated gene transfer inhibit growth of Burkitt's lymphoma in a murine model. 2006 , 8, 253-64	45
1316	VEGF 164 gene transfer by electroporation improves diabetic sensory neuropathy in mice. 2006 , 8, 773-81	38
1315	Vascular endothelial growth factor polymorphisms in gastric cancer development, prognosis, and survival. 2006 , 94, 624-30	78
1314	Role of coagulation factor XIII (FXIII) in angiogenesis and tissue repair. 2006 , 35, 162-5	30
1313	Dopaminergic D2 receptor knockout mouse: an animal model of prolactinoma. 2006 , 35, 50-63	27
1312	Prognostic significance of vascular endothelial growth factor and cyclooxygenase-2 in patients with rectal cancer treated with preoperative radiotherapy. 2006 , 71, 312-9	35
1311	Transducing the signals: a G protein takes a new identity. 2006 , 2006, pe31	26
1310	Novel treatment strategies for aggressive non-Hodgkin's lymphoma. 2006 , 7, 733-48	5
1309	Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. 2006 , 66, 1721-9	246
1308	Antagonistic functions of tetradecanoyl phorbol acetate-inducible-sequence 11b and HuR in the hormonal regulation of vascular endothelial growth factor messenger ribonucleic acid stability by adrenocorticotropin. 2006 , 20, 916-30	33
1307	Recent Clinical Trials in Non-Small Cell Lung Cancer. 2006 , 2, 81-99	
1306	[Influence of V.A.C.-therapy on cytokines and growth factors in traumatic wounds]. 2006 , 131 Suppl 1, S62-7	24
1305	Rauchen alteriert die Sekretion angiogenetischer Substanzen während der Eizellreifung des Menschen. 2006 , 66, 63-67	
1304	Macroscopic appearance of intestinal angiodysplasias under antiangiogenic treatment with thalidomide. 2006 , 38, 1036-9	39
1303	Vascular endothelial growth factor receptor-2 expression is induced by 17beta-estradiol in ZR-75 breast cancer cells by estrogen receptor alpha/Sp proteins. 2006 , 147, 3285-95	41
1302	Recently patented applications of homologous cellular and extracellular agents as therapeutics or targets for the prevention of restenosis post-angioplasty. 2006 , 1, 57-66	5
1301	Cellular signaling molecules as therapeutic targets in glioblastoma multiforme. 2006 , 20, E8	3

1300	VEGF165-binding sites within heparan sulfate encompass two highly sulfated domains and can be liberated by K5 lyase. 2006 , 281, 1731-40	128
1299	Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. 2006 , 2, 71-98	268
1298	Apoptosis of human macrophages by Flt-4 signaling: implications for atherosclerotic plaque pathology. 2006 , 71, 774-84	26
1297	Inhibition of VEGF mRNA by 2'-O,4'-C-ethylene-bridged nucleic acids (ENA) antisense oligonucleotides and their influence on off-target gene expressions. 2006 , 25, 503-21	6
1296	State of the art. Cellular and molecular mechanisms of alveolar destruction in emphysema: an evolutionary perspective. 2006 , 3, 503-10	130
1295	Role of platelet-derived growth factor and vascular endothelial growth factor in obliterative airway disease. 2006 , 174, 1145-52	28
1294	Neuropilin-2 interacts with VEGFR-2 and VEGFR-3 and promotes human endothelial cell survival and migration. 2006 , 108, 1243-50	217
1293	Recombinant human VEGF treatment transiently increases lung edema but enhances lung structure after neonatal hyperoxia. 2006 , 291, L1068-78	90
1292	Autocrine VEGF-A system in podocytes regulates podocin and its interaction with CD2AP. 2006 , 291, F422-8	88
1291	Angiogenesis as a therapeutic target in arthritis: lessons from oncology. 2006 , 12, 2631-44	28
1290	Moderate antiangiogenic activity by local, transgenic expression of endostatin in Rip1Tag2 transgenic mice. 2006 , 80, 669-76	2
1289	Caspases and calpain are independent mediators of cisplatin-induced endothelial cell necrosis. 2006 , 291, F578-87	72
1288	Polymeric Systems for Bioinspired Delivery of Angiogenic Molecules. 191-221	20
1287	Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state. 2006 , 290, G980-7	138
1286	Mechanisms of endothelial response to oxidative aggression: protective role of autologous VEGF and induction of VEGFR2 by H2O2. 2006 , 291, H1395-401	79
1285	Targeted therapy for renal cell carcinoma: a new therapeutic paradigm. 2006 , 24, 640-56	7
1284	Vascular endothelial growth factor biology: clinical implications for ocular treatments. 2006 , 90, 1542-7	117
1283	Mechanisms regulating tumor angiogenesis by 12-lipoxygenase in prostate cancer cells. 2006 , 281, 18601-9	80

1282	Hypoxia regulates cross-talk between Syk and Lck leading to breast cancer progression and angiogenesis. 2006 , 281, 11322-31	46
1281	Sca-1+ progenitors derived from embryonic stem cells differentiate into endothelial cells capable of vascular repair after arterial injury. 2006 , 26, 2244-51	111
1280	Elevated Serum Levels of Vascular Endothelial Growth Factor Are Associated With Tumor-Associated Macrophages in Primary Breast Cancer. 2006 , 125, 111-118	26
1279	Review of the effects of anti-angiogenic compounds on the epiphyseal growth plate. 2006 , 34, 131-47	57
1278	Spatio-temporal analysis of vascular endothelial growth factor expression and blood vessel remodelling in pig ovarian follicles during the periovulatory period. 2006 , 36, 107-19	26
1277	Vascular proliferation is important for clinical progress of endometrial cancer. 2006 , 66, 3303-9	102
1276	Angiogenesis in atherogenesis. 2006 , 26, 1948-57	101
1275	Contribution of individual targets to the antitumor efficacy of the multitargeted receptor tyrosine kinase inhibitor SU11248. 2006 , 5, 1280-9	101
1274	A novel class of vascular endothelial growth factor-responsive genes that require forkhead activity for expression. 2006 , 281, 35544-53	44
1273	Taxotere-induced inhibition of human endothelial cell migration is a result of heat shock protein 90 degradation. 2006 , 66, 8192-9	50
1272	Semaphorin 3d promotes cell proliferation and neural crest cell development downstream of TCF in the zebrafish hindbrain. 2006 , 133, 3983-92	32
1271	Regulation of vascular endothelial growth factor expression and vascularization in the myocardium by insulin receptor and PI3K/Akt pathways in insulin resistance and ischemia. 2006 , 26, 787-93	74
1270	SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. 2006 , 5, 1774-82	86
1269	Vascular endothelial growth factor and kinase domain region receptor are involved in both seminiferous cord formation and vascular development during testis morphogenesis in the rat. 2006 , 75, 56-67	70
1268	Hepatocyte growth factor and inducible nitric oxide synthase are involved in multidrug resistance-induced angiogenesis in hepatocellular carcinoma cell lines. 2006 , 66, 2673-82	52
1267	Tissue factor pathway inhibitor-2 is upregulated by vascular endothelial growth factor and suppresses growth factor-induced proliferation of endothelial cells. 2006 , 26, 2819-25	35
1266	Vascular endothelial growth factor induces proliferation of breast cancer cells and inhibits the anti-proliferative activity of anti-hormones. 2006 , 13, 905-19	106
1265	Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1. 2006 , 12, 5841-9	61

1264	Vascular endothelial growth factor (VEGF) in acute lung injury (ALI) and acute respiratory distress syndrome (ARDS): paradox or paradigm?. 2006 , 61, 621-6	106
1263	Soluble guanylyl cyclase activation promotes angiogenesis. 2006 , 319, 663-71	67
1262	Correlation between high vascular endothelial growth factor-A serum levels and treatment outcome in patients with standard-risk acute lymphoblastic leukemia: a report from Children's Oncology Group Study CCG-1962. 2006 , 12, 6978-84	31
1261	Leaking Capillaries and White Lung in Sepsis: Angiopoietin 2 the Culprit?. 2006 , 17, 1207-1217	
1260	The present and future of angiogenesis-directed treatments of colorectal cancer. 2006 , 11, 992-8	24
1259	Vascular endothelial growth factor receptor 2-based DNA immunization delays development of herpetic stromal keratitis by antiangiogenic effects. 2006 , 177, 4122-31	14
1258	Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1alpha activity and vascular endothelial growth factor expression in small cell lung cancer cells. 2006 , 5, 1415-22	91
1257	MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. 2006 , 1, e116	522
1256	A 76-year-old man with macular degeneration. 2006 , 295, 2394-406	9
1255	Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice. 2006 , 12, 1928-35	77
1254	Heparin-II domain of fibronectin is a vascular endothelial growth factor-binding domain: enhancement of VEGF biological activity by a singular growth factor/matrix protein synergism. 2006 , 99, 853-60	221
1253	Novel combinations based on epidermal growth factor receptor inhibition. 2006 , 12, 4446s-4450s	33
1252	OSI-930: a novel selective inhibitor of Kit and kinase insert domain receptor tyrosine kinases with antitumor activity in mouse xenograft models. 2006 , 66, 1015-24	59
1251	Overexpression of both CXC chemokine receptor 4 and vascular endothelial growth factor proteins predicts early distant relapse in stage II-III colorectal cancer patients. 2006 , 12, 2795-803	148
1250	Tumor-driven paracrine platelet-derived growth factor receptor alpha signaling is a key determinant of stromal cell recruitment in a model of human lung carcinoma. 2006 , 12, 2676-88	98
1249	Estrogen receptor beta inhibits angiogenesis and growth of T47D breast cancer xenografts. 2006 , 66, 11207-13	171
1248	Recombinant human angiostatin (rhAngiostatin) in combination with paclitaxel and carboplatin in patients with advanced non-small-cell lung cancer: a phase II study from Indiana University. 2006 , 17, 97-103	44
1247	Uncoupling of vascular endothelial growth factor with nitric oxide as a mechanism for diabetic vasculopathy. 2006 , 17, 736-45	58

1246	Regulation of the vascular endothelial growth factor (VEGF) receptor Flk-1/KDR by estradiol through VEGF in uterus. 2006 , 188, 91-9	76
1245	Ocular Angiogenesis. 2006 ,	3
1244	Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. 2006 , 26, 859-70	648
1243	Protecting the microvasculature: a Tie-ght connection to ameliorating chronic kidney disease?. 2006 , 17, 2353-5	6
1242	When does the presence of the target predict response to the targeted agent?. 2006 , 24, 213-6	26
1241	Monocytic/macrophagic pneumonitis after intrabronchial deposition of vascular endothelial growth factor in neonatal lambs. 2006 , 43, 689-94	11
1240	Type I collagen limits VEGFR-2 signaling by a SHP2 protein-tyrosine phosphatase-dependent mechanism 1. 2006 , 98, 45-54	53
1239	Low molecular weight fucoidan increases VEGF165-induced endothelial cell migration by enhancing VEGF165 binding to VEGFR-2 and NRP1. 2006 , 281, 37844-52	97
1238	Vascular endothelial growth factor in children with nephrotic syndrome treated with cyclosporine A. 2006 , 95, 291-6	3
1237	Free Flap Head and Neck Reconstruction After Cancer Therapy: Current State of the Art. 2006 , 2, 67-72	
1236	Is the Vasculature a Potential Therapeutic Target in Arthritis?. 2006 , 2, 151-158	1
1235	Improvement by solid dispersion of the bioavailability of KRN633, a selective inhibitor of VEGF receptor-2 tyrosine kinase, and identification of its potential therapeutic window. 2006 , 5, 80-8	7
1234	Increased expression of vascular endothelial growth factor in cardiac structures of fetus with hydrops as compared to nonhydropic controls. 2006 , 21, 84-91	4
1233	Progesterone receptor modulator CDB-2914 down-regulates vascular endothelial growth factor, adrenomedullin and their receptors and modulates progesterone receptor content in cultured human uterine leiomyoma cells. 2006 , 21, 2408-16	70
1232	Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. 2006 , 66, 2650-7	252
1231	Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. 2006 , 203, 2165-75	378
1230	Pancreatic islet production of vascular endothelial growth factor--a is essential for islet vascularization, revascularization, and function. 2006 , 55, 2974-85	341
1229	Cellular and molecular dynamics in the foreign body reaction. 2006 , 12, 1955-70	290

1228	Essential role of nitric oxide in VEGF-induced, asthma-like angiogenic, inflammatory, mucus, and physiologic responses in the lung. 2006 , 103, 11021-6	93
1227	Interaction of vascular endothelial growth factor 165 with neuropilin-1 protects rheumatoid synoviocytes from apoptotic death by regulating Bcl-2 expression and Bax translocation. 2006 , 177, 5727-35	50
1226	Distinct genetic interactions between multiple Vegf receptors are required for development of different blood vessel types in zebrafish. 2006 , 103, 6554-9	208
1225	Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. 2006 , 66, 221-31	243
1224	Anti-VEGF therapy: a new approach to colorectal cancer therapy. 2006 , 6, 1385-96	13
1223	Growth factors in diabetic complications. 2006 , 2, 403-18	10
1222	Clinical trials of antiangiogenic therapy in non-small cell lung cancer: focus on bevacizumab and ZD6474. 2006 , 6, 545-51	10
1221	Role of SCC-S2 in experimental metastasis and modulation of VEGFR-2, MMP-1, and MMP-9 expression. 2006 , 13, 947-55	81
1220	Vascular endothelial growth factor-D activates VEGFR-3 expressed in osteoblasts inducing their differentiation. 2006 , 281, 17961-7	58
1219	Ranibizumab: treatment in patients with neovascular age-related macular degeneration. 2006 , 6, 1237-45	27
1218	The role of neuropilins in cancer. 2006 , 5, 1099-107	203
1217	Vascular endothelial growth factor-induced signaling pathways in endothelial cells that mediate overexpression of the chemokine IFN-gamma-inducible protein of 10 kDa in vitro and in vivo. 2006 , 176, 3098-107	61
1216	Expression and functions of the vascular endothelial growth factors and their receptors in human basophils. 2006 , 177, 7322-31	92
1215	Peptide-matrix-mediated gene transfer of an oxygen-insensitive hypoxia-inducible factor-1alpha variant for local induction of angiogenesis. 2006 , 103, 2506-11	121
1214	Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. 2006 , 66, 11520-39	211
1213	Redundant roles of Sox17 and Sox18 in postnatal angiogenesis in mice. 2006 , 119, 3513-26	157
1212	Membrane ganglioside enrichment lowers the threshold for vascular endothelial cell angiogenic signaling. 2006 , 66, 10408-14	42
1211	Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma. 2006 , 24, 228-40	192

1210	Identification of alterations in DNA copy number in host stromal cells during tumor progression. 2006 , 103, 19848-53	45
1209	Solid lipid nanoparticles: could they help to improve the efficacy of pharmacologic treatments for brain tumors?. 2007 , 29, 324-30	58
1208	Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. 2007 , 25, 4722-9	1119
1207	Flaxseed and its lignans inhibit estradiol-induced growth, angiogenesis, and secretion of vascular endothelial growth factor in human breast cancer xenografts in vivo. 2007 , 13, 1061-7	129
1206	In vivo imaging shows abnormal function of vascular endothelial growth factor-induced vasculature. 2007 , 18, 515-24	59
1205	Neuropilin-1 binds to VEGF121 and regulates endothelial cell migration and sprouting. 2007 , 282, 24049-56	164
1204	Structural basis for ligand and heparin binding to neuropilin B domains. 2007 , 104, 6152-7	186
1203	Quantitative real-time reverse transcription PCR study of the expression of vascular endothelial growth factor (VEGF) splice variants and VEGF receptors (VEGFR-1 and VEGFR-2) in non small cell lung cancer. 2007 , 53, 1433-9	31
1202	Inhibition of angiogenesis and invasion by 3,3'-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. 2007 , 67, 3310-9	189
1201	Stochastic innovation as a mechanism by which catalysts might self-assemble into chemical reaction networks. 2007 , 104, 10098-103	16
1200	Prostaglandin D2 protects neonatal mouse brain from hypoxic ischemic injury. 2007 , 27, 4303-12	69
1199	Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice. 2007 , 179, 708-14	83
1198	NADPH oxidase activity selectively modulates vascular endothelial growth factor signaling pathways. 2007 , 282, 35373-85	122
1197	VEGF overexpression via adeno-associated virus gene transfer promotes skeletal muscle regeneration and enhances muscle function in mdx mice. 2007 , 21, 3737-46	78
1196	Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. 2007 , 13, 1253-9	896
1195	Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. 2007 , 6, 471-83	76
1194	Placental growth factor-1 attenuates vascular endothelial growth factor-A-dependent tumor angiogenesis during beta cell carcinogenesis. 2007 , 67, 10840-8	41
1193	The theory of facilitated variation. 2007 , 104 Suppl 1, 8582-9	257

1192	Advances in the management of retinopathy of prematurity. 2007 , 2, 429-442	
1191	VEGF inhibition: latest developments. 2007 , 2, 621-632	
1190	Angiogenic effects of sequential release of VEGF-A165 and PDGF-BB with alginate hydrogels after myocardial infarction. 2007 , 75, 178-85	294
1189	Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy. 2007 , 97, 391-7	53
1188	RNAi-mediated gene silencing of vascular endothelial growth factor inhibits growth of colorectal cancer. 2007 , 22, 841-52	3
1187	Targets for regulating angiogenesis in the ageing endothelium. 2007 , 11, 1385-99	11
1186	New approaches in systemic treatment of advanced colorectal cancer: the molecular targets era. 2007 , 7, 1027-41	2
1185	Thioredoxin and Thioredoxin Reductase As Redox-Sensitive Molecular Targets for Cancer Therapy. 2007 , 13, 3368-3377	59
1184	Effects of acute exercise, exercise training, and diabetes on the expression of lymphangiogenic growth factors and lymphatic vessels in skeletal muscle. 2007 , 293, H2573-9	12
1183	Tumor Immunology, Host Defense Mechanisms, and Biologic Therapy. 2007 , 593-636	
1182	Genetic Dissection of Hematopoiesis Using Drosophila as a Model System. 2007 , 259-299	6
1181	DNA vaccination against VEGF receptor 2 reduces atherosclerosis in LDL receptor-deficient mice. 2007 , 27, 1095-100	51
1180	Tyrosine kinase inhibitors: a potential approach to the treatment of hepatocellular carcinoma. 2007 , 13, 3301-4	11
1179	Perspectives On: Local and Sustained Delivery of Angiogenic Growth Factors. 2007 , 22, 89-114	22
1178	Hypertonic induction of aquaporin-5: novel role of hypoxia-inducible factor-1alpha. 2007 , 292, C1280-90	38
1177	Tumor hypoxia and targeted gene therapy. 2007 , 257, 181-212	8
1176	Expression of vascular endothelial growth factor and its receptors in rosacea. 2007 , 91, 226-9	64
1175	Molecular imaging by cardiovascular MR. 2007 , 9, 827-43	17

1174	Angiogenesis inhibitors. Drug selectivity and target specificity. 2007 , 13, 2795-809	37
1173	Targeted in vivo imaging of angiogenesis: present status and perspectives. 2007 , 13, 17-31	43
1172	Antiangiogenic therapy in malignant glioma: promise and challenge. 2007 , 13, 3545-58	36
1171	Targeted therapies for non-small cell lung cancer. 2007 , 13, 2810-31	13
1170	Eyes wide s-flt: clearly, avascular fidelity is a vascular endothelial growth factor family affair. 2007 , 91, 412-3	
1169	Reactive oxygen species, PKC-beta1, and PKC-zeta mediate high-glucose-induced vascular endothelial growth factor expression in mesangial cells. 2007 , 293, E1280-8	41
1168	Targeting the tumor vasculature to improve the efficacy of oncolytic virus therapy. 2007 , 99, 1739-41	6
1167	Skeletal-Tissue Engineering. 2007 , 935-944	1
1166	Sunitinib: bridging present and future cancer treatment. 2007 , 18 Suppl 6, vi31-4	17
1165	Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. 2007 , 13, 7487-95	150
1164	Overexpression of wild-type androgen receptor in muscle recapitulates polyglutamine disease. 2007 , 104, 18259-64	134
1163	Molecular and cellular regulators of cancer angiogenesis. 2007 , 7, 743-58	55
1162	Pathogenic angiogenesis in IBD and experimental colitis: new ideas and therapeutic avenues. 2007 , 293, G5-G18	116
1161	Early rise in serum VEGF and PDGF levels predisposes patients with a normal MBL2 genotype to restenosis after eversion endarterectomy. 2007 , 38, 2247-53	15
1160	Current treatment of age-related macular degeneration. 2007 , 84, 559-72	25
1159	Serum angiopoietin-2 as a clinical marker for lung cancer. 2007 , 132, 200-6	83
1158	Serum levels, and bone marrow immunohistochemical expression of, vascular endothelial growth factor in patients with chronic myeloproliferative diseases. 2007 , 12, 481-6	15
1157	Angiogenesis in portal hypertension: involvement in increased splanchnic blood flow and collaterals?. 2007 , 62, 271-5	3

1156	Inhibiting angiogenesis in retinoblastoma. 2007 , 39, 188-90	15
1155	Adenovirus-mediated gene transfer of human vascular endothelial growth factor-d induces transient angiogenic effects in mouse hind limb muscle. 2007 , 18, 232-44	21
1154	Use of long-acting somatostatin analogue treatment in diabetic retinopathy. 2007 , 39, 111-121	15
1153	Notch signalling and the regulation of angiogenesis. 2007 , 1, 104-6	51
1152	Therapieoptionen für Patientinnen mit metastasiertem Mammakarzinom nach vorangegangener Anthrazyklin- und Taxanbehandlung. 2007 , 67, 1311-1316	
1151	Angiogenesefaktoren in der Schwangerschaft: Indikatoren für die Präeklampsie. 2007 , 67, 228-235	2
1150	mda-7 In combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft. 2007 , 15, 287-94	37
1149	[Intravitreal medication for age-related macular degeneration (AMD)]. 2007 , 224, R1-23; quiz R24-7	1
1148	Erythropoietin inhibits basal and stimulated corticotropin-releasing hormone release from the rat hypothalamus via a nontranscriptional mechanism. 2007 , 148, 4711-5	9
1147	Role of bevacizumab for the treatment of non-small-cell lung cancer. 2007 , 3, 131-9	11
1146	Biomarkers of lung injury in primary graft dysfunction following lung transplantation. 2007 , 1, 285-91	2
1145	Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma. 2007 , 9, 412-23	127
1144	Mesothelial RAGE activation by AGEs enhances VEGF release and potentiates capillary tube formation. 2007 , 71, 126-33	64
1143	Fibroblast growth factor 2 is more dynamic than vascular endothelial growth factor A during the follicle-luteal transition in the cow. 2007 , 77, 28-36	44
1142	Nonclassic endogenous novel [corrected] regulators of angiogenesis. 2007 , 59, 185-205	148
1141	Targeting the vascular endothelial growth factor pathway in the treatment of human malignancy. 2007 , 36, 3-23	34
1140	Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. 2007 , 12, 443-50	180
1139	Controlled release systems of angiogenic growth factors for cardiovascular diseases. 2007 , 4, 635-49	16

1138	Targeting VEGF-A to treat cancer and age-related macular degeneration. 2007 , 58, 491-504	202
1137	IRE1 signaling is essential for ischemia-induced vascular endothelial growth factor-A expression and contributes to angiogenesis and tumor growth in vivo. 2007 , 67, 6700-7	166
1136	Anti-VEGF agents in the treatment of neovascular AMD. 2007 , 2, 459-465	
1135	Pretreatment with recombinant human vascular endothelial growth factor reduces virus replication and inflammation in a perinatal lamb model of respiratory syncytial virus infection. 2007 , 20, 188-96	20
1134	Targeting neuropilin 1 as an antitumor strategy in lung cancer. 2007 , 13, 4759-68	142
1133	Inhibition of VEGF-A prevents the angiogenic switch and results in increased survival of Apc+/min mice. 2007 , 104, 10625-30	56
1132	Immunity against tumor angiogenesis induced by a fusion vaccine with murine beta-defensin 2 and mFlk-1. 2007 , 13, 6779-87	26
1131	The BTB-Kelch protein KLEIP controls endothelial migration and sprouting angiogenesis. 2007 , 100, 1155-63	25
1130	The potential of antiangiogenic therapy in non-small cell lung cancer. 2007 , 13, 1961-70	57
1129	A single-nucleotide polymorphism in a half-binding site creates p53 and estrogen receptor control of vascular endothelial growth factor receptor 1. 2007 , 27, 2590-600	50
1128	A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism. 2007 , 13, 3951-9	169
1127	Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. 2007 , 50, 686-92	199
1126	Down-regulation of placenta growth factor by promoter hypermethylation in human lung and colon carcinoma. 2007 , 5, 873-80	36
1125	Moderate consumption of red wine (cabernet sauvignon) improves ischemia-induced neovascularization in ApoE-deficient mice: effect on endothelial progenitor cells and nitric oxide. 2007 , 21, 3845-52	71
1124	Bcl-2 orchestrates a cross-talk between endothelial and tumor cells that promotes tumor growth. 2007 , 67, 9685-93	86
1123	Regulation of vascular endothelial growth factor receptor-1 expression by specificity proteins 1, 3, and 4 in pancreatic cancer cells. 2007 , 67, 3286-94	92
1122	Angiogenic role of LYVE-1-positive macrophages in adipose tissue. 2007 , 100, e47-57	199
1121	Antagonism of platelet-derived growth factor receptor in non small cell lung cancer: rationale and investigations. 2007 , 13, s4632-6	22

1120	VEGFR-1 and -2 regulate inflammation, myocardial angiogenesis, and arteriosclerosis in chronically rejecting cardiac allografts. 2007 , 27, 819-25	19
1119	Neutralization of endogenous vascular endothelial growth factor depletes primordial follicles in the mouse ovary. 2007 , 76, 218-23	31
1118	Metronomic chemotherapy enhances the efficacy of antivasular therapy in ovarian cancer. 2007 , 67, 281-8	124
1117	Mast cell degranulation in rat uterine cervix during pregnancy correlates with expression of vascular endothelial growth factor mRNA and angiogenesis. 2007 , 133, 1045-55	29
1116	Investigation of two dosing schedules of vandetanib (ZD6474), an inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling, in combination with irinotecan in a human colon cancer xenograft model. 2007 , 13, 6450-8	36
1115	Unexplained fetal death: another anti-angiogenic state. 2007 , 20, 495-507	44
1114	Distinct architecture of lymphatic vessels induced by chimeric vascular endothelial growth factor-C/vascular endothelial growth factor heparin-binding domain fusion proteins. 2007 , 100, 1468-75	32
1113	Bevacizumab-induced transient remodeling of the vasculature in neuroblastoma xenografts results in improved delivery and efficacy of systemically administered chemotherapy. 2007 , 13, 3942-50	345
1112	Inverse prognostic impact of angiogenic marker expression in tumor cells versus stromal cells in non small cell lung cancer. 2007 , 13, 6649-57	97
1111	FGF9 and SHH regulate mesenchymal Vegfa expression and development of the pulmonary capillary network. 2007 , 134, 3743-52	115
1110	[Pathophysiology of preeclampsia]. 2007 , 47, 199-204	3
1109	Vascular endothelial growth factor increases pulmonary vascular permeability in cystic fibrosis patients undergoing lung transplantation. 2007 , 32, 35-41	28
1108	VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. 2007 , 104, 4647-52	351
1107	Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition. 2007 , 25, 2894-901	65
1106	Vascular endothelial growth factor trap in non small cell lung cancer. 2007 , 13, s4623-7	42
1105	Hif-1alpha regulates differentiation of limb bud mesenchyme and joint development. 2007 , 177, 451-64	158
1104	Effects of short-term vibration and hypoxia during high-intensity cycling exercise on circulating levels of angiogenic regulators in humans. 2007 , 103, 474-83	84
1103	Meeting Report: Fifth Annual AACR Frontiers in Cancer Prevention Research. 2007 , 67, 8989-93	1

1102	Correlations between cyclooxygenase-2 expression and angiogenic factors in primary tumors and liver metastases in colorectal cancer. 2007 , 37, 679-85	27
1101	Inflammatory breast cancer as a model disease to study tumor angiogenesis: results of a phase IB trial of combination SU5416 and doxorubicin. 2007 , 13, 5862-8	44
1100	The role of bevacizumab in the treatment of non-small cell lung cancer: current indications and future developments. 2007 , 12, 1183-93	51
1099	Myeloma Cells and Their Interactions With the Bone Marrow Endothelial Cells. 2007 , 3, 41-55	5
1098	Vandetanib, A Dual Inhibitor of VEGFR and EGFR Tyrosine Kinase Activity. 2007 , 3, 236-241	
1097	Endothelial Progenitor Cells: A Vascular Perspective for Inflammatory Rheumatic Disorders. 2007 , 3, 95-101	
1096	Altered angiogenesis in preeclampsia: evaluation of a new test system for measuring placental growth factor. 2007 , 45, 1504-10	6
1095	Facial hemangioma and hemispheric migration disorder: presentation of 5 patients. 2007 , 28, 1609-12	16
1094	Functional VEGF and VEGF receptors are expressed in human medulloblastomas. 2007 , 9, 384-92	41
1093	Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist. 2007 , 67, 6899-906	42
1092	Inhibition of c-Src expression and activation in malignant pleural mesothelioma tissues leads to apoptosis, cell cycle arrest, and decreased migration and invasion. 2007 , 6, 1962-72	109
1091	Dexamethasone treatment and ICAM-1 deficiency impair VEGF-induced angiogenesis in adult brain. 2007 , 44, 283-91	25
1090	Islet surface heparinization prevents the instant blood-mediated inflammatory reaction in islet transplantation. 2007 , 56, 2008-15	195
1089	The homeobox gene GAX activates p21WAF1/CIP1 expression in vascular endothelial cells through direct interaction with upstream AT-rich sequences. 2007 , 282, 507-17	30
1088	Des-gamma-carboxyl prothrombin-promoted vascular endothelial cell proliferation and migration. 2007 , 282, 8741-8	47
1087	Bevacizumab (Avastin). 2008 , 779-812	
1086	Antitumor effects of ZD6474 on head and neck squamous cell carcinoma. 2007 , 17, 289	1
1085	Negligible radiation protection of endothelial cells by vascular endothelial growth factor. 2007 ,	1

1084	Methylmercury Retards the Repair of Wounded Monolayer of Human Brain Microvascular Endothelial Cells by Inhibiting Their Proliferation without Nonspecific Cell Damage. 2007 , 53, 450-456	8
1083	VEGFR-1 (FLT-1), beta1 integrin, and hERG K ⁺ channel for a macromolecular signaling complex in acute myeloid leukemia: role in cell migration and clinical outcome. 2007 , 110, 1238-50	147
1082	Vascular endothelial growth factor-A induces plaque expansion in ApoE knock-out mice by promoting de novo leukocyte recruitment. 2007 , 109, 122-9	69
1081	MCP-1 mediates TGF-beta-induced angiogenesis by stimulating vascular smooth muscle cell migration. 2007 , 109, 987-94	170
1080	Orientation of endothelial cell division is regulated by VEGF signaling during blood vessel formation. 2007 , 109, 1345-52	110
1079	Distinct roles of VEGFR-1 and VEGFR-2 in the aberrant hematopoiesis associated with elevated levels of VEGF. 2007 , 110, 624-31	162
1078	VEGF-A produced by chronically inflamed tissue induces lymphangiogenesis in draining lymph nodes. 2007 , 110, 3158-67	149
1077	Nanostructures for Tissue Engineering/Regenerative Medicine. 375-407	3
1076	Bibliography. Current world literature. Hormones, autacoids, neurotransmitters and growth factors. 2007 , 16, 52-7	
1075	Growth factors for therapeutic angiogenesis in peripheral arterial disease. 2007 , 22, 458-63	40
1074	Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model. 2007 , 18, 569-79	26
1073	Antiangiogenic therapy for cancer: an update. 2007 , 13, 345-8	53
1072	The role of neurotrophic factors in adult hippocampal neurogenesis, antidepressant treatments and animal models of depressive-like behavior. 2007 , 18, 391-418	522
1071	Molecular Targets for Promoting Wound Healing in Diabetes. 2007 , 1, 1-13	8
1070	Soluble vascular endothelial growth factor receptor-1 protects mice in sepsis. 2007 , 35, 1955-60	51
1069	Mechanisms operative in the antitumor activity of temozolomide in glioblastoma multiforme. 2007 , 13, 335-44	26
1068	Vascular endothelial growth factor and its receptor as drug targets in hematological malignancies. 2007 , 8, 257-68	42
1067	Clinical implication of vascular endothelial growth factor T-460C polymorphism in the risk and progression of prostate cancer. 2007 ,	1

1066	Assessment of local angiogenesis and vascular endothelial growth factor in the patients with atrophic-erosive and reticular oral lichen planus. 2007 , 103, 661-9	45
1065	Update in colorectal, hepatobiliary and pancreatic cancers. 2007 , 2, 141-156	
1064	Detection of vascular endothelial growth factor (VEGF) and VEGF receptors Flt-1 and KDR in canine mastocytoma cells. 2007 , 115, 320-33	42
1063	Paracrine and autocrine mechanisms of apelin signaling govern embryonic and tumor angiogenesis. 2007 , 305, 599-614	141
1062	Structure-function analysis of the antiangiogenic ATWLPPR peptide inhibiting VEGF(165) binding to neuropilin-1 and molecular dynamics simulations of the ATWLPPR/neuropilin-1 complex. 2007 , 28, 2397-402	86
1061	Regulation and biological activities of the autotaxin-LPA axis. 2007 , 46, 145-60	294
1060	Gene expression and association analysis of vascular endothelial growth factor in major depressive disorder. 2007 , 31, 658-63	77
1059	Expression of angiogenic and neurotrophic factors in the progenitor cell niche of adult monkey subventricular zone. 2007 , 144, 1425-35	37
1058	Insulin-like growth factor type I biology and targeting in malignant gliomas. 2007 , 145, 795-811	87
1057	Squalamine lactate for the treatment of age-related macular degeneration. 2007 , 2, 165-175	8
1056	Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. 2007 , 144, 627-37	179
1055	Activation of growth factor receptors in pancreatic cancer. 2007 , 194, S76-S83	1
1054	A novel angiogenesis inhibitor, Ki23057, is useful for preventing the progression of colon cancer and the spreading of cancer cells to the liver. 2007 , 43, 2612-20	13
1053	New anti angiogenesis developments through electro-immunization: optimization by in vivo optical imaging of intradermal electro gene transfer. 2007 , 1770, 137-42	16
1052	Age-dependent expression of VEGF isoforms and receptors in the rabbit anterior cruciate ligament. 2007 , 1770, 997-1002	13
1051	Vascular endothelial growth factor and activin-a serum levels following allogeneic hematopoietic stem cell transplantation. 2007 , 13, 942-7	20
1050	Supercritical carbon dioxide generated vascular endothelial growth factor encapsulated poly(DL-lactic acid) scaffolds induce angiogenesis in vitro. 2007 , 352, 135-41	73
1049	AMP-activated protein kinase mediates VEGF-stimulated endothelial NO production. 2007 , 354, 1084-8	76

1048	Vascular endothelial growth factor family of ligands and receptors: review. 2007 , 38, 258-68	250
1047	Understanding the biology of angiogenesis: review of the most important molecular mechanisms. 2007 , 39, 212-20	241
1046	Effects of anti-VEGF antibody on blood-brain barrier disruption in focal cerebral ischemia. 2007 , 204, 283-7	49
1045	FoxOs are lineage-restricted redundant tumor suppressors and regulate endothelial cell homeostasis. 2007 , 128, 309-23	836
1044	Vascular endothelial growth factor: biology and therapeutic applications. 2007 , 39, 1349-57	129
1043	Targeting novel and established therapies for non-small cell lung cancer. 2007 , 250, 9-16	10
1042	Bombesin induces angiogenesis and neuroblastoma growth. 2007 , 253, 273-81	49
1041	Vascular endothelial growth factor and its relationship with the dental pulp. 2007 , 33, 524-30	60
1040	Vascular endothelial growth factor receptor-2 expression in the pulp of human primary and young permanent teeth. 2007 , 33, 1408-12	26
1039	VEGF is important for early liver regeneration after partial hepatectomy. 2007 , 138, 291-9	87
1038	Expression of vascular endothelial growth factor receptor-2 in the muscle flap with ischemic injury in rats. 2007 , 140, 45-9	4
1037	Splenic hemodynamics and decreased endothelial nitric oxide synthase in the spleen of rats with liver cirrhosis. 2007 , 80, 2036-44	13
1036	Histological alterations in the livers of Cx43-deficient mice submitted to a cholestasis model. 2007 , 81, 380-4	6
1035	Aldosterone upregulates vascular endothelial growth factor expression in mouse cortical collecting duct epithelial cells through classic mineralocorticoid receptor. 2007 , 81, 570-6	9
1034	Essential factors associated with hepatic angiogenesis. 2007 , 81, 1555-64	7
1033	Expression of vascular endothelial growth factor (VEGF) in normal oral mucosa, oral dysplasia and oral squamous cell carcinoma. 2007 , 36, 263-6	34
1032	The expression and production of vascular endothelial growth factor in oral mucosa equivalents. 2007 , 36, 928-33	19
1031	Antiangiogenic activity of <i>Andrographis paniculata</i> extract and andrographolide. 2007 , 7, 211-21	94

1030	VEGF-targeted cancer therapy strategies: current progress, hurdles and future prospects. 2007 , 13, 223-30	111
1029	Edaravone inhibits the expression of vascular endothelial growth factor in human astrocytes exposed to hypoxia. 2007 , 59, 406-12	25
1028	Collagen vitrigel membrane useful for paracrine assays in vitro and drug delivery systems in vivo. 2007 , 131, 76-83	49
1027	VEGF-A and the induction of pathological angiogenesis. 2007 , 2, 251-75	284
1026	Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. 2007 , 28, 297-321	278
1025	Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. 2007 , 170, 1-15	304
1024	Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human hepatic stellate cells. 2007 , 170, 1942-53	172
1023	Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. 2007 , 171, 53-67	565
1022	Alternative splicing: an emerging topic in molecular and clinical oncology. 2007 , 8, 349-57	211
1021	Vascular endothelial growth factor receptor-3 activity is modulated by its association with caveolin-1 on endothelial membrane. 2007 , 46, 3998-4005	26
1020	Elevated serum sFlt-1/Ang-2 ratio in women with preeclampsia. 2007 , 106, c43-50	24
1019	Drug insight: VEGF as a therapeutic target for breast cancer. 2007 , 4, 181-9	83
1018	Cancer Biology. 2007 , 1-31	1
1017	Soluble Fas ligand inhibits angiogenesis in rheumatoid arthritis. 2007 , 9, R42	26
1016	Selection Strategies I: Monoclonal Antibodies. 18-44	0
1015	Development of Angiogenesis Inhibitors to Vascular Endothelial Growth Factor Receptor 2 for Cancer Therapy. 2007 , 333-382	
1014	Angiogenesis and Cancer. 2007 , 35-61	2
1013	Colorectal Cancer. 2007 ,	1

1012 Angiogenesis. **2007**, 1-6

1011 Alkynylpyrimidine amide derivatives as potent, selective, and orally active inhibitors of Tie-2 kinase. **2007**, 50, 627-40 24

1010 Myeloid leukemias express a broad spectrum of VEGF receptors including neuropilin-1 (NRP-1) and NRP-2. **2007**, 48, 1997-2007 28

1009 The developing trend of monoclonal antibodies in the treatment of colorectal cancer. **2007**, 7, 871-83 6

1008 Clinical trials of VEGF receptor tyrosine kinase inhibitors in pancreatic cancer. **2007**, 16, 467-76 17

1007 A new era in the treatment of age-related macular degeneration: from Factor X to antiangiogenesis. **2007**, 17, 1351-1363 3

1006 The therapeutic potential of VEGF inhibition in diabetic microvascular complications. **2007**, 7, 393-8 23

1005 Investigational agents against platinum-resistant ovarian cancer. **2007**, 16, 325-36 4

1004 Adipogenesis in obesity requires close interplay between differentiating adipocytes, stromal cells, and blood vessels. **2007**, 56, 1517-26 362

1003 Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. **2007**, 16, 239-49 112

1002 VEGF-D is expressed in activated lymphoid cells and in tumors of hematopoietic and lymphoid tissues. **2007**, 48, 2014-21 14

1001 Benzochromenones from the marine crinoid *Comantheria rotula* inhibit hypoxia-inducible factor-1 (HIF-1) in cell-based reporter assays and differentially suppress the growth of certain tumor cell lines. **2007**, 70, 1462-6 22

1000 Molecular-targeted antitumor agents. 15. Neolamellarins from the marine sponge *Dendrilla nigra* inhibit hypoxia-inducible factor-1 activation and secreted vascular endothelial growth factor production in breast tumor cells. **2007**, 70, 1741-5 51

999 Bevacizumab in the treatment of colorectal cancer. **2007**, 7, 739-49 19

998 VEGF: an essential mediator of both angiogenesis and endochondral ossification. **2007**, 86, 937-50 281

997 Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer. **2007**, 13, 898-901 93

996 Vascular disrupting agents in clinical development. **2007**, 96, 1159-65 194

995 Augmented healing process in female mice with acute myocardial infarction. **2007**, 4, 230-47 24

994	Molecular characterization of post-thrombotic syndrome. 2007 , 45 Suppl A, A116-22	29
993	Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages. 2007 , 1, 288-302	125
992	The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. 2007 , 5, 203-20	323
991	[Biologic therapy: current and future applications in oncology]. 2007 , 129, 184-93	3
990	Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins. 2007 , 5, 32	262
989	A cell-based model exhibiting branching and anastomosis during tumor-induced angiogenesis. 2007 , 92, 3105-21	236
988	Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma. 2007 , 67, 333-50	84
987	The direct effects of anti-vascular endothelial growth factor therapy on tumor cells. 2007 , 6, 564-71	7
986	Intravenous infusion of dihydrogensenoside Rb1 prevents compressive spinal cord injury and ischemic brain damage through upregulation of VEGF and Bcl-XL. 2007 , 24, 1037-54	36
985	Physiologic angiodynamics in the brain. 2007 , 9, 1363-71	110
984	Highlights from: The 43rd Annual Meeting of the American Society of Clinical Oncology; Chicago, IL; June 1 st , 2007. 2007 , 6, 614-620	
983	The clinical efficacy of FOLFIRI and bevacizumab in combination as first-line therapy of metastatic colorectal cancer. 2007 , 6, 621-4	5
982	Endothelial activation and dysregulation: A common pathway to organ injury in infectious diseases associated with systemic inflammation. 2007 , 4, 215-222	3
981	Lack of association between -460 C/T and 936 C/T of the vascular endothelial growth factor and angiopoietin-2 exon 4 G/A polymorphisms and ovarian, cervical, and endometrial cancers. 2007 , 26, 453-63	22
980	Current stumbling blocks in oncology drug development. 2007 , 135-49	2
979	Functional significance of apoptosis in chronic obstructive pulmonary disease. 2007 , 4, 347-53	73
978	Inhibition of angiogenesis and invasion in malignant gliomas. 2007 , 7, 1537-60	44
977	Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. 2007 , 357, 2666-76	2529

976	The role of Egfl7 in vascular morphogenesis. 2007 , 283, 18-28; discussion 28-36, 238-41	15
975	Nuclear factor of activated T cells and early growth response-1 cooperate to mediate tissue factor gene induction by vascular endothelial growth factor in endothelial cells. 2007 , 97, 988-97	55
974	Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer. 2007 , Volume 2, 0-0	
973	Synergies of VEGF inhibition and photodynamic therapy in the treatment of age-related macular degeneration. 2007 , 48, 1767-72	29
972	Markers of angiogenesis in ovarian cancer. 2007 , 23, 419-31	20
971	Targeting the molecular effects of a hypoxic tumor microenvironment. 2007 , 12, 4061-78	17
970	Signaling Chains. 2007 , 189-214	
969	Increased vascular endothelial growth factor levels in aqueous humor and serum of patients with quiescent uveitis. 2007 , 17, 938-42	31
968	[VE-cadherin takes a walk on the wild side]. 2007 , 23, 119-21	0
967	The role of VEGF and VEGFR2/Flk1 in proliferation of retinal progenitor cells in murine retinal degeneration. 2007 , 48, 4315-20	18
966	Transforming Growth Factor- β and the Endothelium. 304-323	
965	Expression of vascular endothelial growth factor receptor-3 in the endometrium in menorrhagia. 2007 ,	
964	Liver Sinusoidal Endothelial Cells. 29-35	
963	[The physiology of wound healing]. 2007 , 64, 467-72	2
962	M12-04: EGFR/VEGF Inhibitors in combination with other modalities: Zactima (ZD6474) in combination. 2007 , 2, S186-S187	
961	Mechanisms of angiogenesis in chronic inflammatory liver disease. 2007 , 6, 208-213	32
960	Angiogenesis. 1444-1456	
959	. 2007 ,	

958	. 2007,	21
957	Growth factor gradients in vascular patterning. 2007, 283, 194-201; discussion 201-6, 238-41	24
956	Angiogenesis. 2007,	1
955	Anti-angiogenic and Anti-stromal Therapy. 2007,	
954	Regulation of embryonic lung vascular development by vascular endothelial growth factor receptors, Flk-1 and Flt-1. 2007, 290, 958-73	25
953	Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer. 2007, 29, 1159-68	69
952	Engineered blood and lymphatic capillaries in 3-D VEGF-fibrin-collagen matrices with interstitial flow. 2007, 96, 167-76	107
951	Simultaneous blockade of VEGFR-1 and VEGFR-2 activation is necessary to efficiently inhibit experimental melanoma growth and metastasis formation. 2007, 120, 1899-908	40
950	Effects of oncostatin M on secretion of vascular endothelial growth factor and reconstruction of liver-like structure by fetal liver cells in monolayer and three-dimensional cultures. 2007, 82, 73-9	8
949	The role of the organ microenvironment in the biology and therapy of cancer metastasis. 2007, 101, 927-36	110
948	Tumor microenvironment abnormalities: causes, consequences, and strategies to normalize. 2007, 101, 937-49	411
947	Vasculogenesis, angiogenesis, and arteriogenesis: mechanisms of blood vessel formation and remodeling. 2007, 102, 840-7	223
946	VEGF in biological control. 2007, 102, 1358-67	155
945	Flt-1, but not Flk-1 mediates hyperpermeability through activation of the PI3-K/Akt pathway. 2007, 212, 236-43	54
944	Tubular sprouting as a mode of vascular formation in a colonial ascidian (Tunicata). 2007, 236, 719-31	24
943	Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats. 2007, 46, 1208-17	144
942	Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. 2007, 46, 1919-26	213
941	Helper-dependent adenovirus for the gene therapy of proliferative retinopathies: stable gene transfer, regulated gene expression and therapeutic efficacy. 2007, 9, 862-74	41

940	Role of fibroblasts and fibroblast-derived growth factors in periprosthetic angiogenesis. 2007 , 25, 1378-88	23
939	ortho-Substituted azoles as selective and dual inhibitors of VEGF receptors 1 and 2. 2007 , 17, 1369-75	12
938	Synthesis and biological study of 2-amino-4-aryl-5-chloropyrimidine analogues as inhibitors of VEGFR-2 and cyclin dependent kinase 1 (CDK1). 2007 , 17, 2179-83	14
937	Tumor microenvironment promotes cancer progression, metastasis, and therapeutic resistance. 2007 , 31, 36-100	82
936	Bevacizumab-associated reversible hypotension. 2007 , 19, 800-1	2
935	Characterization and development of a peptide substrate-based phosphate transfer assay for the human vascular endothelial growth factor receptor-2 tyrosine kinase. 2007 , 360, 196-206	6
934	Development of a chemiluminescent screening assay for detection of vascular endothelial growth factor receptor 1 ligands. 2007 , 366, 108-10	36
933	Polymers for pro- and anti-angiogenic therapy. 2007 , 28, 2069-76	78
932	Thienopyridine urea inhibitors of KDR kinase. 2007 , 17, 1246-9	40
931	Antiangiogenesis and vascular endothelial growth factor/vascular endothelial growth factor receptor targeting as part of a combined-modality approach to the treatment of cancer. 2007 , 69, S64-6	17
930	Nucleic acid delivery: Where material sciences and bio-sciences meet. 2007 , 58, 117-161	79
929	Dynamical behavior of the vascular endothelial growth factor: biological implications. 2007 , 67, 517-25	8
928	Green tea polyphenol EGCG suppresses cigarette smoke condensate-induced NF-kappaB activation in normal human bronchial epithelial cells. 2007 , 26, 673-82	106
927	cAMP-responsive element-binding protein regulates vascular endothelial growth factor expression: implication in human prostate cancer bone metastasis. 2007 , 26, 5070-7	106
926	Bevacizumab in the treatment of non-small-cell lung cancer. 2007 , 26, 3691-8	22
925	Gene expression for VEGF-A, VEGF-C, and their receptors in murine lymphocytes and macrophages. 2007 , 72, 1194-8	25
924	Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. 2007 , 25, 911-20	727
923	Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes. <i>Nature Medicine</i> , 2007 , 13, 504-9	50.5 213

922	Angiogenic inhibition reduces germinal matrix hemorrhage. <i>Nature Medicine</i> , 2007 , 13, 477-85	50.5	114
921	Molecular regulation of angiogenesis and lymphangiogenesis. 2007 , 8, 464-78		1445
920	Upregulation of Flk-1 by bFGF via the ERK pathway is essential for VEGF-mediated promotion of neural stem cell proliferation. 2007 , 17, 73-9		76
919	VEGF C-634G polymorphism is associated with protection from isolated ventricular septal defect: case-control and TDT studies. 2007 , 15, 1246-51		24
918	Human blood late outgrowth endothelial cells for gene therapy of cancer: determinants of efficacy. 2007 , 14, 344-56		21
917	Anti-angiogenic properties of a sulindac analogue. 2007 , 152, 1207-14		14
916	Antiangiogenesis to treat cancer and intraocular neovascular disorders. 2007 , 87, 227-30		48
915	Bv8 regulates myeloid-cell-dependent tumour angiogenesis. 2007 , 450, 825-31		510
914	Gene expression profiling in whole liver of bile duct ligated rats: VEGF-A expression is up-regulated in hepatocytes adjacent to the portal tracts. 2007 , 22, 1993-2000		5
913	The significance of VEGF-C/VEGFR-2 interaction in the neovascularization and prognosis of nephroblastoma (Wilms' tumour). 2007 , 50, 358-64		23
912	Photodynamic therapy combined with a cysteine proteinase inhibitor synergistically decrease VEGF production and promote tumour necrosis in a rat mammary carcinoma. 2007 , 40, 38-49		6
911	Bevacizumab, a humanized anti-angiogenic monoclonal antibody for the treatment of colorectal cancer. 2007 , 32, 1-14		90
910	Fas-mediated upregulation of vascular endothelial growth factor and monocyte chemoattractant protein-1 expression in cultured dermal fibroblasts: role in the inflammatory response. 2007 , 34, 99-109		6
909	Glial cell-derived glutamate mediates autocrine cell volume regulation in the retina: activation by VEGF. 2008 , 104, 386-99		46
908	The timed-pregnant baboon animal model can be used for determining the role of soluble vascular endothelial growth factor receptors 1 and 2 during development. 2007 , 36, 370-4		6
907	Guidance for the treatment of neovascular age-related macular degeneration. 2007 , 85, 486-94		28
906	The anti-angiogenic substance TNP-470 impairs peri-implant bone formation: a pilot study in the rabbit metaphysis model. 2007 , 18, 370-5		20
905	Ranibizumab for the treatment of neovascular AMD. 2007 , 61, 501-9		19

904	Expression of connective tissue growth factor is in agreement with the expression of VEGF, VEGF-C, -D and associated with shorter survival in gastric cancer. 2007 , 57, 712-8	23
903	Adjuvant treatment of colorectal cancer. 2007 , 57, 168-85	193
902	Novel small-molecule inhibitors of the vascular endothelial growth factor receptor. 2007 , 8 Suppl 2, S74-8	7
901	Regulation of endothelial glutathione by ICAM-1 governs VEGF-A-mediated eNOS activity and angiogenesis. 2007 , 42, 720-9	44
900	Combination of VEGF(165)/Angiopoietin-1 gene and endothelial progenitor cells for therapeutic neovascularization. 2007 , 568, 222-30	22
899	Serum levels of vascular endothelial growth factor (VEGF) and endostatin in renal cell carcinoma patients compared to a control group. 2007 , 51, 168-73; discussion 174	37
898	Associations of single nucleotide polymorphisms in the vascular endothelial growth factor gene with the characteristics and prognosis of renal cell carcinomas. 2007 , 52, 1147-55	55
897	Neovastat (AE-941) inhibits the airway inflammation via VEGF and HIF-2 alpha suppression. 2007 , 47, 313-8	20
896	Intra- and extracellular signaling by endothelial neuregulin-1. 2007 , 313, 2896-909	40
895	VEGF-induced Rac1 activation in endothelial cells is regulated by the guanine nucleotide exchange factor Vav2. 2007 , 313, 3285-97	136
894	Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies. 2007 , 104, 768-78	59
893	Vascular endothelial growth factor gene polymorphisms in ovarian cancer. 2007 , 105, 385-9	26
892	Recipient vascular endothelial growth factor serum levels predict primary lung graft dysfunction. 2007 , 7, 700-6	42
891	ESDN is a marker of vascular remodeling and regulator of cell proliferation in graft arteriosclerosis. 2007 , 7, 2098-105	19
890	Vascular endothelial growth factor in children with nephrotic syndrome treated with cyclosporine A. 2007 , 95, 291-296	
889	Autonomously vascularized cellular constructs in tissue engineering: opening a new perspective for biomedical science. 2007 , 11, 6-20	68
888	Increased VEGFR2 expression during human late endothelial progenitor cells expansion enhances in vitro angiogenesis with up-regulation of integrin alpha(6). 2007 , 11, 1149-61	81
887	Mesenchymal stem cells and neovascularization: role of platelet-derived growth factor receptors. 2007 , 11, 1012-30	133

886	Cancer stem cells: the lessons from pre-cancerous stem cells. 2008 , 12, 67-96	71
885	Management of neovascular age-related macular degeneration. 2007 , 26, 437-51	64
884	Dynamic contrast-enhanced MR imaging in cancer. 2007 , 13, e45-e53	4
883	Subchronic inhalation of soluble manganese induces expression of hypoxia-associated angiogenic genes in adult mouse lungs. 2007 , 221, 148-57	17
882	Neonatal hypoxic preconditioning involves vascular endothelial growth factor. 2007 , 26, 243-52	50
881	Sustained release of bioactive therapeutic proteins from a biodegradable elastomeric device. 2007 , 117, 80-9	51
880	Expression of vascular endothelial growth factor and its receptors in canine lymphoma. 2007 , 137, 30-40	24
879	Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. 2007 , 50, 203-18	139
878	Fetal growth plate: a developmental model of cellular adaptation to hypoxia. 2007 , 1117, 26-39	51
877	Evolution of a highly selective and potent 2-(pyridin-2-yl)-1,3,5-triazine Tie-2 kinase inhibitor. 2007 , 50, 611-26	82
876	Sunitinib: from rational design to clinical efficacy. 2007 , 25, 884-96	732
875	Placental growth factor-1 potentiates hematopoietic progenitor cell mobilization induced by granulocyte colony-stimulating factor in mice and nonhuman primates. 2007 , 25, 252-61	12
874	Vascular endothelial growth factor and bevacitumab in breast cancer. 2007 , 14, 163-73	33
873	Spatiotemporal control over growth factor signaling for therapeutic neovascularization. 2007 , 59, 1340-50	100
872	Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor. 2007 , 196, 326.e1-13	182
871	Characterization and differential expression of vascular endothelial growth factor isoforms and receptors in swine corpus luteum throughout estrous cycle. 2007 , 74, 163-71	29
870	A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. 2007 , 14, 2367-76	125
869	The synergistic action of a VEGF-receptor tyrosine-kinase inhibitor and a sensitizing PDGF-receptor blocker depends upon the stage of vascular maturation. 2007 , 14, 813-25	21

868	Molecular mechanisms in chronic obstructive pulmonary disease: potential targets for therapy. 2007 , 47, 131-48	32
867	Novel short peptides isolated from phage display library inhibit vascular endothelial growth factor activity. 2007 , 35, 51-63	20
866	Mechanisms of disease: angiogenesis and the management of breast cancer. 2007 , 4, 536-50	93
865	Antibody-based targeting of the tumor vasculature. 2007 , 1776, 175-92	35
864	VEGF isoforms and receptors expression throughout acute acetaminophen-induced liver injury and regeneration. 2007 , 81, 729-41	18
863	Upregulation of VEGF in subchondral bone of necrotic femoral heads in rabbits with use of extracorporeal shock waves. 2007 , 81, 124-31	75
862	Impaired insulin secretion in vivo but enhanced insulin secretion from isolated islets in pancreatic beta cell-specific vascular endothelial growth factor-A knock-out mice. 2007 , 50, 380-9	63
861	Imaging of angiogenesis in cardiology. 2007 , 34 Suppl 1, S9-19	13
860	Challenges for patient selection with VEGF inhibitors. 2007 , 60, 151-70	72
859	Gliostatin/thymidine phosphorylase-regulated vascular endothelial growth-factor production in human fibroblast-like synoviocytes. 2007 , 27, 553-9	9
858	Endogenous expression of angiogenesis-related factors in response to muscle injury. 2007 , 298, 151-9	36
857	Expression of VEGF and its receptor genes in intracranial schwannomas. 2007 , 83, 259-66	45
856	Polymorphisms in the KDR and POSTN genes: association with breast cancer susceptibility and prognosis. 2007 , 101, 83-93	47
855	Functional significance of vascular endothelial growth factor receptors on gastrointestinal cancer cells. 2007 , 26, 433-41	49
854	Molecular pathogenesis and its therapeutic modalities of lung cancer metastasis to bone. 2007 , 26, 685-9	42
853	Tumour vascularization: sprouting angiogenesis and beyond. 2007 , 26, 489-502	397
852	Prophylactic naked DNA vaccination with the human vascular endothelial growth factor induces an anti-tumor response in C57Bl/6 mice. 2007 , 10, 23-34	20
851	Angiogenesis and chronic inflammation: cause or consequence?. 2007 , 10, 149-66	325

850	Angiogenesis as a therapeutic target in arthritis: learning the lessons of the colorectal cancer experience. 2007 , 10, 243-58	34
849	Antikörpertherapie in klinischer und präklinischer Anwendung bei gastrointestinalen Karzinomen. 2007 , 13, 236-249	
848	Angiogenesis in cancer: molecular mechanisms, clinical impact. 2007 , 392, 371-9	72
847	Progress in defining the molecular biology of age related macular degeneration. 2007 , 122, 219-36	58
846	Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors. 2007 , 8, 15-27	98
845	Chemotherapy agents and hypertension: a focus on angiogenesis blockade. 2007 , 9, 320-8	57
844	Impaired TNFalpha-induced VEGF expression in human airway smooth muscle cells from smokers with COPD: role of MAPkinases and histone acetylation--effect of dexamethasone. 2007 , 49, 98-110	19
843	VEGF immunopositivity related to malignancy degree, proliferative activity and angiogenesis in ENU-induced gliomas. 2007 , 33, 163-72	14
842	Metronomic chemotherapy: an antiangiogenic scheduling. 2007 , 9, 93-8	51
841	VEGF: a key therapeutic target for the treatment of cancer--insights into its role and pharmacological inhibition. 2007 , 2, 153-164	8
840	Targeted therapy in advanced colorectal cancer, an update. 2007 , 2, 165-172	2
839	New angiogenic agents and non-small cell lung cancer: current results and future development. 2007 , 2, 211-223	2
838	Underexpression of mineralocorticoid receptor in colorectal carcinomas and association with VEGFR-2 overexpression. 2007 , 11, 1521-8	15
837	Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: from lab to clinic. 2007 , 61, 52-69	132
836	The potential impact of the preparation rich in growth factors (PRGF) in different medical fields. 2007 , 28, 4551-60	369
835	On the structure, interactions, and dynamics of bound VEGF. 2008 , 26, 1091-103	7
834	Spatial distribution of VEGF isoforms and chemotactic signals in the vicinity of a tumor. 2008 , 252, 593-607	14
833	The dosage dependence of VEGF stimulation on scaffold neovascularisation. 2008 , 29, 3531-8	74

832	Expression profile of total VEGF, VEGF splice variants and VEGF receptors in the myocardium and arterial vasculature of diabetic and non-diabetic patients with coronary artery disease. 2008 , 41, 82-7	19
831	Hypoxia-inducible factor 1alpha is closely linked to an aggressive phenotype in breast cancer. 2008 , 110, 465-75	122
830	No association between polymorphism in the vascular endothelial growth factor gene at position -460 and sporadic prostate cancer in the Turkish population. 2008 , 35, 17-22	30
829	Effects of the VEGFR inhibitor ZD6474 in combination with radiotherapy and temozolomide in an orthotopic glioma model. 2008 , 88, 1-9	34
828	Mathematical modelling of the evolution of protein distribution within single PLGA microspheres: prediction of local concentration profiles and release kinetics. 2008 , 19, 1587-93	20
827	Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation. 2008 , 26, 393-7	45
826	Rats surviving injurious mechanical ventilation show reversible pulmonary, vascular and inflammatory changes. 2008 , 34, 948-56	28
825	Anti-angiogenic active immunotherapy: a new approach to cancer treatment. 2008 , 57, 1105-14	12
824	Recombinant adenovirus as a methodology for exploration of physiologic functions of growth factor pathways. 2008 , 86, 161-9	14
823	Does regular consumption of green tea influence expression of vascular endothelial growth factor and its receptor in aged rat erectile tissue? Possible implications for vasculogenic erectile dysfunction progression. 2008 , 30, 217-28	12
822	VEGF-specific siRNAs modified with 2'-deoxy effectively suppress VEGF expression and inhibit growth of nasopharyngeal carcinoma xenograft in a mouse model. 2008 , 51, 104-10	2
821	Advanced non-small cell lung cancer therapy: historical and future perspectives. 2008 , 3, 135-147	2
820	Modeling the VEGF-Bcl-2-CXCL8 pathway in intratumoral angiogenesis. 2008 , 70, 89-117	38
819	The emerging role of anti-angiogenic therapy for malignant glioma. 2008 , 9, 1-22	27
818	Angiogenesis, Kaposi's Sarcoma and Kaposi's Sarcoma-Associated Herpesvirus. 2008 , 23, 449-458	10
817	The determination of VEGF and MVD, among patients with primary breast cancer. 2008 , 14, 137-44	7
816	A dialogue between the hypoxia-inducible factor and the tumor microenvironment. 2008 , 1, 53-68	71
815	Expression and clinical significance of vascular endothelial growth factor in benign and malignant tissues of breast. 2008 , 20, 290-293	1

814	Current status of anti-vascular endothelial growth factor therapy in Europe. 2008 , 52, 433-439	23
813	Selection of DNA aptamers against VEGF165 using a protein competitor and the aptamer blotting method. 2008 , 30, 829-34	66
812	Chemotherapy for metastatic gastric cancer: past, present, and future. 2008 , 43, 256-64	142
811	Expression of the SST receptor 2 in uveal melanoma is not a prognostic marker. 2008 , 246, 1585-92	3
810	Dual inhibition of Raf and VEGFR2 reduces growth and vascularization of hepatocellular carcinoma in an experimental model. 2008 , 393, 333-41	10
809	Levels of VEGF-A mRNA in plasma from patients with colorectal carcinoma as possible surrogate marker of angiogenesis. 2008 , 134, 1165-71	12
808	Chondromodulin-I and tenomodulin are differentially expressed in the avascular mesenchyme during mouse and chick development. 2008 , 332, 111-22	38
807	Cheiradone: a vascular endothelial cell growth factor receptor antagonist. 2008 , 9, 7	7
806	Loss of Notch signalling induced by Dll4 causes arterial calibre reduction by increasing endothelial cell response to angiogenic stimuli. 2008 , 8, 117	57
805	Desferrioxamine-driven upregulation of angiogenic factor expression by human bone marrow stromal cells. 2008 , 2, 272-8	24
804	Structure-based design of a bicyclic peptide antagonist of the vascular endothelial growth factor receptors. 2008 , 14, 767-72	11
803	Maturation changes in laminin, fibronectin, collagen IV, and perlecan in germinal matrix, cortex, and white matter and effect of betamethasone. 2008 , 86, 1482-500	42
802	Multi-targeted therapy by curcumin: how spicy is it?. 2008 , 52, 1010-30	166
801	Potentially functional polymorphisms of the vascular endothelial growth factor gene and risk of gastric cancer. 2008 , 47, 647-51	36
800	Correlations of the expression of vascular endothelial growth factor B and its isoforms in hepatocellular carcinoma with clinico-pathological parameters. 2008 , 98, 190-6	53
799	Low-energy laser irradiation increases endothelial cell proliferation, migration, and eNOS gene expression possibly via PI3K signal pathway. 2008 , 40, 46-54	95
798	VEGF and VEGFR-1 are coexpressed by epithelial and stromal cells of renal cell carcinoma. 2008 , 112, 433-42	18
797	Application of cryobiopsy to morphological and immunohistochemical analyses of xenografted human lung cancer tissues and functional blood vessels. 2008 , 113, 1068-79	36

796	Role of vascular endothelial growth factor and angiopoietin systems in serum of Crohn's disease patients. 2008 , 14, 61-7	32
795	Identification of novel antiangiogenic anticancer activities of deguelin targeting hypoxia-inducible factor-1 alpha. 2008 , 122, 5-14	63
794	Targeting vasculature in urologic tumors: mechanistic and therapeutic significance. 2008 , 103, 691-708	35
793	Human head and neck squamous cell carcinoma cells are both targets and effectors for the angiogenic cytokine, VEGF. 2008 , 105, 1202-10	23
792	TGF-beta1 induces rearrangement of FLK-1-VE-cadherin-beta-catenin complex at the adherens junction through VEGF-mediated signaling. 2008 , 105, 1367-73	18
791	Hemodynamic changes in splanchnic blood vessels in portal hypertension. 2008 , 291, 699-713	32
790	In vivo activity of ABT-869, a multi-target kinase inhibitor, against acute myeloid leukemia with wild-type FLT3 receptor. 2008 , 32, 1091-100	22
789	Progibiteurs endothiaux et maladies rhumatismales. 2008 , 75, 207-213	
788	Prognostic factors and selection for clinical studies of patients with kidney cancer. 2008 , 65, 235-62	60
787	Synthesis and evaluation of heteroaryl-ketone derivatives as a novel class of VEGFR-2 inhibitors. 2008 , 18, 4344-7	8
786	A fluorescence polarization assay for identifying ligands that bind to vascular endothelial growth factor. 2008 , 378, 8-14	21
785	Correlation between tumor growth delay and expression of cancer and host VEGF, VEGFR2, and osteopontin in response to radiotherapy. 2008 , 72, 918-26	37
784	The role of actively released fibrin-conjugated VEGF for VEGF receptor 2 gene activation and the enhancement of angiogenesis. 2008 , 29, 1720-9	119
783	Effective delivery of an angiogenesis inhibitor by neovessel-targeted liposomes. 2008 , 360, 219-24	30
782	Expression of the vascular endothelial growth factor-receptor system in the porcine endometrium throughout the estrous cycle and early pregnancy. 2008 , 75, 362-72	37
781	Messenger RNA expression of vascular endothelial growth factor and its receptors in primary colorectal cancer and corresponding liver metastasis. 2008 , 15, 1232-8	7
780	Decreased airway expression of vascular endothelial growth factor in cigarette smoke-induced emphysema in mice and COPD patients. 2008 , 20, 349-59	45
779	Insights into mechanisms behind arteriogenesis: what does the future hold?. 2008 , 84, 1379-91	31

778	Molecular mechanisms of the antiproliferative activity of somatostatin receptors (SSTRs) in neuroendocrine tumors. 2008 , 13, 822-40	128
777	Animal models for the molecular and mechanistic study of lymphatic biology and disease. 2008 , 1131, 50-74	39
776	Molecular control of lymphatic metastasis. 2008 , 1131, 225-34	209
775	Immunocytochemical localization of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 of the human deciduous molar tooth germ development in the human fetus. 2008 , 190, 246-51	13
774	Soluble and membranous vascular endothelial growth factor receptor-1 in pregnancies complicated by pre-eclampsia. 2008 , 190, 477-89	37
773	Proliferaci3n vascular en las extremidades isqu3micas: una revisi3n de los mecanismos y posible estimulaci3n terap3utica. 2008 , 22, 635-652	
772	Biological properties of "naked" metal nanoparticles. 2008 , 60, 1289-1306	664
771	Impact of vessel maturation on antiangiogenic therapy in ovarian cancer. 2008 , 198, 477.e1-9; discussion 477.e9-10	45
770	Visual prognosis and vitreous cytokine levels after arteriovenous sheathotomy in branch retinal vein occlusion associated with macular oedema. 2008 , 86, 377-84	18
769	A prospective study on intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration of different durations. 2008 , 86, 482-9	68
768	Angiogenesis and expression of angiogenic agents in uterine and ovarian carcinosarcomas. 2008 , 116, 107-17	17
767	Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed. 2008 , 222, 299-315	35
766	Melatonin modulates the expression of VEGF and HIF-1 alpha induced by CoCl2 in cultured cancer cells. 2008 , 44, 121-6	91
765	AKAP12 in astrocytes induces barrier functions in human endothelial cells through protein kinase Czeta. 2008 , 275, 2338-53	20
764	Alternative binding proteins: anticalins - harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities. 2008 , 275, 2677-83	123
763	Oestrogen promotes coronary angiogenesis even under normoxic conditions. 2008 , 103, 273-7	9
762	Neural progenitor cells treated with EPO induce angiogenesis through the production of VEGF. 2008 , 28, 1361-8	103
761	Hyperbaric oxygen attenuates apoptosis and decreases inflammation in an ischemic wound model. 2008 , 128, 2102-12	85

760	Regulation of scar formation by vascular endothelial growth factor. 2008 , 88, 579-90	219
759	Blocking VEGFR-3 suppresses angiogenic sprouting and vascular network formation. 2008 , 454, 656-60	649
758	A role for VEGF as a negative regulator of pericyte function and vessel maturation. 2008 , 456, 809-13	476
757	The zinc-finger transcription factor, early growth response 3, mediates VEGF-induced angiogenesis. 2008 , 27, 2989-98	50
756	Galectin-1, a novel ligand of neuropilin-1, activates VEGFR-2 signaling and modulates the migration of vascular endothelial cells. 2008 , 27, 3746-53	171
755	Vascular endothelial growth factor gene polymorphisms and recurrent pregnancy loss. 2008 , 59, 301-5	42
754	Targeted therapy in the treatment of solid tumors: practice contradicts theory. 2008 , 73, 605-18	30
753	Insulin increases tristetraprolin and decreases VEGF gene expression in mouse 3T3-L1 adipocytes. 2008 , 16, 1208-18	39
752	B-Raf is required for ERK activation and tumor progression in a mouse model of pancreatic beta-cell carcinogenesis. 2008 , 27, 4779-87	20
751	Regulation of angiogenesis: apoptotic cues from the ECM. 2008 , 27, 6285-98	109
750	Maspin modulates prostate cancer cell apoptotic and angiogenic response to hypoxia via targeting AKT. 2008 , 27, 7171-9	29
749	Cisplatin treatment increases survival and expansion of a highly tumorigenic side-population fraction by upregulating VEGF/Flt1 autocrine signaling. 2008 , 27, 3923-34	57
748	Combined analysis of VEGF and EGFR predicts complete tumour response in rectal cancer treated with preoperative radiotherapy. 2008 , 98, 450-6	63
747	Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours. 2008 , 99, 1387-94	15
746	Angiogenesis in pre-malignant conditions. 2008 , 99, 1961-6	51
745	ATL-1, an analogue of aspirin-triggered lipoxin A4, is a potent inhibitor of several steps in angiogenesis induced by vascular endothelial growth factor. 2008 , 153, 956-65	48
744	Stimuli-responsive hydrogels: drugs take control. 2008 , 7, 767-8	32
743	The role of oxygen availability in embryonic development and stem cell function. 2008 , 9, 285-96	699

742	Spatial and temporal role of the apelin/APJ system in the caliber size regulation of blood vessels during angiogenesis. 2008 , 27, 522-34	181
741	Beta2-glycoprotein I inhibits vascular endothelial growth factor and basic fibroblast growth factor induced angiogenesis through its amino terminal domain. 2008 , 6, 1215-23	40
740	Novel single nucleotide polymorphism of the VEGF gene as a risk predictor for gastroduodenal ulcers. 2008 , 23 Suppl 2, S131-9	5
739	Extracellular HSP70 blocks CD40L-induced apoptosis and tubular formation in endothelial cells. 2008 , 23 Suppl 2, S222-8	5
738	Effect of luteinizing hormone and tumour necrosis factor-alpha on VEGF secretion by cultured porcine endometrial stromal cells. 2010 , 45, 481-6	7
737	Endothelial cell-derived bone morphogenetic proteins regulate glial differentiation of cortical progenitors. 2008 , 27, 1596-606	25
736	Vasculogenic maturation of E14 embryonic stem cells with evidence of early vascular endothelial growth factor independency. 2008 , 76, 857-67	3
735	Downregulation of Tie2 gene by a novel antitumor sulfolipid, 3'-sulfoquinovosyl-1'-monoacylglycerol, targeting angiogenesis. 2008 , 99, 1063-70	19
734	Antitumor and antimetastatic actions of anthrone-C-glucoside, cassialoin isolated from <i>Cassia garrettiana</i> heartwood in colon 26-bearing mice. 2008 , 99, 2336-48	37
733	Antitumor activities of synthetic and natural stilbenes through antiangiogenic action. 2008 , 99, 2083-96	38
732	l-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms. 2008 , 99, 2380-6	105
731	Parathyroid hormone stimulates the endothelial expression of vascular endothelial growth factor. 2008 , 38, 798-803	41
730	Anti-angiogenic potential of CoenzymeQ10, riboflavin and niacin in breast cancer patients undergoing tamoxifen therapy. 2008 , 48, 191-201	32
729	Procollagen I COOH-terminal fragment induces VEGF-A and CXCR4 expression in breast carcinoma cells. 2008 , 314, 2289-98	20
728	Neoangiogenesis and expression of hypoxia-inducible factor 1alpha, vascular endothelial growth factor, and glucose transporter-1 in endometrioid type endometrium adenocarcinomas. 2008 , 108, 603-8	36
727	Angiogenèse physiologique et tumorale. 2008 , 145, 4-7	
726	The effect of menopause and hysterectomy on systemic vascular endothelial growth factor in women undergoing surgery for breast cancer. 2008 , 8, 279	6
725	Clinical use of anti-vascular endothelial growth factor monoclonal antibodies in metastatic colorectal cancer. 2008 , 28, 235-305	20

724	Corpus luteum-endometrium-embryo interactions in the dairy cow: underlying mechanisms and clinical relevance. 2008 , 43 Suppl 2, 104-12	55
723	Factors associated with outcome in patients with advanced renal cell carcinoma in the era of antiangiogenic agents. 2008 , 6, 15-20	6
722	Optimizing the dose and schedule of anti-vascular endothelial growth factor antibodies in non-small-cell lung cancer. 2008 , 9 Suppl 2, S51-6	
721	New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer. 2008 , 9 Suppl 3, S100-8	3
720	Tissue reactions to collagen scaffolds in the oral mucosa and skin of rats: environmental and mechanical factors. 2008 , 53, 376-87	25
719	Tumor lymphangiogenesis and lymphangiogenic growth factors. 2008 , 39, 365-72	42
718	Imino proton exchange rates imply an induced-fit binding mechanism for the VEGF165-targeting aptamer, Macugen. 2008 , 582, 1835-9	34
717	Encyclopedia of Cancer. 2017 , 4797-4801	
716	Peripheral Muscle Changes. 2017 , 119-125	1
715	Peri-operative Shift in Angiogenesis-Related Factors in Breast Cancer Patients. 2017 , 55-81	
714	Efficacy of Thalidomide for Recurrent Gastrointestinal Bleeding due to angiodysplasias in a Hemodialysis Patient. 2017 , 27, 489-490	
713	The Role of the Neuropilins in Tumour Angiogenesis and Tumour Progression. 2017 , 163-186	
712	Refractory Mechanisms. 2017 , 351-367	
711	Anti-tumor effect of recombinant plasminogen kringle 1B in KB cells: Histological observation and immunoprecipitation-based high performance liquid chromatography. 2017 , 41, 45-54	
710	Hepatorenal Syndrome-Current Concepts in Pathophysiology. 2017 , 7,	
709	Histopathological Effects of Therapeutic Doses of Combined XO-Inhibitors and ACE-Inhibitors on the Expression of VEGF-A in the Myocardium and Renal Cortex in Chronic Hypertensive Albino Rats.	
708	Induction of vascular endothelial growth factor receptor expression in human umbilical vein endothelial cells after repeated bevacizumab treatment. 2017 , 10, 1064-1068	1
707	Capillary density has no value as an early biomarker of bevacizumab efficacy in metastatic colorectal cancers: a prospective clinical trial. 2018 , 9, 12599-12608	1

- 706 Endothelial Cell-Cell Junctions in Tumor Angiogenesis. **2018**, 1-29
- 705 Nanotechnology for Omics-Based Ocular Drug Delivery. **2018**, 283-298
- 704 Encyclopedia of Ophthalmology. **2018**, 1488-1493
- 703 Association of Polymorphic Variants of *VEGF* and *KDR* Genes with Development and Metastasing of Non-Small Cell Lung Cancer. **2018**, 09, 714-728
- 702 A polymorphism +936C>G of vascular endothelial growth factor as a marker of susceptibility to the obliterating atherosclerosis of arteries of the lower extremities.. **2018**, 96, 234-239 1
- 701 Gebe sınırlara bevacizumab uygulayarak preeklampsi belirtilerinde kullanılabilecek deneysel hayvan modeli oluşturulabilir..
- 700 Human Dental Pulp Stem Cells Grown in Neurogenic Media Differentiate into Endothelial Cells and Promote Neovascuogenesis in the Mouse Brain. 0
- 699 The sustained release of basic fibroblast growth factor accelerates angiogenesis and the survival of the inactivated dermis by high hydrostatic pressure.
- 698  **2019**, 85, 42-45
- 697 Hard Material Modulation for (Skeletal) Tissue Engineering Purposes. **2019**, 1-18
- 696 The Role of the VEGF Signaling Pathway in Tumor Angiogenesis. **2019**, 1-16
- 695 Endothelial Cell-Cell Junctions in Tumor Angiogenesis. **2019**, 91-119 1
- 694 The Implication of Anti-angiogenic Treatment of Malignancies on Human Metabolism. **2019**, 661-672
- 693 Endothelial PKA targets ATG16L1 to regulate angiogenesis by limiting autophagy.
- 692 Notch signaling and taxis mechanisms regulate early stage angiogenesis: A mathematical and computational model.
- 691 Effects of Eight-Week Resistance Training in Different Environmental Conditions on Arterial Factors in Overweight Men. **2019**, 8,
- 690 Principles of anti-VEGF dosing in the treatment of neovascular age-related macular degeneration. **2019**, 12, 102-112
- 689 Mesenchymal Stem/ Stromal Cells metabolomic and bioactive factors profiles: a comparative analysis on the Umbilical Cord and Dental Pulp derived Stem/ Stromal Cells secretome. 0

- 688 Heterogeneity in VEGF Receptor-2 mobility and organization on the endothelial cell surface leads to diverse activation models by VEGF.
- 687 Proangiogenic and Proarteriogenic Therapies in Coronary Microvasculature Dysfunction. **2020**, 271-287
- 686 Implication of VEGFR2 in endometriosis: A structural biological and genetic approach.
- 685 Systemic Treatment for Metastatic or Recurrent Disease. **2020**, 275-287
- 684 The role of tumor-derived exosomes in tumor angiogenesis and tumor progression. **2019**, 32, 193-202 5
- 683 Inflammatory Choroidal Vascular Membranes. **2020**, 139-158
- 682 Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program..
- 681 Angiogenesis and epidermal growth factor receptor inhibitors in non-small cell lung cancer. **2020**, 1, 117-130
- 680 VEGF receptor targeted imaging of angiogenic response to limb ischemia in diabetic vs. non-diabetic Yucatan minipigs. **2020**, 10, 48 1
- 679 Vascular Endothelial Growth Factor Expression in the Pathological Angiogenesis in Oral Squamous Cell Carcinoma. 0
- 678 Heart-lung crosstalk in pulmonary arterial hypertension following myocardial infarction (Review). **2020**, 46, 913-924
- 677 Placental and fetal characteristics of the Ohia mouse line recapitulate outcomes in human hypoplastic left heart syndrome. 1
- 676 Shared changes in angiogenic factors across gastrointestinal vascular conditions: A pilot study. **2020**, 11, 40-47 1
- 675 An Intense, But Ecologically Valid, Resistance Exercise Session Does Not Alter Growth Factors Associated With Cognitive Health. **2020**, 1-8 0
- 674 Phase 3 Trial of BI 695502 Plus Chemotherapy Versus Bevacizumab Reference Product Plus Chemotherapy in Patients With Advanced Nonsquamous NSCLC.. **2022**, 3, 100248 0
- 673 Recombinant thrombomodulin domain 1 rescues pathological angiogenesis by inhibition of HIF-1 β /VEGF pathway. **2021**, 78, 7681-7692 2
- 672 VEGFR2 and hepatocellular carcinoma inhibitory activities of trisubstituted triazole derivatives. **2021**, 131832 2
- 671 PLGA/ β TCP composite scaffold incorporating cucurbitacin B promotes bone regeneration by inducing angiogenesis. **2021**, 31, 41-51 3

- 670 Development of bioactive catechol functionalized nanoparticles applicable for 3D bioprinting. **2021**, 131, 112515 1
- 669 Cancer Stem Cells and Therapeutic Angiogenesis. **2020**, 185-196
- 668 Exploiting Kinase Inhibitors for Cancer Treatment: An Overview of Clinical Results and Outlook. **2020**, 125-153
- 667 CHAPTER 9. Biosynthesis of Curcumin and Molecular Targets and the Biological Mechanism of Curcumin. **2020**, 196-220
- 666 Changrui enema inhibits inflammation-induced angiogenesis in acute radiation proctitis by regulating NF- κ B and VEGF. **2020**, 35, e202000502 0
- 665 Drug Targets for Biologics. **2020**, 71-88
- 664 Metabolism and Distribution of Novel Tumor Targeting Drugs In Vivo. **2020**, 21, 996-1008
- 663 Levels of growth factors in the lungs affected by cancer with preventive effect of 1,3-diethylbenzimidazolium triiodide in the experiment. **2020**, 7, 27-35
- 662 Preoperative bevacizumab does not increase complications following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. **2020**, 15, e0243252 1
- 661 Plexus-specific retinal capillary avascular area in exudative age-related macular degeneration with projection-resolved OCT angiography. **2020**, 0
- 660 A DNA-functionalized graphene field-effect transistor for quantitation of vascular endothelial growth factor. **2022**, 351, 130964 2
- 659 Nanoparticles as a Therapeutic Approach for Tumor Angiogenesis. **2022**, 52-113
- 658 Vascular endothelial growth factor and epithelial cell adhesion molecule immunoexpression in enzootic nasal adenocarcinoma of goats.
- 657 Hard Material Modulation for (Skeletal) Tissue Engineering Purposes. **2020**, 449-466
- 656 Is gene therapy for limb ischemia a reality?. **2020**, 19, e20190059 0
- 655 Local Skin Flaps for Lower Extremity Wounds. **2020**, 115-127 1
- 654 Encyclopedia of Behavioral Medicine. **2020**, 2304-2305
- 653 [Modern approaches to treatment of postsurgical macular edema]. **2020**, 136, 289-295

652	Esophageal Tumor Microenvironment. 2020 , 1296, 103-116	1
651	The Role of Medical Therapy for Meningiomas. 2020 , 201-215	
650	Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program..	
649	Specific humoral response in cancer patients treated with a VEGF-specific active immunotherapy procedure within a compassionate use program. nbsp;	
648	Pathogenesis and Treatment of Keloids. 2020 , 16, 8-17	
647	Influence of urokinase gene-knockout in C57BL/6-Plautml. I Bug This Plau6FDhu/GFDhu mice on growth factors in malignant melanoma. 2020 , 7, 25-37	
646	Characterization of Antineovascularization Activity and Ocular Pharmacokinetics of Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GNE-947. 2020 , 48, 408-419	1
645	ANALYSIS OF EXPEDIENCY TO USE PLATELET-ENRICHED PLASMA FOR TREATMENT OF ANDROGENETIC ALOPECIA. 2020 , 64-67	1
644	Influence of VEGF deprivation upon vascular formation by endothelium in the presence of macrophages. 2020 , 22, 231-248	
643	SKLB1002, a potent inhibitor of VEGF receptor 2 signaling, inhibits endothelial angiogenic function in vitro and ocular angiogenesis in vivo. 2020 , 21, 2571-2579	1
642	Identification of 1,3-thiazinan-4-one urea-Based Derivatives as Potent FLT3/VEGFR2 Dual Inhibitors for the Treatment of Acute Myeloid Leukemia. 2021 , 1250, 131862	
641	Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer. 2021 , 1	2
640	SUCNR1 Is Expressed in Human Placenta and Mediates Angiogenesis: Significance in Gestational Diabetes. 2021 , 22,	1
639	Echinacea purpurea suppresses the cell survival and metastasis of hepatocellular carcinoma through regulating the PI3K/Akt pathway. 2021 , 142, 106115	0
638	CSMD3 is Associated with Tumor Mutation Burden and Immune Infiltration in Ovarian Cancer Patients. 2021 , 14, 7647-7657	1
637	The Therapeutic Effects of Oral Intake of Hydrogen Rich Water on Cutaneous Wound Healing in Dogs. 2021 , 8,	
636	Fluorescence grid analysis for the evaluation of piecemeal surgery in sinonasal inverted papilloma: a proof-of-concept study. 2021 , 1	0
635	Changes in Systemic Levels of Vascular Endothelial Growth Factor After Intravitreal Injection of Aflibercept or Brolucizumab for Neovascular Age-Related Macular Degeneration. 2021 ,	0

- 634 Cancer Drug Delivery. 52-95
- 633 Current and Future Therapeutic Targets of the Tumour-Host Microenvironment. **2005**, 345-367
- 632 Endothelial Activation and Neointimal Hyperplasia: A Double-Edged Sword. **2007**, 75-84
- 631 Integrative Pro-angiogenic Activation: HIF- β . **2007**, 123-137
- 630 Molekulare Ursachen myokardialer Insuffizienz beim Neugeborenen. **2005**, 533-571
- 629 Angiogenesis and Lung Cancer. **2005**, 13-30
- 628 Integration of Biological Therapies in Locally Advanced Non-Small-Cell Lung Cancer. **2006**, 261-270
- 627 The Role of Vascular Endothelial Growth Factor in Lung Injury and Repair. **2007**, 299-309
- 626 The Regulation of Retinal Angiogenesis by Cyclooxygenase and the Prostanoids. **2008**, 241-257
- 625 Novel Therapeutic Strategies For Posterior Segment Neovascularization. **2008**, 445-526
- 624 Role of angiogenesis in portal hypertension. 112-129
- 623 Thrombospondin. **2006**, 233-255
- 622 Ocular Inflammation and Neovascularization. **2006**, 291-305
- 621 Vascular Endothelial Growth Factor Family and Its Receptors. **2008**, 3-26
- 620 Prognostic and Predictive Significance of Surrogate Biomarkers of Angiogenesis. **2008**, 487-508
- 619 The Extracellular Matrix and VEGF Processing. **2008**, 85-97
- 618 Integration of Antiangiogenic Strategies Into Colorectal Cancer Treatment. **2007**, 85-98
- 617 Molecular Targets in Ovarian Cancer and Endometrial Cancer. **2008**, 291-308

616 Molecular Targeting of Colorectal Cancer. **2008**, 133-163

615 Targeted Therapy in Breast Cancer. **2008**, 43-59

614 Targeted Therapy in Lymphoma. **2008**, 157-182

613 Biopsies and Cytological Punctures. **2008**, 137-147

612 Antiangiogenic Therapies in Renal Cell Carcinoma. **2008**, 449-456

611 Agents antiangiogéniques dans le cancer du sein. **2008**, 81-91

610 Biological Therapies for Metastatic Breast Cancer: Antiangiogenesis. **2006**, 671-704

609 Clinical Development of the VEGFR Signalling Inhibitor AZD2171. **2008**, 673-688

608 Surgical Treatment of Retinal Vasculitis with Occlusion, Neovascularization or Traction. **2008**, 209-218

607 Age-Related Macular Degeneration: Immunological Factors in the Pathogenesis and Therapeutic Consequences. **2009**, 73-85

606 Atorvastatin improves the proliferation and migration of endothelial progenitor cells via the miR-221/VEGFA axis. **2020**, 40, 4

605 A Meta-Analysis of the Association Between the Gene Polymorphism and Digestive System Cancer Susceptibility. **2020**, 24, 732-744 2

604 Probing the Effects of the FGFR-Inhibitor Derazantinib on Vascular Development in Zebrafish Embryos. **2020**, 14, 1

603 Role of intercellular adhesion molecules and antibodies to oxidized LDL in pathogenesis of cardiovascular diseases under mercury exposure. **2020**, 99, 1120-1126

602 Assessment of anti-cancer potential of Hyalomma dromedarii salivary glands extract: in vitro study. **2021**, 76, 1215-1225

601 Evaluation of the expression of VIII factor and VEGF in the regeneration of non-vital teeth in dogs using propolis. **2017**, 20, 172-177 3

600 Renal cell carcinoma and the use of sorafenib. **2006**, 2, 87-98 11

599 Neutralizing antibody to VEGF reduces intravitreal neovascularization and may not interfere with ongoing intraretinal vascularization in a rat model of retinopathy of prematurity. **2008**, 14, 345-57 48

598	Ocular biodistribution of bevasiranib following a single intravitreal injection to rabbit eyes. 2008 , 14, 997-1005	37
597	Pegaptanib in the treatment of wet, age-related macular degeneration. 2006 , 1, 263-8	46
596	Triamcinolone acetonide and anecortave acetate do not stimulate uveal melanoma cell growth. 2008 , 14, 1752-9	9
595	Training-induced vascular adaptations to ischemic muscle. 2008 , 59 Suppl 7, 57-70	20
594	Alveolar epithelial and endothelial cell apoptosis in emphysema: what we know and what we need to know. 2009 , 4, 19-31	33
593	Hypoxia preconditioning protection of corneal stromal cells requires HIF1alpha but not VEGF. 2009 , 15, 1020-7	6
592	Future therapeutic treatment of COPD: struggle between oxidants and cytokines. 2007 , 2, 205-28	18
591	Vascular endothelial growth factor upregulates expression of annexin A2 in vitro and in a mouse model of ischemic retinopathy. 2009 , 15, 1231-42	23
590	Targeted therapy of advanced non-small cell lung cancer: the role of bevacizumab. 2007 , 1, 185-94	4
589	Association of vascular endothelial growth factor polymorphisms with asthma in Tunisian children. 2008 , 2, 89-96	5
588	Effect of subconjunctival and intraocular bevacizumab injection on angiogenic gene expression levels in a mouse model of corneal neovascularization. 2009 , 15, 2326-38	24
587	Polymorphisms in the VEGFA and VEGFR-2 genes and neovascular age-related macular degeneration. 2009 , 15, 2710-9	39
586	Estradiol and nicotine exposure enhances A549 bronchioloalveolar carcinoma xenograft growth in mice through the stimulation of angiogenesis. 2006 , 28, 337-44	24
585	Tear cytokine and chemokine analysis and clinical correlations in evaporative-type dry eye disease. 2010 , 16, 862-73	205
584	Signal transduction induced in endothelial cells by growth factor receptors involved in angiogenesis. 2007 , 97, 355-63	36
583	Targeted therapies in the management of colorectal carcinoma: role of bevacizumab. 2009 , 2, 1-15	8
582	Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer. 2007 , 2, 31-49	3
581	Studies on the pathogenesis of avascular retina and neovascularization into the vitreous in peripheral severe retinopathy of prematurity (an american ophthalmological society thesis). 2010 , 108, 96-119	33

580	Expression of vascular endothelial growth factor and pigment epithelial-derived factor in a rat model of retinopathy of prematurity. 2011 , 17, 1577-87	9
579	A placenta growth factor 2 variant acts as dominant negative of vascular endothelial growth factor A by heterodimerization mechanism. 2011 , 1, 265-274	8
578	Increased expression of vascular endothelial growth factor in neo-vascularized canine brain tissue. 2012 , 76, 62-8	1
577	Cloning and expression of human vascular endothelial growth factor gene and inhibition of its expression by antisense in prokaryotic system. 2010 , 18, 281-5	2
576	Expression of FLT4 in hypoxia-induced neovascular models in vitro and in vivo. 2011 , 4, 26-9	1
575	Effect of VEGF-targeted antisense gene therapy on retinoblastoma cell line SO-RB50 in vitro and in vivo. 2012 , 5, 440-7	6
574	The role of VEGF in melanoma progression. 2012 , 17, 534-9	23
573	The role of SRC family kinases in prostate cancer. 2007 , 2, 67-77	6
572	A review on angiogenesis and its assays. 2012 , 15, 1110-26	69
571	Vascular endothelial growth factor A polymorphisms and age-related macular degeneration: a systematic review and meta-analysis. 2013 , 19, 1211-21	17
570	Both vascular endothelial growth factor and soluble Flt-1 are increased in type 2 diabetes but not in impaired fasting glucose. 2010 , 58, 804-6	10
569	Combination therapy for scalp angiosarcoma using bevacizumab and chemotherapy: a case report and review of literature. 2013 , 25, 358-61	5
568	Continuum of care with anti-angiogenic therapies in metastatic colorectal cancer. 2013 , 4, 299-307	5
567	Association DENV1 and DENV2 infection with high serum levels of soluble thrombomodulin and VEGF in patients with dengue fever and dengue hemorrhagic fever. 2014 , 7, 370-8	8
566	Comparison of bevacizumab and ranibizumab in age-related macular degeneration: a systematic review and meta-analysis. 2014 , 7, 355-64	17
565	The proliferation of malignant melanoma cells could be inhibited by ranibizumab via antagonizing VEGF through VEGFR1. 2014 , 20, 649-60	7
564	Anandamide inhibits breast tumor-induced angiogenesis. 2014 , 10, 8-12	14
563	Ab-initio and Conformational Analysis of a Potent VEGFR-2 Inhibitor: A Case Study on Motesanib. 2014 , 13, 405-15	8

562	Treatment with capecitabine + bevacizumab following induction treatment with FOLFIRI + bevacizumab in metastatic colorectal carcinoma. 2014 , 7, 2191-6	2
561	New Insights into VEGF-A Alternative Splicing: Key Regulatory Switching in the Pathological Process. 2014 , 6, 192-9	16
560	Gene expression analysis of VEGF and its receptors and assessment of its serum level in unexplained recurrent spontaneous abortion. 2015 , 16, 538-45	18
559	Epidermal growth factor receptor pathway polymorphisms and the prognosis of hepatocellular carcinoma. 2015 , 5, 396-410	14
558	Serum levels of vascular endothelial growth factor in chronic obstructive pulmonary disease. 2014 , 28, 85	3
557	Optical coherence tomographic and visual results at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis). 2014 , 112, 160-98	20
556	Cytokine changes in tears and relationship to contact lens discomfort. 2015 , 21, 293-305	25
555	Angiogenesis, multitarget kinase inhibitors and non-small cell lung cancer: a lesson from MONET1 trial. 2013 , 2, E13-6	
554	Prognostic role of vascular endothelial growth factor in prostate cancer: a systematic review and meta-analysis. 2015 , 8, 2289-98	11
553	mRNA expression of VEGF and its receptors in fallopian tubes of women with ectopic pregnancies. 2015 , 9, 55-64	3
552	Pachymic acid modified carbon nanoparticles reduced angiogenesis via inhibition of MMP-3. 2015 , 8, 5464-70	4
551	Therapeutic challenges in renal cell carcinoma. 2015 , 3, 77-90	9
550	State of the art management of metastatic gastroesophageal cancer. 2015 , 3, 236	4
549	Corneal neovascularization and biological therapy. 2015 , 8, 444-8	33
548	Progesterone in Breast Cancer Angiogenesis. 2015 , 1,	2
547	Radiolabeling and evaluation of (64)Cu-DOTA-F56 peptide targeting vascular endothelial growth factor receptor 1 in the molecular imaging of gastric cancer. 2015 , 5, 3301-10	9
546	The distinct signatures of VEGF and soluble VEGFR2 increase prognostic implication in gastric cancer. 2015 , 5, 3376-88	6
545	Knockdown of WISP1 inhibit proliferation and induce apoptosis in ALL Jurkat cells. 2015 , 8, 15489-96	7

544	Exome sequencing on malignant meningiomas identified mutations in neurofibromatosis type 2 (NF2) and meningioma 1 (MN1) genes. 2014 , 18, 301-311	15
543	Vascular endothelial growth factor from embryonic status to cardiovascular pathology. 2014 , 2, 59-69	18
542	Hypoxia inducible factor-1 alpha and multiple myeloma. 2016 , 4, 706-715	12
541	Quinazoline derivative compound (11d) as a novel angiogenesis inhibitor inhibiting VEGFR2 and blocking VEGFR2-mediated Akt/mTOR /p70s6k signaling pathway. 2016 , 19, 411-6	3
540	Treatment of chronic ulcer in diabetic rats with self assembling nanofiber gel encapsulated-polydeoxyribonucleotide. 2016 , 8, 3067-76	11
539	Inhibition of AGS Cancer Cell Proliferation following siRNA-Mediated Downregulation of VEGFR2. 2016 , 18, 381-8	1
538	Metformin inhibits development of diabetic retinopathy through inducing alternative splicing of VEGF-A. 2016 , 8, 3947-3954	21
537	Soluble Flt-1 improves the repair of ankle joint injury in rats. 2016 , 8, 4942-4950	
536	Revisiting the hallmarks of cancer. 2017 , 7, 1016-1036	267
535	Curcumin inhibits human non-small cell lung cancer xenografts by targeting STAT3 pathway. 2017 , 9, 3633-3641	19
534	Increased Levels of VEGF-A and HIF-1 α in Turkish Children with Crimean-Congo Hemorrhagic Fever. 2017 , 11, 19-26	3
533	Poly-L-Lysine Inhibits Tumor Angiogenesis and Induces Apoptosis in Ehrlich Ascites Carcinoma and in Sarcoma S-180 Tumor. 2017 , 18, 2255-2268	9
532	Anti-Vascular Endothelial Growth Factor Targeting by Curcumin and Thalidomide in Acute Myeloid Leukemia Cells. 2017 , 18, 3055-3061	2
531	[Predictive biomarkers for bevacizumab in anti-tumor therapy]. 2011 , 14, 606-12	
530	[Adverse events related to bevacizumab and the management principles in non-small cell lung cancer]. 2010 , 13, 563-7	0
529	Potential Impact of Vascular Endothelial Growth Factor Gene Variation (-2578C>A) on Breast Cancer Susceptibility in Saudi Arabia: a Case-Control Study. 2018 , 19, 1135-1143	10
528	Co-suppression of VEGF-A and VEGF-C inhibits development of experimental hemangioma. 2018 , 10, 2911-2919	4
527	VEGF-C/Flt-4 axis in tumor cells contributes to the progression of oral squamous cell carcinoma via upregulating VEGF-C itself and contactin-1 in an autocrine manner. 2018 , 8, 2046-2063	8

526	Anti-Vascular Endothelial Growth Factor Effects of Sorafenib and Arsenic Trioxide in Acute Myeloid Leukemia Cell Lines. 2017 , 18, 1655-1661	11
525	[Effect of Apatinib on Invasion and Migration of Lung Cancer Cells?and Its Mechanism]. 2019 , 22, 264-270	
524	A New Model to Describe the Single-dose Pharmacokinetics of Bevacizumab and Predict Its Multiple-Dose Pharmacokinetics in Beagle Dogs. 2019 , 18, 1147-1155	
523	PPAR β mediates sunitinib resistance via NF- κ B activation in clear cell renal cell carcinoma. 2018 , 11, 2389-2400	3
522	Correlations between VEGF-A expression and prognosis in patients with gastric adenocarcinoma. 2017 , 10, 8461-8469	5
521	Rapid and efficient angiogenesis directed by electro-assisted bioprinting of alginate/collagen microspheres with human umbilical vein endothelial cell coating layer. 2019 , 5, 194	3
520	Cyclin G2 Is Involved in the Proliferation of Placental Trophoblast Cells and Their Interactions with Endothelial Cells. 2020 , 26, e926414	0
519	Safety of apatinib plus S-1 for advanced solid tumor as palliative treatment. 2021 , 21, 62	
518	Cell Specific Expression of Vascular Endothelial Growth Factor Receptor-2 (Flk-1/KDR) in Developing Mice Embryo and Supporting Maternal Uterine Tissue during Early Gestation (D4-D7). 2021 , 15, 148-157	0
517	NEAT1 promotes the repair of abdominal aortic aneurysms of endothelial progenitor cells via regulating miR-204-5p/Ang-1. 2021 , 13, 2111-2126	
516	Comparison of vascular endothelial growth factor/vascular endothelial growth factor receptor 2 expression and its relationship to tumor cell proliferation in canine epithelial and mesenchymal tumors. 2021 ,	0
515	Scaffolds with drug delivery capability. 2022 , 817-840	
514	Bone tissue engineering. 2022 , 587-644	0
513	All roads lead to Rome - a review of the potential mechanisms by which exerkines exhibit neuroprotective effects in Alzheimer's disease. 2022 , 17, 1210-1227	0
512	VEGF α /VEGFR2 autocrine and paracrine signaling promotes cervical carcinogenesis via β catenin and snail. 2021 , 142, 106122	0
511	Molecular mechanisms of cancer metastasis via the lymphatic versus the blood vessels. 2021 , 1	5
510	Aneurysm and Artery Dissection Following the Use of Vascular Endothelial Growth Factor Inhibitor: A Real-World Analysis Using a Spontaneous Reporting System. 2021 , 10, e020844	0
509	Novel Mechanisms of Tumor Promotion by the Insulin Receptor Isoform A in Triple-Negative Breast Cancer Cells. 2021 , 10,	2

508	Netrin-1 promotes retinoblastoma-associated angiogenesis.. 2021 , 9, 1683	0
507	In Silico Studies of Two Biphenyl Based Oxime Containing Ligands.	
506	Catalpol improves impaired neurovascular unit in ischemic stroke rats via enhancing VEGF-PI3K/AKT and VEGF-MEK1/2/ERK1/2 signaling. 2021 ,	2
505	Tumor-Targeting Agents. 2022 , 217-236	1
504	Atherosclerosis: nexus of vascular dynamics and cellular cross talks. 2021 , 1	2
503	What do cellular responses to acidity tell us about cancer?. 2021 , 1	3
502	MTA1, a metastasis-associated protein, in endothelial cells is an essential molecule for angiogenesis. 2022 , 25,	0
501	construction of a nano-structured akermanite coating for promoting bone formation and osseointegration of Ti-6Al-4V implants in a rabbit osteoporosis model. 2021 , 9, 9505-9513	3
500	Immunohistochemical localization of VEGFR-2 in mouse mammary gland during reproductive cycle.. 2021 , 8, 581-588	
499	Long Non-Coding RNAs in Lung Cancer: The Role in Tumor Microenvironment.. 2021 , 9, 795874	0
498	The diagnostic value of cytokines for the discrimination of vertebral osteomyelitis and degenerative diseases of the spine.. 2021 , 150, 155782	0
497	Regenerative strategies for the consequences of myocardial infarction: Chronological indication and upcoming visions.. 2021 , 146, 112584	1
496	Daphnetin inhibits corneal inflammation and neovascularization on a mouse model of corneal alkali burn.. 2021 , 103, 108434	0
495	Molecular pathways and role of epigenetics in the idiopathic pulmonary fibrosis.. 2022 , 291, 120283	1
494	Abnormal angiogenesis associated with HIF-1 α /VEGF signaling pathway in recurrent miscarriage along with therapeutic goals. 2022 , 26, 101483	0
493	Buyang Huanwu Decoction promotes angiogenesis in myocardial infarction through suppression of PTEN and activation of the PI3K/Akt signalling pathway.. 2021 , 114929	0
492	Cyclin G2 Is Involved in the Proliferation of Placental Trophoblast Cells and Their Interactions with Endothelial Cells. 2020 , 26, e926414	0
491	Screening of potential genes and transcription factors involved in post-radiation cognitive dysfunction in mice via bioinformatics.. 2020 , 9, 6383-6391	

490	Role of macrophages in fetal development and perinatal disorders. 2021 , 90, 513-523	4
489	Safety of apatinib plus S-1 for advanced solid tumor as palliative treatment. 2020 , 21, 62	
488	Limonin inhibits angiogenesis and metastasis of human breast cancer cells by suppressing the VEGFR2/IGFR1-mediated STAT3 signaling pathway.. 2020 , 9, 6820-6832	0
487	Elevated baseline C-reactive protein levels predict poor progression-free survival in sporadic vestibular schwannoma. 2021 , 156, 365	0
486	Protective Effects of against Blue Light-Induced Retinal Damages in A2E-Laden ARPE-19 Cells and Balb/c Mice.. 2022 , 14,	3
485	ALKBH5 Regulates SPHK1-Dependent Endothelial Cell Angiogenesis Following Ischemic Stress.. 2021 , 8, 817304	1
484	Evaluation of the Structural, Physicochemical, and Biological Characteristics of SB11, as Lucentis (Ranibizumab) Biosimilar.. 2022 , 11, 639	0
483	Expression of angiogenic markers in jawbones and femur in a rat model treated with zoledronic acid.. 2022 , 15, 12	
482	Enhanced growth factor expression in chronic diabetic wounds treated by cold atmospheric plasma.. 2022 , e14787	3
481	Antiangiogenic agents in the treatment of colorectal, gastric, and gastroesophageal junction adenocarcinoma. 2022 , 67-78	
480	Functional In Vitro Assessment of VEGFA/NOTCH2 Signaling Pathway and pRB Proteasomal Degradation and the Clinical Relevance of Mucolipin TRPML2 Overexpression in Glioblastoma Patients.. 2022 , 23,	0
479	Effect of swimming exercise, insulin-associated or not, on inflammatory cytokines, apoptosis, and collagen in diabetic rat placentas.. 2022 , 1	1
478	Assessment of peripheral biomarkers potentially involved in episodic and chronic migraine: a case-control study with a focus on NGF, BDNF, VEGF, and PGE2.. 2022 , 23, 3	2
477	Injectable Hydrogel as a Unique Platform for Antitumor Therapy Targeting Immunosuppressive Tumor Microenvironment.. 2021 , 12, 832942	3
476	Nano-Bio-engineered Silk Matrix based Devices for Molecular Bioanalysis.. 2021 ,	2
475	Local Application of Mineral-Coated Microparticles Loaded With VEGF and BMP-2 Induces the Healing of Murine Atrophic Non-Unions.. 2021 , 9, 809397	0
474	Synthesis, Physicochemical and Biological Study of Gallium-68- and Lutetium-177-Labeled VEGF-A/NRP-1 Complex Inhibitors Based on Peptide A7R and Branched Peptidomimetic.. 2022 , 14,	1
473	Effects of Stem Cell Therapy on Diabetic Mellitus Erectile Dysfunction: A Systematic Review and Meta-analysis.. 2022 , 19, 21-36	0

472	Prognostic Significance of Platelet (PLT) and Platelet to Mean Platelet Volume (PLT/MPV) Ratio During Apatinib Second-Line or Late-Line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients.. 2022 , 21, 15330338211072974	1
471	Dioscin Reduces Vascular Damage in the Retina of Mice by Inhibiting the VEGFA Signaling Pathway.. 2021 , 12, 811897	0
470	Crosstalk Communications Between Islets Cells and Insulin Target Tissue: The Hidden Face of Iceberg.. 2022 , 13, 836344	1
469	Potential Advances of Adjunctive Hyperbaric Oxygen Therapy in Infective Endocarditis.. 2022 , 12, 805964	0
468	Tumor-microenvironmental-response Bi-functional molecules for efficient imaging and anti-tumor activity therapy.. 2022 , 230, 114120	0
467	Impact of Chronic Kidney Disease on the Associations of Cardiovascular Biomarkers With Adverse Outcomes in Patients With Suspected or Known Coronary Artery Disease: The EXCEED-J Study.. 2022 , e023464	0
466	Vascular endothelial growth factor A (VEGFA) promoter rs2010963 polymorphism and cancer risk: An updated meta-analysis and trial sequential analysis. 2022 , 31, 101017	1
465	XSSJS inhibits hepatic fibrosis by promoting the mir29b-3p/VEGFA axis in vitro and in vivo.. 2022 ,	0
464	FRAT1 promotes the angiogenic properties of human glioblastoma cells via VEGFA.. 2022 , 25,	1
463	Sustained delivery of vascular endothelial growth factor mediated by bioactive methacrylic anhydride hydrogel accelerates peripheral nerve regeneration after crush injury.. 2022 , 17, 2064-2071	1
462	Simultaneously enhanced osteogenesis and angiogenesis via macrophage-derived exosomes upon stimulation with titania nanotubes.. 2022 , 112708	1
461	Placental sFlt-1 Gene Delivery in Early Primate Pregnancy Suppresses Uterine Spiral Artery Remodeling.. 2022 ,	0
460	High Expression of PLAGL2 is Associated With Poor Prognosis in High-Grade Glioma.. 2021 , 12, 787746	1
459	Doxorubicin-Loaded UiO-66/BiS Nanocomposite-Enhanced Synergistic Transarterial Chemoembolization and Photothermal Therapy against Hepatocellular Carcinoma.. 2022 ,	1
458	Membrane progesterone receptor 4 (mPR4) enhances hypoxia-induced vascular endothelial growth factor secretion and angiogenesis in lung adenocarcinoma through STAT3 signaling.. 2022 , 20, 72	1
457	Endoglin Modulates TGF β 2 Induced VEGF and Proinflammatory Cytokine Axis Mediated Angiogenesis in Prolonged DEHP-Exposed Breast Cancer Cells.. 2022 , 10,	0
456	Ethoxy-erianin phosphate and afatinib synergistically inhibit liver tumor growth and angiogenesis via regulating VEGF and EGFR signaling pathways.. 2022 , 438, 115911	0
455	Chemokine (C-C motif) ligand 2-enhanced adipogenesis and angiogenesis of human adipose-derived stem cell and human umbilical vein endothelial cell co-culture system in adipose tissue engineering. 2021 ,	2

- 454 Modulating Angiogenesis by Proteomimetics of Vascular Endothelial Growth Factor.. **2021**, 5
- 453 Targeting PI3K/Akt signal transduction for cancer therapy.. **2021**, 6, 425 27
- 452 Bone marrow endothelial dysfunction promotes myeloid cell expansion in cardiovascular disease. **2022**, 1, 28-44 4
- 451 Hypoxia-related prognostic model in bladder urothelial reflects immune cell infiltration. **2021**, 11, 5076-5093
- 450 Therapeutic Intervention of Signaling Pathways in Colorectal Cancer. **2022**, 143-171
- 449 Emerging roles of lncRNA in Nasopharyngeal Carcinoma and therapeutic opportunities.. **2022**, 18, 2714-2728 1
- 448 Analysis of single-cell RNA-sequencing data identifies a hypoxic tumor subpopulation associated with poor prognosis in triple-negative breast cancer. **2022**, 19, 5793-5812 0
- 447 Diffusion MRI Evaluation of Vitreous Humor Changes in Diabetic Retinopathy Patients:.
- 446 The effect of the RadioProtect cosmetic formulation on the skin of oncological patients treated with selected cytostatic drugs and ionizing radiation.. **2022**, 39, 47-51 0
- 445 Advances in Vascular Endothelial Growth Factor, Interleukin-6 and Homocysteine in Liver Cirrhosis and Gastroesophageal Varices. **2022**, 12, 1413-1418
- 444 Fabrication and characterization of a pro-angiogenic hydrogel derived from the human placenta.. **2022**, 2
- 443 A radiologist's guide to novel anticancer therapies in the era of precision medicine.. **2022**, 9, 100406 0
- 442 Tumor lysates cancer vaccine. **2022**, 21-49
- 441 A Case of Thrombotic Microangiopathy, Podocytopathy, and Damage to the Renal Tubules with Severe Proteinuria and Acute Renal Dysfunction Induced by Lenvatinib.. **2022**, 0
- 440 Efficacy of Arthroscopic Shavers for the Retrieval and Processing of Connective Tissue Progenitor Cells from Subacromial Bursal Tissue.. **2022**, 11,
- 439 Angiogenesis: A Pivotal Therapeutic Target in the Drug Development of Gynecologic Cancers.. **2022**, 14, 0
- 438 Key Role of Astrocytes in Postnatal Brain and Retinal Angiogenesis.. **2022**, 23, 1
- 437 Multi-Omics Characterization of a Human Stem Cell-Based Model of Cardiac Hypertrophy.. **2022**, 12, 1

436	Epigenetics of Dendritic Cells in Tumor Immunology.. 2022 , 14,	1
435	Network pharmacology-based predictions of active components and pharmacological mechanisms of <i>Artemisia annua</i> L. for the treatment of the novel Corona virus disease 2019 (COVID-19).. 2022 , 22, 56	1
434	Mechanistic insights into the interplays between neutrophils and other immune cells in cancer development and progression.. 2022 , 1	2
433	EGFR-Based Targeted Therapy for Colorectal Cancer-Promises and Challenges.. 2022 , 10,	3
432	Role of the Endothelium in Neonatal Diseases. 2022 , 1, 44-57	
431	Human umbilical cord mesenchymal stem cell promotes angiogenesis via integrin α /ERK1/2/HIF-1 β /VEGF-A signaling pathway for off-the-shelf breast tissue engineering.. 2022 , 13, 99	1
430	The promoting effects of activated olfactory ensheathing cells on angiogenesis after spinal cord injury through the PI3K/Akt pathway.. 2022 , 12, 23	0
429	The impact of deproteinized bovine bone particle size on histological and clinical bone healing outcomes in the augmented sinus: A randomized controlled clinical trial.. 2022 ,	0
428	Regulation of the Tec family of non-receptor tyrosine kinases in cardiovascular disease.. 2022 , 8, 119	0
427	Tuning the surface potential to reprogram immune microenvironment for bone regeneration.. 2022 , 282, 121408	3
426	Effects of nitrite exposure on metamorphosis and skeletal development of <i>Bufo gargarizans</i> .. 2022 , 1	0
425	Formulation and Characterization of Doxycycline-Loaded Polymeric Nanoparticles for Testing Antitumor/Antiangiogenic Action in Experimental Colon Cancer in Mice.. 2022 , 12,	1
424	Bevacizumab in High-Risk Corneal Transplantation: a Pilot Multi-Center Prospective Randomized Control Trial.. 2022 ,	0
423	Inverting angiogenesis with interstitial flow and chemokine matrix-binding affinity.. 2022 , 12, 4237	
422	A study of the genotyping and vascular endothelial growth factor polymorphism differences in diabetic and diabetic retinopathy patients. 2022 , 23,	
421	Targeting VEGFA with Soluble VEGFR1 Ameliorates Nerve Injury-Induced Neuropathic Pain.. 2022 , 1744806922109452	
420	Haplotype and VEGF-A and VEGF-R2 Protein Associations with Exudative Age-Related Macular Degeneration.. 2022 , 11,	0
419	Phospholipase C β Promotes Vascular Endothelial Growth Factor Induced Vascular Permeability.	0

418	The role of irinotecan-bevacizumab as rescue regimen in children with low-grade gliomas: a retrospective nationwide study in 72 patients.. 2022 , 1	2
417	Construction of adipose tissue using a silica expander capsule and cell sheet-assembled of decellularized adipose tissue.. 2021 ,	0
416	Hotspots and Frontiers in Inflammatory Tumor Microenvironment Research: A Scientometric and Visualization Analysis.. 2022 , 13, 862585	0
415	The impact of VEGF on cancer metastasis and systemic disease.. 2022 ,	5
414	Anti-angiogenic properties of rapamycin on human retinal pericytes in an in vitro model of neovascular AMD via inhibition of the mTOR pathway.. 2022 , 22, 138	0
413	Cross-Communication Between Knee Osteoarthritis and Fibrosis: Molecular Pathways and Key Molecules.. 2022 , 13, 1-15	1
412	KSI-301: an investigational anti-VEGF biopolymer conjugate for retinal diseases.. 2022 , 1-7	2
411	A review on inflammation and angiogenesis as key mechanisms involved in the pathogenesis of bovine cystic ovarian disease.. 2022 , 186, 70-85	
410	Angioregulatory role of miRNAs and exosomal miRNAs in glioblastoma pathogenesis.. 2022 , 148, 112760	0
409	Effects of Exercise Training on PPAR γ Expression in Skeletal Muscle of Rats with Spontaneous Hypertension.. 2022 ,	
408	Early biomarkers of nephrotoxicity associated with the use of anti-VEGF drugs. 2022 , 16,	0
407	Remodeling of gene regulatory networks underlying thermogenic stimuli-induced adipose beiging.	
406	Naturally occurring combinations of receptors from single cell transcriptomics in endothelial cells.. 2022 , 12, 5807	0
405	Soluble Fms-like tyrosine kinase-1 (sFlt-1) is associated with subclinical and clinical atherosclerotic cardiovascular disease: The Dallas Heart Study.. 2022 , 346, 46-52	1
404	Lysine demethylase 2B regulates angiogenesis via Jumonji C dependent suppression of angiogenic transcription factors.. 2022 , 605, 16-23	
403	Exploration of novel VEGFR2 tyrosine kinase inhibitors via design and synthesis of new alkylated indolyl-triazole Schiff bases for targeting breast cancer.. 2022 , 122, 105708	7
402	Dendritic cell-based cancer immunotherapy in the era of immune checkpoint inhibitors: From bench to bedside.. 2022 , 120466	2
401	Primary Dysmenorrhea: pathophysiology. 2021 , 62, 378-406	0

400	Immobilization of Glycogen Synthase Kinase-3 Inhibitor on 316L Stainless Steel Polydopamine to Accelerate Endothelialization. 2021 , 9, 806151	
399	Overcoming ischemia in the diabetic foot: Minimally invasive treatment options.. 2021 , 12, 2011-2026	1
398	Progress and Current Limitations of Materials for Artificial Bile Duct Engineering. 2021 , 14,	2
397	Tumor-associated macrophages, dendritic cells, and neutrophils: biological roles, crosstalk, and therapeutic relevance. 2021 , 1, 222-243	0
396	Therapeutic advances in non-small cell lung cancer: Focus on clinical development of targeted therapy and immunotherapy.. 2021 , 2, 692-729	2
395	Silicon-Phosphorus-nanosheets-integrated 3D-printable Hydrogel as a Bioactive and Biodegradable Scaffold for Vascularized Bone Regeneration. 2021 , e2101911	2
394	Psoriasis and pathological angiogenesis: pathogenetic significance and therapeutic perspectives. 2021 , 58-63	
393	Management of Endothelial Dysfunction in Systemic Sclerosis: Current and Developing Strategies.. 2021 , 8, 788250	3
392	Effects of Low-Dose Atorvastatin on the Peripheral Blood Mononuclear Cell Secretion of Angiogenic Factors in Type 2 Diabetes.. 2021 , 11,	1
391	Using Patient-Derived Xenografts to Explore the Efficacy of Treating Head-and-Neck Squamous Cell Carcinoma With Anlotinib.. 2021 , 27, 1610008	1
390	A review of neovascular glaucoma. Etiopathogenesis and treatment.. 2021 , 65, 315-329	2
389	HIF-1 α Activation Impacts Macrophage Function during Murine Infection.. 2021 , 10,	0
388	The role of vascular endothelial growth factor as a prognostic and clinicopathological marker in osteosarcoma: a systematic review and meta-analysis.. 2021 , 16, 738	2
387	Therapeutic Potential of Thymoquinone in Triple-Negative Breast Cancer Prevention and Progression through the Modulation of the Tumor Microenvironment.. 2021 , 14,	3
386	A Case of Chorioretinitis with Retinal Angiomatous Proliferation.. 2021 , 2021, 3564939	
385	Covid-19 Impact on Macular Neovascularization and Retinal Vein Occlusion Treatment: Single-Center Experience.. 2021 , 6, 145-152	
384	A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities.. 2021 , 12, 778978	1
383	Intravitreal aflibercept following treat and extend protocol versus fixed protocol for treatment of neovascular age-related macular degeneration. 2021 , 7, 74	

- 382 Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind study. **2021**, 42, 101187 2
- 381 Multiphasic modelling and computation of metastatic lung-cancer cell proliferation and atrophy in brain tissue based on experimental data.. **2021**, 21, 277 1
- 380 Anti-VEGF Therapy in Refractory Pituitary Adenomas and Pituitary Carcinomas: A Review. **2021**, 11, 773905 0
- 379 A Fokker-Planck feedback control framework for optimal personalized therapies in colon cancer-induced angiogenesis.. **2022**, 84, 23 0
- 378 MSC Transplantation Attenuates Inflammation, Prevents Endothelial Damage and Enhances the Angiogenic Potency of Endogenous MSCs in a Model of Pulmonary Arterial Hypertension.. **2022**, 15, 2087-2101⁰
- 377 Different subpopulations of regulatory T cells in human autoimmune disease, transplantation, and tumor immunity.. **2022**, 3, e137 0
- 376 Role of the IL-6/Jak/Stat Pathway in Tumor Angiogenesis: Influence of Estrogen Status. 1
- 375 The Give-and-Take Interaction Between the Tumor Microenvironment and Immune Cells Regulating Tumor Progression and Repression.. **2022**, 13, 850856 1
- 374 Astrocytic responses to high glucose impairs barrier formation in cerebral microvessel endothelial cells.. **2022**, 0
- 373 Pushing the Natural Frontier: Progress on the Integration of Biomaterial Cues towards Combinatorial Biofabrication and Tissue Engineering.. **2022**, e2105645 3
- 372 N-VEGF, the Autoregulatory Arm of VEGF-A.. **2022**, 11,
- 371 In Vitro Angiogenesis Inhibition and Endothelial Cell Growth and Morphology.. **2022**, 23, 1
- 370 Data_Sheet_1.PDF. **2019**,
- 369 Data_Sheet_1.PDF. **2020**,
- 368 Table_1.DOCX. **2020**,
- 367 Table_1.DOCX. **2019**,
- 366 Image_1.TIF. **2020**,
- 365 Image_2.TIF. **2020**,

364 Image_3.TIF. 2020,

363 Image_4.TIF. 2020,

362 Image_5.TIF. 2020,

361 Image_6.TIF. 2020,

360 Image_7.TIF. 2020,

359 Table_1.docx. 2020,

358 Table_2.docx. 2020,

357 Table_1.docx. 2018,

356 Image_1.PDF. 2018,

355 Image_10.PDF. 2018,

354 Image_11.PDF. 2018,

353 Image_12.PDF. 2018,

352 Image_2.PDF. 2018,

351 Image_3.pdf. 2018,

350 Image_4.pdf. 2018,

349 Image_5.pdf. 2018,

348 Image_6.pdf. 2018,

347 Image_7.pdf. 2018,

346 Image_8.pdf. 2018,

345 Image_9.PDF. 2018,

344 Video_1.mp4. 2018,

343 Video_2.mp4. 2018,

342 Video_3.mp4. 2018,

341 Video_4.mp4. 2018,

340 Data_Sheet_1.PDF. 2019,

339 Data_Sheet_2.ZIP. 2019,

338 Table_3.XLSX. 2019,

337 Table_4.XLSX. 2019,

336 Video_1.MP4. 2019,

335 Video_2.MP4. 2019,

334 Video_3.MP4. 2019,

333 Video_4.MP4. 2019,

332 Video_5.MP4. 2019,

331 Video_6.MP4. 2019,

330 Video_7.MP4. 2019,

329 Video_8.MP4. 2019,

328 Video_9.MP4. 2019,

327 Table_1.DOCX. 2019,

326 DataSheet_1.pdf. 2020,

325 DataSheet_2.pdf. 2020,

324 DataSheet_3.pdf. 2020,

323 DataSheet_1.zip. 2019,

322 Image_1.png. 2019,

321 Image_2.png. 2019,

320 Image_3.png. 2019,

319 Image_4.png. 2019,

318 Image_5.png. 2019,

317 Non-coding RNA regulatory networks in post-transcriptional regulation of VEGFA in cancer.. 2022, 2

316 A microRNA binding site polymorphism in the 3' UTR region of VEGF-A gene modifies colorectal cancer risk based on ethnicity: a meta-analysis.. 2022, 34, 18

315 Anti-tumor activity of motesanib in a medullary thyroid cancer model. 2012, 35, 181-90 13

314 Personalizing first-line treatment in advanced colorectal cancer: Present status and future perspectives.. 2021, 7, 771-785

313 Pharmacotherapy of Age-Related Macular Degeneration. 2022, 3619-3644

312 Novel biomarkers in triple-negative breast cancer - role and perspective. 2022, 29-60

311 Aortic stiffness and systemic inflammation changes predict clinical response to intravitreal anti-vascular endothelial growth factor therapy in patients with age-related macular degeneration.. 2022,

310	Small GTPases and Their Regulators: A Leading Road toward Blood Vessel Development in Zebrafish.. 2022 , 23,	0
309	Tendon and Ligament Genetics: How Do They Contribute to Disease and Injury? A Narrative Review. 2022 , 12, 663	1
308	Molecular mediators involved in skin healing: a narrative review. 11, 465	0
307	A Review of Intraocular Biomolecules in Retinal Vein Occlusion: Toward Potential Biomarkers for Companion Diagnostics.. 2022 , 13, 859951	1
306	In Silico Screening for Novel Tyrosine Kinase Inhibitors with Oxindole Scaffold as Anti-Cancer Agents: Design, QSAR Analysis, Molecular Docking and ADMET Studies. 1-16	0
305	De novo dual functional 3D scaffold using computational simulation with controlled drug release. 2022 ,	1
304	Circular RNA CircSHKBP1 accelerates the proliferation, invasion, angiogenesis, and stem cell-like properties via modulation of microR-766-5p/high mobility group AT-hook 2 axis in laryngeal squamous cell carcinoma.. 2022 , 13, 11551-11563	0
303	Pericyte dynamics in the mouse germinal matrix angiogenesis.. 2022 , 36, e22339	2
302	Analysis of conditional colocalization relationships and hierarchies in three-color microscopy images.. 2022 , 221,	
301	Tyrosine Phosphorylation Profiling Revealed the Signaling Network Characteristics of CAMKK2 in Gastric Adenocarcinoma. 2022 , 13,	1
300	ZKSCAN5 Activates VEGFC Expression by Recruiting SETD7 to Promote the Lymphangiogenesis, Tumour Growth, and Metastasis of Breast Cancer. 2022 , 12,	1
299	Novel Thienyl-Based Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma. 2022 , 12, 738	0
298	Preparation, characterization, and antitumor activity of Chaenomeles speciosa polysaccharide-based selenium nanoparticles. 2022 , 103943	0
297	Molecular Progression of Breast Cancer and Personalized Medicine in Terms of Clinical Trials. 2022 , 367-401	
296	Distinguishing placenta accreta from placenta previa via maternal plasma levels of sFlt-1 and PLGF and the sFlt-1/PLGF ratio. 2022 ,	
295	The roles of TGF- β and VEGF pathways in the suppression of antitumor immunity in melanoma and other solid tumors.. 2022 , 108211	3
294	A Naturally Occurring Soluble Form of Vascular Endothelial Growth Factor Receptor 2 Detected in Mouse and Human Plasma. 2004 , 2, 315-326	125
293	Biomarkers of Myocardial Injury and Remodeling in Heart Failure. 2022 , 12, 799	2

- 292 Current Advances in Structure-Function Relationships and Dose-Dependent Effects of Human Milk Oligosaccharides.. **2022**, 0
- 291 Investigation of Vascular Endothelial Growth Factor Polymorphisms on Risk, Metastasis, Laterality, and Prognosis of Colorectal Cancer in Turkish Subjects.. **2022**, 0
- 290 Therapeutic potential of traditional Chinese medicine for vascular endothelial growth factor.. **2022**, 23, 353-364
- 289 Spontaneous Browning of White Adipose Tissue Improves Angiogenesis and Reduces Macrophage Infiltration After Fat Grafting in Mice.. **2022**, 10, 845158 0
- 288 Association between IL-37 and VEGF Gene Expression in Psoriasis Pathogenesis in Egyptian Population. **2022**, 10, 136-149
- 287 Anlotinib Downregulates RGC32 Which Provoked by Bevacizumab. **2022**, 12,
- 286 Catalpol Enhances Random-Pattern Skin Flap Survival by Activating SIRT1-Mediated Enhancement of Autophagy. **2022**, 2022, 1-17
- 285 A cell retrievable strategy for harvesting extracellular matrix as active biointerface. **2022**, 0
- 284 First Year Real Life Experience With Intravitreal Brolucizumab for Treatment of Refractory Neovascular Age-Related Macular Degeneration. **2022**, 13, 2
- 283 Paeoniflorin alleviates the progression of retinal vein occlusion via inhibiting hypoxia inducible factor-1 α /vascular endothelial growth factor/STAT3 pathway. **2022**, 13, 13622-13631 0
- 282 Effect of Platelet-Derived Growth Factor C on Mitochondrial Oxidative Stress Induced by High d-Glucose in Human Aortic Endothelial Cells. **2022**, 15, 639 1
- 281 Vascular endothelial growth factor levels in tuberculosis: A systematic review and meta-analysis. **2022**, 17, e0268543 0
- 280 Tumour Angiogenesis in Breast Cancer.
- 279 Synthesis of new thienylnicotinamidines: Proapoptotic profile and cell cycle arrest of HepG2 cells. 0
- 278 Specific bio-functional CBD-PR1P peptide binding VEGF to collagen hydrogels promotes the recovery of cerebral ischemia in rats. 0
- 277 Lymphangiogenesis: Lymphatic System and Lymph Nodes; Cancer Lymphangiogenesis and Metastasis. **2022**, 209-229
- 276 Biological aspects in controlling angiogenesis: current progress. **2022**, 79, 0
- 275 Stimulation of human bone marrow mesenchymal stem cells by electromagnetic transduction therapy - EMTT. 1-11 0

- 274 Dimeric G-quadruplex DNA Structure in the Proximal Promoter of VEGFR -2 Reveals A New Drug Target to Inhibit Tumor Angiogenesis.
- 273 Neuroprotective Effects of VEGF in the Enteric Nervous System. **2022**, 23, 6756 1
- 272 The Effect of Platelet-Rich Plasma on Type I Collagen Production, VEGF Expression, and Neovascularization after Femoral Bone Implants: A Study on Rat Models. Volume 14, 207-214 0
- 271 Novel Drugs with High Efficacy against Tumor Angiogenesis. **2022**, 23, 6934 1
- 270 From infection to repair: Understanding the workings of our innate immune cells.
- 269 Concentration of hypoxia-inducible factor-1, glucose transporter 1 and vascular endothelial growth factor in tissue samples and serum in patients with primary laryngeal carcinoma. 1-5 0
- 268 Identification of novel somatic fusions of ERG-VEGFA, TMPRSS2-ERG , and VEGFA-TMPRSS2 in prostate cancer treated with anlotinib and androgen deprivation therapy: A case report.
- 267 Target-Based Small Molecule Drug Discovery for Colorectal Cancer: A Review of Molecular Pathways and In Silico Studies. **2022**, 12, 878 1
- 266 Remodeling of gene regulatory networks underlying thermogenic stimuli-induced adipose beiging. **2022**, 5, 0
- 265 Coaxially Fabricated Dual-Drug Loading Electrospinning Fibrous Mat with Programmed Releasing Behavior to Boost Vascularized Bone Regeneration. 2200571 2
- 264 Dual-responsive nanoparticles loading bevacizumab and gefitinib for molecular targeted therapy against non-small cell lung cancer. 1
- 263 Network pharmacology and molecular docking approach to elucidate the mechanisms of Liuwei Dihuang pill in diabetic osteoporosis. **2022**, 17, 0
- 262 Fusion Peptide-Engineered Polyetheretherketone Implants with Photo-Assisted Anti-Pathogen and Enhanced Angiogenesis for in vivo Osseointegrative Fixation. **2022**, 446, 137453 2
- 261 Role of platelet-derived growth factor c on endothelial dysfunction in cardiovascular diseases. **2022**, 1866, 130188 0
- 260 Tumor-Fibroblast Interactions in Carcinomas. **2022**, 109-124
- 259 Vascular Co-option in the Brain Tumor Microenvironment. **2022**, 537-547
- 258 Biomimetically constructing a hypoxia-activated programmable phototheranostics at the molecular level. 0
- 257 Cardiotoxic effects of tyrosine kinase inhibitors directed against VEGFR. **2022**, 83-102

- 256 Tumor-Vascular Interactions in Non-Small Cell Lung Cancer. **2022**, 497-508
- 255 Overview of Vascular Morphology Undergoing Angiogenesis Based on Mathematical Modeling. **2022**, 2042-2060
- 254 Flexible Sensing Systems for Cancer Diagnostics. **2022**, 275-306
- 253 The Role of the Microenvironment in Endometriosis: Parallels and Distinctions to Cancer. **2022**, 483-496
- 252 Skin wound healing: The critical role of angiogenesis. **2022**, 439-463
- 251 Effects of teriparatide on bone formation in rats with experimentally induced premaxillary expansion. **2022**, 27,
- 250 Cells of Cerebrovascular Endothelium and Perivascular Astroglia in the Regulation of Neurogenesis. **2022**, 58, 728-741
- 249 Systemtherapie beim fortgeschrittenen Zervixkarzinom. **2022**, 55, 524-530
- 248 Apatinib: A Novel Antiangiogenic Drug in Monotherapy or Combination Immunotherapy for Digestive System Malignancies. 13, 1
- 247 Relevance of NLRP3 Inflammasome-Related Pathways in the Pathology of Diabetic Wound Healing and Possible Therapeutic Targets. **2022**, 2022, 1-15 1
- 246 Dynamic Interactions between Tumor Cells and Brain Microvascular Endothelial Cells in Glioblastoma. **2022**, 14, 3128 1
- 245 Tannic Acid Exhibits Antiangiogenesis Activity in Nonsmall-Cell Lung Cancer Cells. **2022**, 7, 23939-23949 0
- 244 Biocompatible silane adhesion layer on titanium implants improves angiogenesis and osteogenesis. **2022**, 213033 0
- 243 Gene Expression Profiling of Markers of Inflammation, Angiogenesis, Coagulation and Fibrinolysis in Patients with Coronary Artery Disease with Very High Lipoprotein(a) Levels Treated with PCSK9 Inhibitors. **2022**, 9, 211 1
- 242 Benzoxazine: a privileged scaffold in medicinal chemistry. **2022**, 29, 2
- 241 Differential Impacts of HHV-6A versus HHV-6B Infection in Differentiated Human Neural Stem Cells. 13,
- 240 Ultrasound-Targeted Microbubble Destruction: Modulation in the Tumor Microenvironment and Application in Tumor Immunotherapy. 13, 1
- 239 Research progress in targeted therapy and immunotherapy for gastric cancer. Publish Ahead of Print, 1

238	The Relationship between VEGFC Gene Polymorphisms and Autoimmune Thyroiditis. 2022 , 2022, 1-8	
237	Targeting the CD47-SIRPβ Innate Immune Checkpoint to Potentiate Antibody Therapy in Cancer by Neutrophils. 2022 , 14, 3366	0
236	RNA-Seq Provides Insights into VEGF-Induced Signaling in Human Retinal Microvascular Endothelial Cells: Implications in Retinopathy of Prematurity. 2022 , 23, 7354	0
235	Research Advances of Injectable Functional Hydrogel Materials in the Treatment of Myocardial Infarction. 2022 , 8, 423	1
234	Poloxamer 407 and Hyaluronic Acid Thermosensitive Hydrogel-Encapsulated Ginsenoside Rg3 to Promote Skin Wound Healing. 10,	1
233	Tumor-associated neutrophils and neutrophil-targeted cancer therapies. 2022 , 188762	1
232	Inhibition of EZH2 suppresses peritoneal angiogenesis by targeting a VEGFR2/ERK1/2/HIF-1β dependent signaling pathway.	0
231	Design, synthesis and anti-tumor activity of asiatic acid derivatives as VEGF inhibitors. 1-12	
230	Identification of Publication Characteristics and Research Trends in the Management of Gallbladder Cancer. 2022 ,	
229	Alpha-1 antitrypsin in autoimmune diseases: Roles and therapeutic prospects. 2022 , 110, 109001	
228	Structure, anti-tumor activity, and potential anti-tumor mechanism of a fungus polysaccharide from Fomes officinalis. 2022 , 295, 119794	1
227	Targeting Tumor Angiogenesis with Adenovirus-Delivered Anti-Tie-2 Intrabody. 2005 , 65, 972-981	14
226	Differentiation and Definition of Vascular-Targeted Therapies. 2005 , 11, 416-420	74
225	KRN633: A selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase that suppresses tumor angiogenesis and growth. 2004 , 3, 1639-1649	23
224	Reducing VEGFB expression regulates the balance of glucose and lipid metabolism in mice via VEGFR1. 2022 , 26,	0
223	VEGF receptor heterodimers and homodimers are differentially expressed in neuronal and endothelial cell types. 2022 , 17, e0269818	0
222	PLC (Phospholipase C) β Promotes VEGF (Vascular Endothelial Growth Factor) Induced Vascular Permeability.	0
221	Single-Cell Transcriptomics of Proliferative Phase Endometrium: Systems Analysis of Cell-Cell Communication Network Using CellChat. 10,	1

- 220 The Thioredoxin-1 Inhibitor 1-Methylpropyl 2-Imidazolyl Disulfide (PX-12) Decreases Vascular Permeability in Tumor Xenografts Monitored by Dynamic Contrast Enhanced Magnetic Resonance Imaging. **2005**, 11, 529-536 11
- 219 Pharmacodynamic Analysis of Target Inhibition and Endothelial Cell Death in Tumors Treated with the Vascular Endothelial Growth Factor Receptor Antagonists SU5416 or SU6668. **2005**, 11, 678-689 10
- 218 Innate Immunity in the Development of Connective Tissue Dysplasia: Pilot Study in Children with Congenital Hip Dislocation. **2022**, 10, 155-170
- 217 Hypoxia-regulated microRNAs: the molecular drivers of tumor progression. 1-26 1
- 216 The Roles of Vascular Endothelial Growth Factor, Angiostatin, and Endostatin in Nasal Polyp Development. **2022**, 29, 82-87
- 215 Pharmacophore Modeling of Targets Infested with Activity Cliffs via Molecular Dynamics Simulation Coupled with QSAR and Comparison with other Pharmacophore Generation Methods: KDR as Case Study. 0
- 214 Serum vascular endothelial growth factor is associated with cardiovascular involvement and response to therapy in Erdheim-Chester disease.
- 213 The Efficacy and Safety of Anlotinib in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study. Volume 14, 2273-2287
- 212 New quinoline and isatin derivatives as apoptotic VEGFR-2 inhibitors: design, synthesis, anti-proliferative activity, docking, ADMET, toxicity, and MD simulation studies. **2022**, 37, 2191-2205 2
- 211 The application and progression of CRISPR/Cas9 technology in ophthalmological diseases.
- 210 Recombinant Human Arresten and Canstatin Inhibit Angiogenic Behaviors of HUVECs via Inhibiting the PI3K/Akt Signaling Pathway. **2022**, 23, 8995 1
- 209 Novel Designed Proteolytically Resistant VEGF-B186R127S Promotes Angiogenesis in Mouse Heart by Recruiting Endothelial Progenitor Cells. 10, 0
- 208 Triggered Drug Release of Surface Cyclic Peptide Gatekeepers with Endothelial Cell Targeting Sequence Conjugated to Mesoporous Nanocontainers. **2022**, 133061
- 207 DIA proteomics identified the potential targets associated with angiogenesis in the mammary glands of dairy cows with hemorrhagic mastitis. 9,
- 206 Polycaprolactone/Chitosan Composite Nanofiber Membrane as a Preferred Scaffold for the Culture of Mesothelial Cells and the Repair of Damaged Mesothelium. **2022**, 23, 9517 0
- 205 Long-term Effects of Anti-VEGF Monotherapy for Retinopathy of Prematurity on the Retinal and Refractive Development of Eye. **2022**, Publish Ahead of Print,
- 204 The hypoxia-dependent angiogenic process in dental pulp. **2022**, 0
- 203 Soluble Flt-1 in AMI Patients Serum Inhibits Angiogenesis of Endothelial Progenitor Cells by Suppressing Akt and Erk β Activity. **2022**, 11, 1194

202	Urinary biomarkers of kidney injury in patients treated with anti-VEGF drugs. 2022 , 94, 725-730	
201	Bevacizumab combined with re-irradiation in recurrent glioblastoma. 12 ,	0
200	Autologous humanized PDX modeling for immuno-oncology recapitulates the human tumor microenvironment.	
199	Mucosal Immune Profiles Associated with Diarrheal Disease Severity in Shigella - and Enteropathogenic Escherichia coli-Infected Children Enrolled in the Global Enteric Multicenter Study.	1
198	Macrophages Treated with VEGF and PDGF Exert Paracrine Effects on Olfactory Ensheathing Cell Function. 2022 , 11, 2408	0
197	Mechanisms and prospects of circular RNAs and their interacting signaling pathways in colorectal cancer. 12 ,	0
196	Anterior Mandibular Displacement in Growing Rats A Systematic Review. 2022 , 12, 2059	0
195	Dermatopontin Influences the Development of Obesity-Associated Colon Cancer by Changes in the Expression of Extracellular Matrix Proteins. 2022 , 23, 9222	0
194	Targeting angiogenesis in gliomas: Potential role of phytochemicals. 2022 , 96, 105192	0
193	Development of polymeric microparticles for controlled release of bioactive drugs using modified solution enhanced dispersion by supercritical CO ₂ . 2022 , 189, 105723	
192	Flavonoid-based nanomedicines to target tumor microenvironment. 2022 , 8, 100081	1
191	PAR2 promotes tumor-associated angiogenesis in lung adenocarcinoma through activating EGFR pathway. 2022 , 79, 101918	0
190	TIE2-high cervical cancer cells promote tumor angiogenesis by upregulating TIE2 and VEGFR2 in endothelial cells. 2022 , 26, 101539	1
189	Insight into the molecular mechanism of action of anticancer drugs. 2023 , 477-502	0
188	Pyridine ring as an important scaffold in anticancer drugs. 2023 , 375-410	0
187	Signaling Metabolite Succinylacetone Activates HIF-1 α and Promotes Angiogenesis in <i>GSTZ1</i>-Deficient Hepatocellular Carcinoma.	0
186	Effects of Acute and Chronic Exercise in Hypoxia on Cardiovascular and Glycemic Parameters in Patients with Type 2 Diabetes: A Systematic Review.	0
185	The landscape of aging.	3

184	Anti-PTK7 Monoclonal Antibodies Inhibit Angiogenesis by Suppressing PTK7 Function. 2022 , 14, 4463	0
183	Heat Shock Protein 27 Affects Myeloid Cell Activation and Interaction with Prostate Cancer Cells. 2022 , 10, 2192	0
182	Taxifolin attenuates inflammation via suppressing MAPK signal pathway in vitro and in silico analysis. 2022 ,	0
181	Recent advances in CAR-T cells therapy for colorectal cancer. 13,	2
180	GENES EXPRESSION AND SERUM BIOMARKERS FOR DIAGNOSIS OF HEPATOCELLULAR CARCINOMA, CIRRHOSIS AND HEPATITIS C. 2022 , 59, 394-401	1
179	Vascular endothelial growth factor and its receptors regulation in gestational diabetes mellitus and eclampsia. 2022 , 20,	1
178	Risk factors for the development of an early recurrence of gemistocytic astrocytomas and their clinical significance. 2022 , 2, 14-22	0
177	Therapeutic potential of exosomes from adipose-derived stem cells in chronic wound healing. 9,	1
176	The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study. 12,	0
175	Implanted synthetic cells trigger tissue angiogenesis through de novo production of recombinant growth factors. 2022 , 119,	1
174	The relation of VEGFA, VEGFR2, VEGI, and HIF1A genetic variants and their serum protein levels with breast cancer in Egyptian patients.	0
173	Successes and failures of angiogenesis blockade in gastric and gastro-esophageal junction adenocarcinoma. 12,	1
172	Exploring the mechanism of action of TwHF in the treatment of rheumatoid arthritis based on network pharmacology and molecular docking.	0
171	Vascular toxicity of multi-walled carbon nanotubes targeting vascular endothelial growth factor. 1-13	0
170	Circulating vascular endothelial growth factor and cancer risk: A bidirectional mendelian randomization. 13,	0
169	Extracellular vesicles as central regulators of blood vessel function in cancer. 2022 , 15,	1
168	Hypoxia-Inducible Factors Signaling in Osteogenesis and Skeletal Repair. 2022 , 23, 11201	1
167	VEGF and Neuronal Survival. 107385842211208	0

- 166 G-CSF-mobilized Peripheral Blood Mononuclear Cells Combined with Platelet-rich Plasma Restored the Ovarian Function of aged rats via angiogenesis and glycolysis modulation. ○
- 165 Hypervascularized Large Vestibular Schwannomas: single-center experience in a series of 40 cases.. **2022**, 100142 ○
- 164 Investigation of the therapeutic potential of recombinant bispecific bivalent anti-PD-L1/VEGF nanobody in inhibition of angiogenesis. 1-8 ○
- 163 Metformin pre-treatment of stem cells from human exfoliated deciduous teeth promotes migration and angiogenesis of human umbilical vein endothelial cells for tissue engineering. **2022**, 24, 1095-1104 ○
- 162 Perioperative bevacizumab in the treatment of colorectal cancer in patients with liver metastases. **2022**, 75, 12-18 ○
- 161 Animal Models for Angiogenesis on Cancer Research. **2022**, 1-23 ○
- 160 Squalamines in Blockade of Tumor-Associated Angiogenesis and Cancer Progression. **2022**, 14, 5154 ○
- 159 The thiophene ether thienylmethanol isolated from *Tagetes minuta* inhibits angiogenesis by targeting protein kinase C isozymes β and δ . 13, ○
- 158 Importance of Heparan Sulfate Proteoglycans in Pancreatic Islets and β Cells. **2022**, 23, 12082 ○
- 157 Patient-Derived Organoids for In Vivo Validation of In Vitro Data. **2023**, 111-126 ○
- 156 Upgrading Monocytes Therapy for Critical Limb Ischemia Patient Treatment: Pre-Clinical and GMP-Validation Aspects. **2022**, 23, 12669 ○
- 155 Modern breast cancer therapy: from tamoxifen to T-cell engineering. **2022**, 21, 109-122 1
- 154 FOXP3+ regulatory T cells and the immune escape in solid tumours. 13, ○
- 153 Mechanisms of Epithelial-Mesenchymal Transition and Prevention of Disperse-Induced PVR by Delivery of an Antioxidant β Crystallin Peptide. **2022**, 11, 2080 1
- 152 Molecular mechanism of VEGF and its role in pathological angiogenesis. ○
- 151 Endothelial cell diversity: the many facets of the crystal. ○
- 150 Principles of Dose, Schedule, and Combination Therapy. 1-13 ○
- 149 Repurposing Lenvatinib as A Potential Therapeutic Agent against Thyroid Eye Disease by Suppressing Adipogenesis in Orbital Adipose Tissues. **2022**, 15, 1305 1

- 148 Regulation of epigenetic modifications in the head and neck tumour microenvironment. 13, 0
- 147 Intravitreal Vascular Endothelial Growth Factor Inhibitor Use and Renal Function Decline in Patients with Diabetic Retinopathy. **2022**, 19, 14298 0
- 146 Evidence of air pollution-related ocular signs and altered inflammatory cytokine profile of the ocular surface in Beijing. **2022**, 12, 1
- 145 In vivo prevascularization strategy enhances neovascularization of β -tricalcium phosphate scaffolds in bone regeneration. **2022**, 37, 143-151 0
- 144 Intercellular communication analysis of the human retinal pigment epithelial and choroidal cells predicts pathways associated with aging, cellular senescence and age-related macular degeneration. 14, 1
- 143 An endogenous inhibitor of angiogenesis downregulated by hypoxia in human aortic valve stenosis promotes disease pathogenesis. **2022**, 0
- 142 Combined delivery of small molecule and protein drugs as synergistic therapeutics for treating corneal neovascularization by a one-pot coassembly strategy. **2022**, 17, 100456 0
- 141 MCP-1 facilitates VEGF production by removing miR-374b-5p blocking of VEGF mRNA translation. **2022**, 206, 115334 0
- 140 Uninterrupted dynamic stiffening microenvironment enhances the paracrine function of mesenchymal stem cells for vascularization through chromatin remodeling. **2022**, 224, 111328 0
- 139 Targeted therapy and molecular genetics. **2023**, 464-488.e11 0
- 138 Pathology of Vascular Remodeling -Molecular Mechanism of Functional Angiogenesis-. **2004**, 15, 277-285 0
- 137 Synthesis and antiproliferative activity of 1H-1,2,3-triazole-4H-chromene-D-glucose hybrid compounds with dual inhibitory activity against EGFR/VEGFR-2 and molecular docking study. 0
- 136 Functional Characterization and Development of Novel Human Kinase Insert Domain Receptor Chimeric Antigen Receptor T-cells for Immunotherapy of Non-Small Cell Lung Cancer. **2022**, 106331 0
- 135 Phase IIIb study of the bevacizumab biosimilar candidate BI 695502 plus mFOLFOX6 in metastatic colorectal cancer. 0
- 134 Alginate-Chitosan Hydrogel Formulations Sustain Baculovirus Delivery and VEGFA Expression Which Promotes Angiogenesis for Wound Dressing Applications. **2022**, 15, 1382 1
- 133 Myocardial Protection and Current Cancer Therapy: Two Opposite Targets with Inevitable Cost. **2022**, 23, 14121 1
- 132 Targeted Therapies for Hepatocellular Carcinoma Treatment: A New Era Ahead? A Systematic Review. **2022**, 23, 14117 1
- 131 Cafestol, Kahweol and Their Acylated Derivatives: Antitumor Potential, Pharmacokinetics, and Chemopreventive Profile. 1-33 1

- 130 Topical Administration of a Novel Acetylated Tetrapeptide Suppresses Vascular Permeability and Immune Responses and Alleviates Atopic Dermatitis in a Murine Model. **2022**, 23, 13498 ○
- 129 Adjuvant therapy options in renal cell carcinoma [targeting the metastatic cascade. ○
- 128 Gold nanoparticles as antiangiogenic and antimetastatic agents. **2022**, 103438 ○
- 127 Application basis of combining antiangiogenic therapy with radiotherapy and immunotherapy in cancer treatment. 12, 1 ○
- 126 Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy. 28, 6034-6044 ○
- 125 Analysis of spatial transcriptomics at varying resolution levels using the unified framework of SpaSEG. ○
- 124 Ginsenoside Rg1 Nanoparticles Induce Demethylation of H3K27me3 in VEGF-A and Jagged 1 Promoter Regions to Activate Angiogenesis After Ischemic Stroke. Volume 17, 5447-5468 ○
- 123 The biophysical perspective of the vascular alteration due to angiogenesis and inflammation in population at risk of atherosclerosis. **2022**, ○
- 122 Research progress on the antitumor effects of astragaloside IV. **2023**, 938, 175449 ○
- 121 Antibacterial hydrogel with pH-responsive microcarriers of slow-release VEGF for bacterial infected wounds repair. **2023**, 144, 198-212 ○
- 120 Faricimab in the Treatment Landscape for Retinal Diseases: A Review. **2022**, 16, 92 ○
- 119 Liver Cirrhosis in Chronic Hepatitis B: is it due to Hepatic Vena Cava Syndrome: case report. **2022**, 9, 65-73 ○
- 118 Thienopyrimidine-based agents bearing diphenylurea: Design, synthesis, and evaluation of antiproliferative and antiangiogenic activity. ○
- 117 Restoration of spinal cord injury: From endogenous repairing process to cellular therapy. 16, ○
- 116 Pulmonary Fibrosis as a Result of Acute Lung Inflammation: Molecular Mechanisms, Relevant In Vivo Models, Prognostic and Therapeutic Approaches. **2022**, 23, 14959 2
- 115 The Influence of Carboxytherapy on Scar Reduction. Volume 15, 2855-2872 ○
- 114 Recent and Future Strategies to Overcome Resistance to Targeted Therapies and Immunotherapies in Metastatic Colorectal Cancer. **2022**, 11, 7523 ○
- 113 Kidney endothelial cell heterogeneity, angiocrine activity and paracrine regulatory mechanisms. **2022**, 107139 ○

112	Leading Roles of Heparan Sulfate in Angiogenesis and Cancer. 2023 , 229-256	0
111	Molecular Complementarity of Proteomimetic Materials for Target-Specific Recognition and Recognition-Mediated Complex Functions. 2208309	0
110	First genome-wide association study and genomic prediction for growth traits in spotted sea bass (<i>Lateolabrax maculatus</i>) using whole-genome resequencing. 2022 , 739194	0
109	The VEGF/VEGFR Axis Revisited: Implications for Cancer Therapy. 2022 , 23, 15585	2
108	A phase II study to explore biomarkers for the use of mFOLFOX6/XELOX plus bevacizumab as a first-line chemotherapy in patients with metastatic colorectal cancer (WJOG7612GTR). 2022 , 7, 100592	0
107	Bioactive lipid-nanoparticles with inherent self-therapeutic and anti-angiogenic properties for cancer therapy. 2022 ,	0
106	Bovine Lactoferrin Suppresses Tumor Angiogenesis through NF- κ B Pathway Inhibition by Binding to TRAF6. 2023 , 15, 165	1
105	Inadvertent Use of Bevacizumab to Treat Choroidal Neovascularisation During Pregnancy: A Case Report. 2010 , 39, 143-145	2
104	Biology and Genetics of Vestibular Schwannomas in Tumors of the Cerebellopontine Angle. 2022 , 121-132	0
103	Gel formulated with <i>Bryophyllum pinnatum</i> leaf extract promotes skin wound healing in vivo by increasing VEGF expression: A novel potential active ingredient for pharmaceuticals. 13,	1
102	The Antimicrobial Peptide Cathelicidin Exerts Immunomodulatory Effects via Scavenger Receptors. 2023 , 24, 875	1
101	Angiogenesis under Opioids Preconditioning in Renal Ischemia Reperfusion. 2023 , 2, 1-13	0
100	Molecular mechanism of binding between a therapeutic RNA aptamer and its protein target VEGF : A molecular dynamics study.	0
99	Histone deacetylase inhibitors as sanguine epitherapeutics against the deadliest lung cancer. 2023 ,	0
98	Modularly designed peptide-based nanomedicine inhibits angiogenesis to enhance chemotherapy for post-surgical recurrence of esophageal squamous cell carcinomas.	1
97	Dorsal aorta polarization and haematopoietic stem cell emergence. 2023 , 150,	0
96	Heparin-Induced Changes of Vascular Endothelial Growth Factor (VEGF165) Structure. 2023 , 13, 98	0
95	Efficient delivery of VEGF-A mRNA for promoting diabetic wound healing via ionizable lipid nanoparticles. 2023 , 632, 122565	0

- 94 Development of an in-vitro high-throughput screening system to identify modulators of genitalia development. **2023**, 2, ○
- 93 CURRENT STATE OF TECHNOLOGY FOR THERAPEUTIC TREATMENT OF BREAST CANCER. **2022**, 7-9 ○
- 92 Expression of Markers Ki-67, Nestin, VEGF, CD34 and Apoptosis in Relatively Healthy Lung Tissue with Non-Changed and Metaplastic Bronchial Epithelium. **2023**, 11, 7 ○
- 91 Peptide-assembled nanoparticles targeting tumor cells and tumor microenvironment for cancer therapy. 11, ○
- 90 Impact of Hypertension in Cancer Patients Treated With Anti-Vascular Endothelial Growth Factor Therapy. **2023**, ○
- 89 Effects of Early Weight-Bearing Treadmill Training Combined with Pre-Emptive Analgesia on Femoral Fracture Recovery. **2023**, 2023, 1-16 ○
- 88 Optical spectral diagnostics of the oxygenation level in periodontal tissues and photodynamic therapy using methylene blue in children with cerebral palsy. 11, ○
- 87 SENP6-Mediated deSUMOylation of VEGFR2 Enhances Its Cell Membrane Transport in Angiogenesis. **2023**, 24, 2544 ○
- 86 Recombinant Endostatin as a Potential Radiosensitizer in the Treatment of Non-Small Cell Lung Cancer. **2023**, 16, 219 ○
- 85 Design and cytotoxic evaluation via apoptotic and antiproliferative activity for novel 11(4-aminophenylamino)neocryptolepine on hepatocellular and colorectal cancer cells. ○
- 84 Understanding LncRNAs in Biomaterials Development for Osteointegration. **2023**, 269-285 ○
- 83 Biomaterials tools to modulate the tumour microenvironment in immunotherapy. 1
- 82 Differential gene expression profiling in alveolar echinococcosis identifies potential biomarkers associated with angiogenesis. ○
- 81 Cancer-Associated Adipocytes and Breast Cancer: Intertwining in the Tumor Microenvironment and Challenges for Cancer Therapy. **2023**, 15, 726 ○
- 80 Design, Synthesis, Biological Evaluation, and Preliminary Mechanistic Study of a Novel Mitochondrial-Targeted Xanthone. **2023**, 28, 1016 ○
- 79 More than germ cells: vascular development in the early zebrafish (*Danio rerio*) gonad. ○
- 78 Role of HIF-1 α in pathogenic mechanisms of keloids. ○
- 77 Vascular Endothelial Growth Factor Supplementation Enhance Skin Antioxidant Capacity in Hyperglycemic Rats. ○

- 76 The effect of natural products combination on MCF-7 cells exceeds tamoxifen therapeutic dose effects in vitro. **2023**, 47, 891-904 ○
- 75 Can ⁹⁹Tcm-3PRGD2(B) and ¹⁸F-FDG dual-tracer molecular imaging change the therapeutic strategy for progressive refractory differentiated thyroid cancer: Case report. **2023**, 102, e32751 ○
- 74 Insight on the cellular and molecular basis of blood vessel formation: A specific focus on tumor targets and therapy. **2023**, 2, ○
- 73 Resistance to targeted therapy in metastatic colorectal cancer: Current status and new developments. 29, 926-948 ○
- 72 Angiotensin-converting enzyme inhibitor promotes angiogenesis through Sp1/Sp3-mediated inhibition of notch signaling in male mice. **2023**, 14, ○
- 71 Targeting VCAM-1: a therapeutic opportunity for vascular damage. 1-17 ○
- 70 Sinomenine promotes flap survival by upregulating eNOS and eNOS-mediated autophagy via PI3K/AKT pathway. **2023**, 116, 109752 ○
- 69 A small-diameter vascular graft immobilized peptides for capturing endothelial colony-forming cells. 11, ○
- 68 Nanomaterial-Based Antivascular Therapy in the Multimodal Treatment of Cancer. **2023**, 15, 1207 ○
- 67 Low-grade mammary gland tumours in dogs have greater VEGF-A and BMP2 immunostaining and higher CD31 blood vessel density. **2023**, 100778 ○
- 66 Molecular Mechanism of the Therapeutic Effect of Peach Blossom against Constipation: An Exploratory Study Based on Network Pharmacology Analysis and Molecular Docking Verification. **2023**, 2023, 1-14 ○
- 65 Topical delivery of Anti-VEGF nanomedicines for treating psoriasis. **2023**, 83, 104365 ○
- 64 Design, synthesis, and antiproliferative properties of new 1,2,3-triazole-carboximidamide derivatives as dual EGFR/VEGFR-2 inhibitors. **2023**, 1282, 135165 ○
- 63 Evaluation of natural protein-based nanofiber composite photocrosslinking hydrogel for skin wound regeneration. **2023**, 226, 113292 ○
- 62 Harnessing function of EMT in hepatocellular carcinoma: From biological view to nanotechnological standpoint. **2023**, 227, 115683 ○
- 61 Acute inflammatory reaction during anti-angiogenesis therapy combined with immunotherapy as a possible indicator of the therapeutic effect: Three case reports and literature review. 13, ○
- 60 Treatment of neovascular age-related macular degeneration within 48h from diagnosis improves long-term functional outcome. **2023**, 160, 114368 ○
- 59 The extract of Curcumae Longae Rhizoma suppresses angiogenesis via VEGF-induced PI3K/Akt-eNOS-NO pathway. **2023**, 308, 116299 ○

- 58 Stimulation of soluble guanylate cyclase activity with riociguat promotes angiogenesis and improves neovascularization after limb ischemia. **2023**, 372, 32-40 ○
- 57 Connexin 43 trafficking and regulation of gap junctional intercellular communication alters ovarian cancer cell migration and tumorigenesis. **2023**, 159, 114296 ○
- 56 Y-27632 Impairs Angiogenesis on Extra-Embryonic Vasculature in Post-Gastrulation Chick Embryos. **2023**, 11, 134 ○
- 55 Animal Models for Angiogenesis on Cancer Research. **2023**, 397-419 ○
- 54 Application of an angiogenesis-related genes risk model in lung adenocarcinoma prognosis and immunotherapy. 14, ○
- 53 Strategic Management of Bleeding Small Bowel Gastrointestinal Angiodysplasias (GIADs): A 12 Year Retrospective Review in a Veteran Population and Cost Comparison. **2023**, 13, 525 ○
- 52 Research Progress in the Treatment of Malignant Pleural Effusion with Intrathoracic Perfusion of Antiangiogenic Drugs. **2023**, 13, 123-1237 ○
- 51 Systemic Cytokines in Retinopathy of Prematurity. **2023**, 13, 291 ○
- 50 Exploring anticancer potential of nintedanib conjugated magnetic nanoparticles: In-vitro and in-silico studies. **2023**, 81, 104213 ○
- 49 Effect of Shan Zha (Hawthorn or Crataegus) on gastrointestinal cancer: A network pharmacology and molecular docking study. **2023**, ○
- 48 Prediction of zebrafish embryonic developmental toxicity by integrating omics with adverse outcome pathway. **2023**, 448, 130958 ○
- 47 Secretome of Adipose-Derived Stem Cells Cultured in Platelet Lysate Improves Migration and Viability of Keratinocytes. **2023**, 24, 3522 ○
- 46 Roxadustat, a HIF-PHD inhibitor with exploitable potential on diabetes-related complications. 14, ○
- 45 Advances in Molecular Regulation of Prostate Cancer Cells by Top Natural Products of Malaysia. **2023**, 45, 1536-1567 1
- 44 Injectable hydrogel encapsulated with VEGF-mimetic peptide-loaded nanoliposomes promotes peripheral nerve repair in vivo. **2023**, 160, 225-238 ○
- 43 Perspectives on the Use of Placental Growth Factor (PlGF) in the Prediction and Diagnosis of Pre-Eclampsia: Recent Insights and Future Steps. Volume 15, 255-271 1
- 42 Scandium-44 Radiolabeled Peptide and Peptidomimetic Conjugates Targeting Neuropilin-1 Co-Receptor as Potential Tools for Cancer Diagnosis and Anti-Angiogenic Therapy. **2023**, 11, 564 1
- 41 DNA methylation profiling reveals novel pathway implicated in cardiovascular diseases of diabetes. 14, ○

- 40 Elucidating activation and deactivation dynamics of VEGFR-2 transmembrane domain with coarse-grained molecular dynamics simulations. **2023**, 18, e0281781 ○
- 39 A critical role of VEGFR2 in lymphatic tumor metastasis. ○
- 38 Identification of Four New Chemical Series of Small Drug-Like Natural Products as Potential Neupilin-1 Inhibitors by Structure-Based Virtual Screening: Pharmacophore-Based Molecular Docking and Dynamics Simulation. **2023**, 20, ○
- 37 Association of Ang/Tie2 pathway mediators with endothelial barrier integrity and disease severity in COVID-19. 14, ○
- 36 Screening for Coronary Artery Disease in Cancer Survivors. **2023**, 5, 22-38 ○
- 35 Angiogenesis after ischemic stroke. ○
- 34 What Is the Correlation between Preeclampsia and Cancer? The Important Role of Tachykinins and Transition Metal Ions. **2023**, 16, 366 ○
- 33 Invasion and Metastasis. **2023**, 205-234 ○
- 32 Piezoelectric Bioactive Glasses Composite Promotes Angiogenesis by the Synergistic Effect of Wireless Electrical Stimulation and Active Ions. 2300064 ○
- 31 The transient receptor potential channels in rheumatoid arthritis: Need to pay more attention. 14, ○
- 30 The role of class IIa histone deacetylases in regulating endothelial function. 14, ○
- 29 Interplay Between Extracellular Matrix Remodeling and Angiogenesis in Tumor Ecosystem. **2023**, 22, 291-305 ○
- 28 Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing. **2023**, 24, 4877 ○
- 27 Raltitrexed enhanced antitumor effect of anlotinib in human esophageal squamous carcinoma cells on proliferation, invasiveness, and apoptosis. **2023**, 23, ○
- 26 The New Frontier of Immunotherapy: Chimeric Antigen Receptor T (CAR-T) Cell and Macrophage (CAR-M) Therapy against Breast Cancer. **2023**, 15, 1597 1
- 25 Preventing Persistence of HPV Infection with Natural Molecules. **2023**, 12, 416 ○
- 24 Small-Caliber Tissue-Engineered Vascular Grafts Based on Human-Induced Pluripotent Stem Cells: Progress and Challenges. ○
- 23 The Tissue Response to Hypoxia: How Therapeutic Carbon Dioxide Moves the Response toward Homeostasis and Away from Instability. **2023**, 24, 5181 ○

- 22 Nanofabrication Technologies to Control Cell and Tissue Function in Three-Dimension. **2023**, 9, 203 ○
- 21 USP22 upregulates ZEB1-mediated VEGFA transcription in hepatocellular carcinoma. **2023**, 14, ○
- 20 Angiogenesis Inhibitors in the Treatment of Cancer. **2023**, 1-33 ○
- 19 Integration of pharmacoproteomic and computational approaches reveals the cellular signal transduction pathways affected by apatinib in gastric cancer cell lines. **2023**, 21, 2172-2187 ○
- 18 Crenolanib inhibits retinal fibrosis associated with resistance to anti-VEGF in neovascular age-related macular degeneration in retinal Müller cells. ○
- 17 Effects and possible mechanisms of intermittent fasting on health and disease: a narrative review. ○
- 16 Suramin Affects the Renal VEGF-A/VEGFR Axis in Short-Term Streptozotocin-Induced Diabetes. **2023**, 16, 470 ○
- 15 Pilot Biomarker Analysis and Decision Tree Algorithm Modeling of Patients with Chronic Subdural Hematomas. **2023**, 4, 184-196 ○
- 14 The vascular endothelial growth factor (VEGF) system as a key regulator of ovarian follicle angiogenesis and growth. **2023**, 90, 201-217 ○
- 13 Stem cell therapy combined with controlled release of growth factors for the treatment of sphincter dysfunction. **2023**, 13, ○
- 12 In vitro angiogenesis in response to biomaterial properties for bone tissue engineering: a review of the state of the art. **2023**, 10, ○
- 11 Magic Chloro—Profound Effects of the Chlorine Atom in Drug Discovery. ○
- 10 Angiogenesis Evaluation Techniques Developed by Using Microfluidic Devices. **2023**, 72, 73-78 ○
- 9 Structure, Function and Responses to Injury. **2024**, 1-95 ○
- 8 Targeting angiogenesis in oncology, ophthalmology and beyond. ○
- 7 Hypoxia Inhibitor Combined with Chemotherapeutic Agents for Antitumor and Antimetastatic Efficacy against Osteosarcoma. ○
- 6 Hypoxia and Its Biological Implications for Cancer Therapy. **2023**, 1-18 ○
- 5 Effect of algal metabolites in the inhibition of angiogenic channels for breast tumour. ○

- 4 Effects of the interactions between platelets with other cells in tumor growth and progression. 14, ○
- 3 A novel VEGFR inhibitor ZLF-095 with potent antitumor activity and low toxicity. **2023**, e15152 ○
- 2 The tissue-specific transcriptional landscape underlines the involvement of endothelial cells in health and disease. **2023**, 108418 ○
- 1 Anti-scarring effects of conbercept on human Tenon's fibroblasts: comparisons with bevacizumab. **2023**, 23, ○